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1 Introduction 
1.1 α,β-Unsaturated carbonyl compounds and inflammation 
α,β-Unsaturated carbonyl compounds possessing a Michael acceptor functionality represent a 
prominent class of biologically and pharmacologically active electrophiles amongst the vast 
number of electrophilic compounds with numerous biological targets.1 Of great importance are 
thiol-regulated signal transduction pathways essential for the cellular redox homeostasis and 
cell protection. Especially under pathological conditions involving chronic inflammation, athero-
sclerosis, diabetes, liver, lung and brain injury, kidney disease and cancer, these particular re-
dox-sensitive and cytoprotective signaling cascades are promising targets of therapeutic drugs.2 
Already in the late 1980’s Talalay et al. reported that the beneficial biological activity of 
chemoprotective agents is directly connected to their Michael acceptor activity.3 On one hand, 
α,β-unsaturated carbonyl compounds possess a distinct Michael acceptor reactivity by which 
they can react with nucleophilic sulfhydryl groups of sensor cysteins on key signaling proteins. 
On the other hand the α,β-unsaturated carbonyl moiety itself as well as additional groups, i.e. 
phenolic hydroxyls can react as radical scavengers or antioxidants due to their pronounced re-
duction potential (Figure 1).4 
 
Figure 1. Reactivities of α,β-unsaturated carbonyl compounds.  
The electrophilic nature of the α,β-unsaturated carbonyl unit enables many natural products, 
which possess this functionality to act as powerful antioxidant, anti-inflammatory, neurochemo-
protective and cancer chemopreventive agents. A high drug design potential emerges from the 
class of Michael acceptors because they can selectively address certain cellular targets in fairly 
complex signaling pathways, due to a distinct and moderate electrophilic behavior. Prominent 
α,β-unsaturated compounds, where their Michael acceptor reactivity was shown to be closely 
related to their biological potency, comprise phytochemicals such as the food polyphenols 
curcumin, butein and isoliquiritigenin (ISL), endogenous inducers like the cyclopentenone pros-
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taglandin 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2)5 and the highly potent pentacyclic 
triterpenoids (CDDOs) as well as the monocyclic cyanoenone (MCE) relatives6-9 (Figure 2).  
 
Figure 2. Structures of prominent α,β-unsaturated compounds as biological active Michael acceptors. 15d-
PGJ2, 15-deoxy-Δ12,14-prostaglandin J2; CDDO, bardoxolone; BARD, bardoxolone methyl; MCE, monocyclic 
cyanoenone. 
α,β-Unsaturated carbonyl compounds can act as redox active agents by directly neutralizing 
reactive oxygen species (ROS) such as the superoxide radical (O2•-), hydroxyl radical (•OH) and 
hydrogen peroxide (H2O2) produced as a consequence of unbalanced biochemical processes in 
the body (e.g. in the mitochondria or under chronic inflammation) or as a result of increased 
exposure to xenobiotics, thus reinstalling redox homeostasis.2 A more important reactivity of the 
α,β-unsaturated carbonyl compounds is their ability to modulate certain sulfhydryl groups on 
cysteine-dependent signaling pathways. Two major signaling pathways can be targeted by α,β-
unsaturated carbonyl compounds particularly leading to beneficial effects: the inflammatory 
signaling pathway regulated by the transcriptional factor NF-κB and the redox-sensitive and 
anti-inflammatory Keap1/Nrf2/ARE signaling system.  
The transcriptional factor Nrf2 (NF-E2 related factor 2) is a member of the cap’n collar family of 
basic leucine transcription factors. Under basal conditions Nrf2 is sequestered in the cytosol as 
an inactive complex with Keap1 (Kelch-like ECH-associated protein 1). Electrophiles and other 
inducers can modify critical surface SH groups of cysteins (e.g. Cys151, Cys273 and Cys288) of 
Keap1 covalently or by oxidation.10 This leads to a conformational change in Keap1, thereby al-
lowing Nrf2 to stabilize and accumulate in the nucleus. Here, the Nrf2-dependent gene expres-
sion is triggered by binding of Nrf2 to the antioxidant response element ARE on the 5’ upstream 
DNA sequence. The phase II proteins encoded by the Nrf2/ARE-regulated genes are detoxifying 
proteins and enzymes controlling the redox status of the cell, possessing direct antioxidant activ-
ity and synthesizing endogenous reducing agents such as glutathione (GSH), regulators of apop-
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tosis, cell cycle and differentiation, heat shock proteins, regulators of immune response and in-
flammation and enzymes involved in cellular metabolism11-12 (Figure 3). 
 
Figure 3. The molecular mechanism of the redox-sensitive Keap1/Nrf2/ARE signaling pathway. Under basal 
conditions Nrf2 is inactivated by the chaperon protein Keap1 in the cytosol. α,β-Unsaturated carbonyl com-
pounds (α,β) can modify certain SH groups of cysteines of Keap1 covalently or by oxidation. This leads to a 
conformational change in Keap1, which dissociates from Nrf2. The free form of Nrf2 translocates into the 
nucleus where it binds to the antioxidant response element (ARE) on the DNA and triggers the expression of 
anti-inflammatory and cytoprotective proteins.  
The Keap1/Nrf2/ARE system acts as a master switch13 in the cellular redox stress response and 
mediates the cytoprotective signaling, especially by the induction of NAD(P)H:quinine oxido-
reductase 1 (NQO1), glutathione S-transferase (GST) and heme oxygenase-1 (HO-1). Due to its 
sensing mechanisms activated by a wide range of electrophiles and antioxidants of natural or 
synthetic origin, the Keap1/Nrf2/ARE system is raised to a promising target against the devel-
opment of several diseases, such as cancer, diabetes, neurodegenerative and cardiovascular dis-
orders involving inflammation and oxidative stress.14-17  
The nuclear factor-kappa B (NF-κB) is a major and ubiquitous transcription factor implicated in 
the immune and inflammatory responses through the regulation of genes encoding pro-
inflammatory cytokines (IL-1β, IFN-γ, TNF-α), adhesion molecules (ICAM-1), chemokines (IP-10, 
IL-8), growth factors (PEGF, VEGF) and inducible enzymes such as cyclooxygenase 2 (COX-2) 
and inducible nitric oxide synthase (iNOS). It consists of homo- and heterodimers of the Rel pro-
tein family (RelA (p65), RelB, cRel, p50 and p52) and is kept inactive in the cytosol through an 
association with an inhibitory protein of the IκB family (inhibitor of NF-κB). Following cell stim-
ulation, NF-κB is released, accumulating within the nucleus, binding to the 5’ downstream κB 
promoter region on the DNA and inducing the transcription of inflammatory genes. The activa-
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tion of NF-κB is mediated by the IκB kinase (IKK) complex, causing the phosphorylation of IκB 
followed by a proteasomal degradation. Electrophiles like α,β-unsaturated carbonyl compounds 
can inhibit the NF-κB pathway by reacting with specific SH groups of the cysteine residues of 
IKK, thus abolishing the NF-κB activation. Alternatively, they can directly modulate SH groups of 
cysteines of the NF-κB subunits, suppressing the DNA binding activity of the transcriptional fac-
tor and causing a down regulation of the protein expression of inflammatory proteins and cyto-
kines (Figure 4). 
 
Figure 4. Inhibition of the inflammatory NF-κB signaling pathway by electrophiles. NF-κB is kept inactive 
through an association with the inhibitor IκB. The activation of NF-κB is mediated by the IκB kinase (IKK) 
complex, causing the phosphorylation of IκB. Subsequently, NF-κB is released and binds to the κB promoter 
region on the DNA inducing the transcription of inflammatory genes. α,β-Unsaturated carbonyl compounds 
(α,β) can react with SH groups of the cysteines of IKK, thus abolishing the NF-κB activation. Alternatively, the 
DNA binding of the active NF-κB can be inhibited, which leads to a suppression of the protein expression of 
inflammatory proteins and a reduced immune response. 
The NF-κB pathway was shown to be activated by a wide range of stimuli including inflammato-
ry cytokines (TNF-α), endotoxins (lipopolysaccharide, bacteria, viruses), growth factors (TGF-
1β), reactive oxygen species (ROS), therapeutic drugs (Taxol, acetylsalicylic acid), environmental 
hazards (heavy metals, cigarette smoke) and several chemical agents. Although NF-κB is essen-
tial for normal T and B cell development in the cellular defense system and in the expression of 
stress response proteins (COX-2, iNOS), its dysfunction leads to various diseases such as athero-
sclerosis, multiple sclerosis, Alzheimer’s disease, inflammatory bowel disease, neuropathological 
and renal diseases, asthma, diabetes and cancer. The inhibition of the NF-κB pathway is there-
fore regarded as a potential therapeutic approach in inflammation and cancer.18-21  
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1.2 Heme oxygenase-1 (HO-1) 
1.2.1 Activity and induction of HO-1 
Heme oxygenase-1 (HO-1) is a redox sensitive, inducible stress protein converting heme to CO, 
Fe2+ and biliverdin (BV), which is further reduced to bilirubin (BR) by biliverdin reductase (BVR). 
These products are particularly important for the overall chemopreventive, chemoprotective 
and anti-inflammatory activities of HO-1 (Scheme 1). Biliverdin and bilirubin act as radical scav-
engers through their conjugated π-system that leads to a decrease of reactive oxygen species, 
ROS. CO is an inhibitor of proinflammatory heme-containing proteins such as inducible NO syn-
thase (iNOS) or cyclooxygenase-2 (COX-2) and the released iron (II) ion can induce the anti-
inflammatory protein ferritin. Finally, the breakdown of free heme itself can reduce oxidative 
damage, since heme acts as a promoter in the Fenton reaction.22-25  
 
Scheme 1. Heme degradation catalyzed by heme oxygenase-1 (HO-1) and biliverdin reductase (BVR) together 
with the resulting cytoprotective, anti-inflammatory and antioxidative effects.  
As a member of the cytoprotective phase II enzymes the transcription of HO-1 is mainly regulat-
ed by the Keap1/Nrf2/ARE signaling pathway.12 Amongst other stimuli of HO-1 induction such 
as UV light, heavy metals, oxidative stress,26 especially electrophiles like α,β-unsaturated car-
bonyl compounds can react with nucleophilic sulfhydryl groups of the Nrf2-complexing chaper-
on Keap1.27-28 Thereby the Nrf2 regulated antioxidant-responsive element (ARE) is activated 
which leads to a transcriptional induction of HO-1 (Figure 3). Other regulatory mechanisms of 
HO-1 gene induction have been discussed, such as the MAPK (mitogen-activated protein kinases) 
signaling pathway,29 several kinases24 and transcriptional factors, such as NF-κB and AP-1 (acti-
vator protein 1).30-31 However, the specific MAPK and/or other kinases involved in the HO-1 in-
duction appear to vary in an inducer- and cell-specific fashion.  
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1.2.2 HO-1 as therapeutic target 
The upregulation of heme oxygenase-1 has proved to be a useful tool to fight inflammation. The 
potent cytoprotective effects of HO-1 have been associated with therapeutic benefits in various 
pathological conditions such as systematic inflammation in response to infections (sepsis), 
asthma, oxidative lung injury (hyperoxia) and cardiovascular injury (hypertension, atheroscle-
rosis) as well as organ transplantation, ischemia and reperfusion.32 Moreover, evidence that oxi-
dative stress leads to chronic inflammation in HO-1 deficient mice33-34 and to an inflammatory 
syndrome35 in the first reported human to lack of HO-1 enzyme activity, supports the fact that 
the induction of HO-1 serves as an adaptive mechanism to protect against oxidative damage. In 
this respect, the development of anti-inflammatory, antioxidant and cytoprotective drugs based 
on their induction of HO-1 activity is a promising approach. 
1.2.3 Techniques for measuring HO-1 activity 
HO-1 activity has been measured using several techniques. HO assays that use gas chromatog-
raphy of carbon monoxide have been described.36-37 However, the most common HO-1 activity 
assay relies on the formation of bilirubin, which is in comparison to biliverdin the more stable 
downstream product. Since its formation from biliverdin by BVR is a lot faster than the initial 
HO-1 reaction, the amount of bilirubin per time corresponds directly to the HO-1 activity, as long 
as there is enough active BVR present. Another enzymatically active form of heme oxygenases, 
namely HO-2 is constitutively expressed and present only in very low amounts in most cell types, 
except for brain, liver, spleen and the testis.38 Thus, the determination of bilirubin has to be con-
sidered as the sum of HO-1 and HO-2 activity, which is expressed as the overall HO activity. 
The amount of bilirubin can be determined by quite a range of methods such as direct spectro-
photometric quantification at 468 nm39 or the difference in absorbance at 464 to 530 nm (ɛ464-530 
= 40 mM-1 cm-1),40 using the specific radioactivity of 14C-bilirubin,41 quantification by HPLC,42-43 
different fluorescence-based techniques,44-49 SERS Raman spectroscopy,50 LC-MS/MS quantifica-
tion with 13C-labeled bilirubin as tracer51 or by ELISA with specific anti-bilirubin antibodies.52 
Moreover, particularly when serum samples are analyzed, bilirubin is derivatized by diazo-
tization-based methods prior to its quantification,53 oxidation by bilirubin oxidase54 or a for-
mation bilirubin-zinc complexes was utilized.55  
In a heme oxygenase activity assay the bilirubin is formed in situ from the active protein, which 
originates from stimulated cell cultures or tissues of interest. By employing microsomal frac-
tions (100,000 g centrifugation precipitate) the amount of the membrane-bound proteins HO-1 
and HO-2 was elevated compared to the “normal” 20,000 g supernatant in tissue fractions,42, 56-57 
but a disadvantage of this method is that it cannot be scaled down to a microplate level on the 
centrifugation step. Variations of the HO-1 activity assay can be found throughout the literature, 
and many rely on the formation and the extraction/solubilization of bilirubin. Its solubility is 
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greatly enhanced in organic solvents, therefore mostly a chloroform extraction is used together 
with a spectrophotometric quantification58-59 or EtOH:DMSO 95:5 is added prior to an HPLC 
quantification.43 Based on the originally developed HO assay concept by Tenhunen,56 the typical 
assay components added to the 18,000 g supernatant are hemin, a NADPH-generating system60 
containing NADPH, glucose-6-phosphate, glucose-6-phosphate dehydrogenase and rat liver cy-
tosol prepared from a 100,000 g supernatant as a source of biliverdin reductase61-62 in buffer, pH 
7.4. HO activity was measured by this method in different cell types, including porcine58, 63 or 
bovine aortic endothelial cells,64-66 astrocytes,67 porcine renal epithelial proximal tubule cells 
and rat kidney epithelial cells68 as well as murine macrophages RAW264.7.69-70  
Despite these many examples, the extraction methods cannot easily be transformed into a plate 
assay. This makes them less attractive when many samples have to be analyzed at a time and a 
wider screening is targeted. One possibility to overcome this shortcoming is to ‘extract’ and ana-
lyze bilirubin at the same time by using the specific monoclonal anti-bilirubin antibody 24G7.71 
1.2.3.1 An-ELISA for bilirubin quantification 
The group of Izumi et al. developed an enzyme-linked immunosorbent assay (ELISA), using the 
anti-bilirubin antibody 24G7 and a second HRP-conjugated rabbit anti-mouse antibody to de-
termine unconjugated and conjugated bilirubin and also bilirubin derivatives. They could meas-
ure 10-7-10-5 mol L-1 of unconjugated and conjugated bilirubin in human serum samples. The 
assay results gave a good correlation coefficient (CC = 0.86) compared with the HPLC results.72  
 
Scheme 2. The bilirubin-ELISA procedure. (i) Samples containing bilirubin are incubated with an excess of 
specific anti-bilirubin antibody. (ii) The mixture is transferred to an immunoplate coated with a bilirubin-BSA 
conjugate (BR-BSA). (iii) Free, unbound anti-bilirubin antibodies are washed from the plate. (iv) A second 
HRP-conjugated antibody is added and allowed to bind to the anti-bilirubin antibody. (v) The HRP enzyme 
substrate is added to quantify the anti-bilirubin antibody bound to the immunoplate. 
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The bilirubin-ELISA is built as a non-competitive, indirect assay (Scheme 11). The sample con-
taining bilirubin (BR) is incubated with an excess of the specific anti-bilirubin antibody. The free 
unbound anti-bilirubin antibody is captured on an immunoplate coated with the bilirubin-BSA 
(BR-BSA)-conjugate and detected with a second horse radish peroxidase (HRP)-conjugated anti-
body. After adding the substrate solution containing ortho-phenylenediamine dihydrochloride 
(OPD) and H2O2, the reaction is stopped with H2SO4 and the absorbance of the yellow product 
can be measured at 492 nm. The intensity of the absorbance is proportional to the amount of 
anti-bilirubin antibody bound to the immunoplate, which is inversely proportional to the 
amount of bilirubin in the sample. 
The anti-bilirubin monoclonal antibody 24G7 was used in immunohistochemistry to study bili-
rubin IXα accumulation in atherosclerotic lesions of rabbit foam cells73 and the involvement of 
HO-1 activity in neuronal survival of kainate model rats.74 The ELISA method was used to meas-
ure an increased bilirubin level in cerebrospinal fluid in Alzheimer’s disease,75 to assess the an-
tioxidant activity of serum and urinary bilirubin oxidative metabolites76 and to examine the HO-
1 activity in oxidant-induced injury in cultured human airway epithelial cells.77 
1.2.4 Development of a HO-1 activity assay 
Because of the lack of a high throughput method to determine HO-1 activity to screen many po-
tential new HO-1 inducers, which could be used as lead structures for drug development, a sim-
ple and reliable cell line-based assay is needed. This can be achieved by developing a HO-1 activ-
ity assay, which can be used in a microtiter plate setting, applicable on non-microsomal fractions 
of cell lysates by combining the HO enzymatic reaction with the ELISA method determining the 
produced bilirubin in the sample. The purpose of the HO-1 activity assay is to screen for HO-1 
activity inducers in vitro in a feasible way by using a 96-well plate format for all steps of the as-
say, including cell culture, cell sample preparation, HO enzymatic reaction, protein determina-
tion and bilirubin quantification via ELISA. A concept of the HO-1 activity assay is shown in 
Scheme 3. As an in vitro model system, cells are cultured in a 96-well plate and incubated with 
the potential HO-1 inducers. Cell lysis is then performed in the same microtiter plate by using a 
mild and efficient cell lysis buffer containing a protease inhibitor cocktail and a detergent in or-
der to solubilize and stabilize the target proteins from degradation. Without further centrifuga-
tion step, the obtained whole cell lysate is transferred to a new microtiter plate and incubated 
with the HO enzyme reaction mixture consisting of hemin, biliverdin reductase (BVR) and 
NADPH. The final product of the HO and the BVR reaction, bilirubin, is then quantified by ELISA 
using the specific anti-bilirubin antibody 24G7 and a second HRP-conjugated antibody for detec-
tion.  
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Scheme 3. Concept of the HO-1 activity assay to screen for new HO-1 inducers in vitro. 
Finally, the total protein amount in the whole cell lysate is determined using a protein assay kit. 
Bilirubin amounts in samples are calculated from a bilirubin calibration curve carried out on 
each plate and HO activity is expressed as pmol bilirubin h-1 mg-1 total protein. For HO-1 activity 
determination, the HO activity of the cells stimulated with the test compound is compared to 
control cells incubated only with culture medium and expressed as x-fold HO-1 activity of con-
trol.  
1.2.4.1 Preliminary optimizations of the HO-1 activity assay 
First optimizations of the HO-1 activity assay were started in the diploma thesis (Hannelore 
Rücker, Universität Regensburg, October 2009)78 and were continued and further developed in 
the present work.  
As an in vitro model system, the human colon cancer cell line HT-29 was used to develop the HO-
1 activity assay. For this purpose HT-29 cells (1 · 105 cells/well) were incubated in a 96-well 
plate with potential HO-1 inducers in several concentrations for a maximum of 24 h and control 
cells were treated with culture medium alone. The cell lysis was performed in the 96-well plate 
and included two steps: i) cells were incubated with a concentrated lysis buffer (40 mM TRIS-
HCl, pH 7.4, 250 mM sucrose, 10 mM EDTA, 100 mM NaCl, 1% (v/v) SDS detergent, 4% protease 
inhibitor cocktail) on an orbital plate shaker for 15 min at 4 °C and ii) diluted with lysis buffer 
(without detergent and protease inhibitor) to a final detergent concentration of 0.05% in the cell 
lysate sample. Low concentrations of detergent in the lysis buffer (<0.1%) gave poor cell lysis 
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results. More importantly, higher concentrations of detergent (>0.05%) interfered with the pro-
tein detection when using the Bradford protein assay to give false positive results.  
For determining the HO activity, the whole cell lysates (10 µg protein/well) were incubated for 
1 h at 37 °C with the HO reaction mixture containing 25 µM hemin, 3 mM NADPH, 100 µg guinea 
pig liver cytosol extract prepared by ultracentrifugation as a source of biliverdin reductase in 
TRIS-HCl-sucrose buffer, pH 7.4. HO assay components based on the HPLC assay method devel-
oped by Ryter et al.43 The enzymatic reaction was stopped with a 1 M HCl aqueous solution and 
pH was then adjusted to 7.4 with 1.2 M NaOH aqueous solution. Here several stop solutions and 
procedures were screened and the HCl/NaOH procedure was found to be the best solution. Bili-
rubin standard solutions prepared in TRIS-HCl-sucrose buffer, pH 7.4 were added after the incu-
bation step to the HO reaction mixture containing only whole cell lysate and the liver cytosol 
extract. The bilirubin in the standards and the samples was then quantified with the ELISA 
method described by Izumi et al., which was slightly modified.52 Samples were incubated with 
the specific anti-bilirubin antibody (0.571 µg mL-1) and then the mixture was transferred on an 
immunoplate coated with a bilirubin-BSA conjugate (3.5 µg mL-1). Both parameters, the anti-
bilirubin antibody and bilirubin-BSA conjugate concentration were optimized. Next, the bound 
anti-bilirubin antibody on the immunoplate was incubated with a second HRP-conjugated anti-
body (0.2 µg mL-1) and then detected by adding the substrate OPD and H2O2. The reaction was 
terminated by a 3 M H2SO4 solution and absorbance was measured at 492 nm. Unknown biliru-
bin concentration in the samples was calculated by using the linear regression curve generated 
from the bilirubin standards (5-50 · 10-9 M bilirubin) on each plate. Finally, the protein amount 
in the whole cell lysate was determined using the Bradford protein assay. HO activity was ex-
pressed as pmol bilirubin h-1 mg-1 total protein. 
First results with the HO-1 activity assay were promising, but insufficient stimulation of HT-29 
with known HO-1 inducer compounds and a poor reproducibility of data were persistent. There-
fore, further troubleshooting and optimization of the HO-1 activity assay was aimed.  
Crucial for the assay is the cell lysis step which requires a more feasible one step procedure in 
the 96-well plate format by using a mild but sufficient detergent in the lysis buffer. Components 
of the lysis buffer, especially the detergent should not interfere with the protein detection or the 
ELISA. The use of a detergent compatible protein assay kit can avoid this problem and be also 
suitable for detecting small amounts of protein in the sample. Components of the HO enzymatic 
reaction and the reaction buffer should be suitable and sufficient to estimate the HO activity in 
the whole cell sample. The HO-1 activity assay should be applicable on different cell lines as 
in vitro model systems, as long as they are adherent. Also, the preparation of the test compound 
solutions for their incubation with the cells should be simplified to avoid compound precipita-
tion in the cell culture medium.  
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1.3 The activity of inducible nitric oxide synthase (iNOS) 
Nitric oxide (NO) is an ubiquitous key signaling molecule implicated in neurotransmission,79 
vasodilatation80 and regulation of the immune system.81 NO is produced by three isoforms of NO 
synthase, which are: endothelial NOS (eNOS), inducible NOS (iNOS), and neuronal NOS (nNOS). 
All isoforms contain heme as a prosthetic group and catalyze the reaction of L-arginine to 
L-citrulline using O2 and NADPH.82 The catalytic activity of the inducible NO-synthase is given in 
Figure 5.  
 
Figure 5. The enzymatic activity of the inducible nitric oxide synthase (iNOS). The amino acid L-arginine is 
converted to L-citrulline by the active iNOS dimer with heme as the prosthetic group, using oxygen and 
NADPH to produce NO.  
The function of the iNOS enzyme depends on its expression level, which is regulated by the 
proinflammatory NF-κB signaling pathway (Figure 4). iNOS, when induced in macrophages, gen-
erates large amounts of NO that has cytostatic or cytotoxic effects on parasitic or tumor target 
cells. This is caused by the high affinity of NO to protein-bound iron, thus inhibiting the catalytic 
centers of iron-sulfur cluster-dependent enzymes involved in mitochondrial electron transport, 
DNA replication (ribonucleotide reductase) or in the citric acid cycle (acotinase). Furthermore, 
NO and peroxynitrites (ONOO−), yielding from the reaction with superoxide radicals (O2•-) can 
directly interfere with the DNA of target cells and cause strand breaks and fragmentation. High 
levels of NO produced by activated macrophages may not only be toxic to parasites or tumor 
cells, but may also harm healthy cells, contributing to the pathophysiology of inflammatory dis-
eases and septic shock. In inflammation, hypertension and atherosclerosis increased reactive 
nitrogen species (NO, ONOO−) induce tyrosine nitration, oxidation of SH groups of cysteins and 
lipid peroxidation. Targeting nitrosative stress may represent a therapeutic potential in pathol-
ogies like Alzheimer's disease or cancer.83-84 The activity of iNOS can be inhibited on the tran-
scriptional level by inactivating the NF-κB pathway, were i.e. α,β-unsaturated carbonyl com-
pounds can react with key SH groups of cysteine residues of IKK or NF-κB and suppress the pro-
tein expression of iNOS and other proinflammatory enzymes as displayed in Figure 4. The pre-
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vention of the overproduction of NO through control of regulatory pathways may assist in the 
treatment of NO-mediated disorders without changing the physiological levels of NO.85 
1.3.1 The nitrite (Griess) assay 
The potential anti-inflammatory activity of α,β-unsaturated carbonyl compounds or other com-
pounds can be assessed by their ability to inhibit the iNOS activity causing a suppression in the 
NO production. iNOS activity can be determined by the quantification of nitrite, the more stable 
oxidation product of nitric oxide, using the Griess reaction in the so called nitrite assay.86 In the 
murine macrophage cell line RAW264.7, the NO synthesis can be induced by lipopolysaccharide 
(LPS), a bacterial wall constitute.87  
 
Figure 6. The Griess reaction is used to quantify the nitrite derived from the NO production in RAW264.7 
macrophages stimulated with lipopolysaccharide (LPS) in the nitrite assay. Under acidic conditions nitrite 
reacts with the amino group of sulfanilamide to form the diazonium cation, which couples to N-(1-
naphthyl)ethylenediamine (NED) in para-position to form the azo dye. 
Nitric oxide which oxidizes to nitrite and accumulates in the cell culture medium is quantified by 
the Griess reaction, which is a diazotization reaction followed by an azo coupling using sulfanil-
amide, N-(1-naphthyl)ethylenediamine (NED) and phosphoric acid (Figure 6). Under acidic con-
ditions the nitrite in the cell culture medium reacts with the amino group of sulfanilamide to 
form the diazonium cation, which couples to NED in para-position to form the corresponding 
azo dye, which absorbance can be measured at 560 nm. The NO production is quantified in LPS-
stimulated macrophages in the presence or absence of a test compound. Consequently, a poten-
tial inhibition of the NO production by the compound estimates its anti-inflammatory activity. 
1.4 The oxygen radical absorbance capacity-(ORAC)-fluorescein assay 
The radical scavenging activity of antioxidants can be determined by the cell free oxygen radical 
absorbance capacity-(ORAC)-fluorescein method generating peroxyl radicals from AAPH (2,2'-
azobis(2-methylpropionamidine) dihydro-chloride) as a free radical initiator and using fluores-
cein as a fluorescent probe.88 The protecting effect of an antioxidant, reacting as radical scaven-
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ger can be quantified by assessing the area under the fluorescence decay curve (AUC) of the 
sample compared to the blank, in which no antioxidant is present (Figure 7).  
 
 
 
 
 
 
 
Figure 7. ORAC-fluorescein assay. The fluorescence decay from the reaction of radicals generated from AAPH 
with fluorescein in the absence (blank) or presence of an antioxidant (sample) is measured over time. The net 
area under the fluorescence decay curve (net AUC) determines the antioxidant capacity of the test compound. 
 
Figure 8. Structures of fluorescein used as fluorescence probe and Trolox, a standard antioxidant in the ORAC-
fluorescein assay. 
From the curves (relative fluorescence intensity versus time) the area under the fluorescence 
decay curve (AUC) is calculated as 
            
     
   
 
Equation 1 
where f0 is the initial fluorescence reading at 0 min and fi is the fluorescence reading at time i. 
The net AUC corresponding to a sample is calculated by subtracting the AUC corresponding to 
the blank. Linear regression equations between net AUC and antioxidant concentration are de-
termined for all the samples and ORAC values are compared to Trolox, a water-soluble vitamin E 
(α-tocopherol) derivative (Figure 8). The final ORAC values are expressed as Trolox equivalents 
by using the standard curve determined for each assay.  
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1.5 Anti-inflammatory activity of a diverse group of α,β-unsaturated 
carbonyl compounds and polyphenols 
A structurally diverse group of natural products and synthetic compounds were investigated for 
their HO-1 induction behavior using the ELISA-based HO-1 activity assay in the model cell line 
RAW264.7. Known Nrf2 inducers possessing the α,β-unsaturated carbonyl moiety11 together 
with polyphenols which are also a prominent class of inducers of cytoprotective proteins16 were 
focused on for the screening. The following pharmacologically interesting compounds were ex-
amined (Figure 9.): the chalcones cardamonin,89-91 flavokawain A92 and xanthohumol,93-95 the 
flavonoids (-)-epicatechin,96-97 kaempferol98-101 and quercetin,102-103 three cinnamic acid deriva-
tives caffeic acid,104-105 chlorogenic acid104, 106-107 and CAPE,108-111 the isothiocyanate sulfo-
raphane28, 112-114 and the disulfide oltipraz,115-117 curcumin118 and 3-hydroxycoumarin,27, 119 the 
sesquiterpene zerumbone,120-121 rosolic acid,66 dexamethasone,89, 122 a synthetic glucocorticoid, 
and two compounds lacking the α,β-unsaturated carbonyl moiety resveratrol123-124 and 
carnosol,125-126 a diterpene with a catechol unit.  
The mechanism by which these compounds lead to a HO-1 induction is commonly by activating 
the Keap1/Nrf2/ARE pathway. Although the Nrf2 inducers are from distinct chemical classes, 
comprising diphenols, quinones, Michael acceptors and isothiocyanat, all have in common that 
they are electrophiles and can covalently modify thiol groups on Keap1 by alkylation or oxida-
tion. The activation of the transcriptional factor Nrf2 that binds to the ARE and promotes the 
phase II protein expression, is mediated by a direct reaction with thiol groups of the suppressor 
protein Keap1 as shown for sulforaphane,127 zerumbone128 and xanthohumol.129 Certainly, there 
are also other indirect mechanisms, which lead to activation of the Nrf2/ARE pathway and thus 
to HO-1 induction, involving the activation of kinase pathways which phosphorylates Nrf2 and 
Keap1. The involvement of protein kinase in Nrf2 activation was suggested for resveratrol,130 
curcumin131 and carnosol.132  
A HO-1 induction on mRNA, protein or enzyme activity levels were shown for most of the biolog-
ically active compounds in different cell and tissue types, summarized in Table 1. No HO-1 induc-
tion tests have been described for 3-hydroxycoumarin, oltipraz, cardamonin and flavokawain A. 
Since the HO-1 inductive activity is known for some compounds, the screening aimed also at the 
establishment and validation of the ELISA-based HO-1 activity assay as a simple and reliable 
screening method for HO-1 activity. 
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Figure 9. Structures of biologically active natural compounds and synthetic drugs screened in the ELISA-based 
HO-1 activity assay.  
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Table 1. HO-1 inducer activity of natural products and synthetic drugs. 
Compound 
(Dose) 
Mechanism of HO-1 induction Model cells or mam-
malian 
Ref. 
Xanthohumol 
2-10 µM 
 
induction of HO-1 mRNA and HO-1 protein level in 
normal hepatocytes (THLE-2) by activation of Nrf2; 
no HO-1 induction was observed in carcinoma 
hepatocytes HepG2 
 
human hepatocytes, 
THLE-2 and HepG2 
 
133 
 
CAPE 
15-50 µM 
5-30 µM 
20 µM 
 
increase of HO-1 protein expression and HO-1 activ-
ity  
increase of HO-1 protein expression and HO-1 activ-
ity by binding of Nrf2 to ARE 
HO-1 mRNA an protein expression induction 
 
DI TNC1 rat astrocytes 
LLC-PK1 renal epithelial 
cells  
HUVEC, human vascu-
lar endothelium cells 
 
67 
68 
134 
Carnosol 
10 µM 
 
increase of HO-1 mRNA and protein expression by 
binding of Nrf2 to ARE, activation of ERK, p38 
MAPK and JNK 
 
PC12 rat pheochromo-
cytoma 
 
135 
(-)-Epicatechin 
50 µM 
 
induction of HO-1 and Nrf2 protein expression 
 
ARPE-19 human retinal 
pigment epithelial cells  
 
136 
Curcumin 
15-50 µM 
5-30 µM 
5-15 µM 
200 mg kg-1 
15 µM 
 
increase of HO-1 protein expression and HO-1 activ-
ity  
increase of HO-1 protein expression and HO-1 activ-
ity by binding of Nrf2 to ARE 
increase of HO-1 mRNA, HO-1 protein expression 
and HO-1 activity 
HO-1 expression and activity in liver, DNA binding 
of Nrf2-ARE in liver 
increase of HO-1 mRNA expression by binding of 
Nrf2 to ARE, activation of PKC-δ and p38 MAPK 
 
DI TNC1 rat astrocytes 
LLC-PK1 renal epithelial 
cells  
bovine aortic endothe-
lial cells 
male Albino rats 
THP-1 human mono-
cytes 
 
67 
68 
65 
137 
131 
Kaempferol 
100 µM 
 
increase of HO-1 mRNA and protein expression 
 
RAW264.7 murine 
macrophages 
 
138 
10-100 µM increase of HO-1 mRNA expression RAW264.7 murine 
macrophages 
139 
10 µM induction of HO-1 protein expression by activation 
of Nrf2 and JNK 
HEI-OC1, auditory mice 
cells 
140 
Quercetin    
100 µM increase of HO-1 mRNA and protein expression RAW264.7 murine 
macrophages 
138 
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Compound 
(Dose) 
Mechanism of HO-1 induction Model cells or mam-
malian 
Ref. 
30 µM increase of HO-1 protein expression microglial BV2 cells 141 
100 µM induction of HO-1 activity and Nrf2 activation EtOH-treated human 
hepatocytes isolated 
from liver cancer pa-
tience 
142 
50 µM induction of HO-1 and Nrf2 activation ARPE-19 human retinal 
pigment epithelial cells 
136 
Resveratrol    
15 µM induction of HO-1 mRNA and protein expression by 
activation of Nrf2/ARE and ERK 
PC12 rat pheochromo-
cytoma 
130 
1-10 µM induction of HO-1 mRNA and protein expression via 
NF-κB activation 
human aortic smooth 
muscle cells  
143 
5-100 µM increase of HO-1 protein expression cortical neuronal mice 
cells 
144 
5-100 µM increase of HO-1 mRNA, no induction of HO-1 pro-
tein expression, reduction of HO-1 activity 
DI TNC1 rat astrocytes 145-
146 
Rosolic acid    
15 µM induction of HO-1 protein expression and HO-1 
activity 
bovine aortic endothe-
lial cells 
66 
Zerumbone    
1-25 µM induction of HO-1 expression and activation of 
Nrf2/ARE 
RL34 rat liver epithelial 
cells 
147 
10 µM induction of HO-1 mRNA and protein expression by 
a Nrf2/ARE dependent pathway 
JB6 Cl41 mouse epi-
dermal cells and mouse 
skin from female hair-
less mice 
128 
Sulforaphane    
0.1 µM induction of HO-1 protein expression rat aortic smooth mus-
cle cells 
148 
20 µM induction of HO-1 protein expression and activation 
of Nrf2/ARE 
HepG2 human hepato-
cytes 
149 
Dexamethasone    
5 µM induction of HO-2 mRNA, protein expression and 
HO activity, no HO-1 mRNA induction observed  
HeLa, human cervix 
cancer cells  
150 
0.5-50 µg mL-1 suppression of HO-1 mRNA in cytokine-stimulated 
cells 
rat astroglial cells 151 
1 µg mL-1 no induction of HO-1 activity GT1-7 hypothalamic 
neurons 
152 
1.2 mg kg-1 suppression of HO-1 protein expression and HO-1 
activity in LPS stimulated macrophages 
alveolar macrophages 
of chronic bronchitis 
model rats 
 
 
 
153 
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Compound 
(Dose) 
Mechanism of HO-1 induction Model cells or mam-
malian 
Ref. 
Caffeic acid 
   
20 µM no HO-1 induction observed HUVEC, human vascu-
lar endothelium cells 
134 
150 µM no HO-1 mRNA induction bovine aortic endothe-
lial cells 
154 
Chlorogenic 
acid 
   
150 µM no HO-1 mRNA induction bovine aortic endothe-
lial cells 
154 
1.6 Reactivity and biological activity of natural and synthetic 
chalcones 
1.6.1 Reactivity of chalcones 
Chalcones (1,3-diphenylprop-2-en-1-ones) are a diverse group of naturally occurring plant me-
tabolites that can be regarded as open-chain flavonoids, where the two aromatic rings are 
bridged by an α,β-unsaturated carbonyl moiety possessing a Michael acceptor reactivity. 
Chalcones can be regarded as bifunctional antioxidants: i) they possess a distinct Michael accep-
tor reactivity, due to the α,β-unsaturated carbonyl moiety, allowing them to interact with reac-
tive SH-groups on “sensor” proteins involved in cytoprotective and also in inflammatory signal-
ing pathways, (Scheme 4, pathway A) and ii) the α,β-unsaturated carbonyl moiety itself and ad-
ditional phenolic hydroxy groups on the aromatic rings can react as radical scavengers (Scheme 
4, pathway B) or antioxidants due to their reduction potential (Scheme 4, pathway C).4, 155-156  
 
Scheme 4. General structure and reactivities of chalcones. 
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Several structural and electronic characteristics of chalcones influence the reactivity of the Mi-
chael acceptor moiety and thus the potential biological activity of chalcones. Aromatic OH-
groups display a positive resonance effect (+M effect), due to the free electron pairs on the oxy-
gen atom, which contributes to the conjugated aromatic π-electron system and further to the 
α,β-unsaturated carbonyl moiety of the chalcone. However, when deprotonated, hydroxylates 
are present in the chalcone, which is to a certain degree possible under physiological conditions 
(pKA (phenol) = 10). In this case the strong resonance effect is pushing electrons into the conju-
gated π-electron system of the chalcone resulting in a more electron rich α,β-unsaturated car-
bonyl unit, which leads to a reduced electrophilic character and therefore to a weaker Michael 
acceptor reactivity towards nucleophiles. If methoxy groups are present on the aromatic rings of 
the chalcone, the resonance effect is weaker compared to hydroxylates, due to the alkylation. 
The position of the hydroxy and methoxy groups on the aromatic ring plays an important role 
and can influence the reactivity of chalcones in a tremendous way. As proven in several 
studies,27, 66, 157 the 2’-hydroxy group is essential for the Michael acceptor reactivity of chalcones, 
due to the intramolecular H-bond which activates the carbonyl group. Furthermore, the H-bond 
of the 2’-OH group contributes to a stabilized conjugation in the π-system. Generally, a replace-
ment of a more electron donating OH group by a methoxy in the A- or B-ring restores the reac-
tivity of the chalcone. Moreover, since the double bond of the Michael acceptor functionality can 
be referred to as a push-pull double bond, an exchange in the B-ring restores more reactivity 
compared to a similar exchange in the A-ring. Methoxy groups in 3 or 4-position on the B-ring 
and 4’-position on the A-ring can contribute to a stabilization of the conjugated π-system. A loss 
in reactivity can occur when OMe groups are present in 2 or 6-position on both rings, due to 
steric hindrance, which can hamper the nucleophilic attack on the β-position of the α,β-
unsaturated carbonyl moiety or destabilize the conjugation of the π-system.  
2’-Hydroxychalcones can readily isomerize to flavanones through an intramolecular Michael 
addition, leading to a loss of the functional group and thus altering the reactivity of the chalcone 
under biological conditions. This important effect was recently investigated by the group of Pauli 
under several biological conditions typical for cell-based assay systems using the chalcone 
isoliquiritigenin (ISL).158 Also significant for the reactivity and thus biological activity of 
chalcones acting as a Michael acceptors is the stability of the thiol adduct. Here, electron donat-
ing groups like OMe, can decrease the acidity of the α-hydrogen, slowing down the retro-Michael 
reaction. A balanced activation of the Michael acceptor unit and stabilization of the resulting 
adduct is therefore crucial for the overall reactivity of chalcones.157  
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1.6.2 Reactivity assessment of chalcones by a kinetic thiol assay 
In order to predict the biological activity of electrophiles based on thiol-mediated regulation 
processes, a kinetic assay for the assessment of the second rate constant k2 in thia-Michael addi-
tions was developed in our group. The chemical reactivity of hydroxy-alkoxychalcones was re-
cently determined using the kinetic thiol assay for the thia-Michael addition reactions with the 
S-nucleophile cysteamine (Figure 10).159  
 
Figure 10. Michael addition reaction of natural and synthetic chalcones with the S-nucleophile cysteamine. k2 
is the second order rate constant of the addition reaction. 
Reactions were carried out in 100 mM TRIS-HCl pH 7.4, 2 mM EDTA/ethylene glycol 20:80, 25 °C 
under pseudo-first order conditions at concentrations of 40 µM for chalcones and 12 to 500 fold 
cysteamine. The calculated thia-Michael addition reaction rate was displayed as k2 value in M-1 s-
1. Hydroxy- and methoxychalcones gave quite different reactivities in the Michael additions of 
thiols, with k2 values in the range of 5.08 - 0.193 M-1 s-1, displaying an overall good electro-
philicity. The results showed that a 2’-OH group on the A-ring is essential for the reactivity of the 
chalcones. Not only electronic effects, but also steric effects can influence the Michael acceptor 
reactivity. One aspect is the conformation of the conjugated system determined by the dihedral 
angel between the two aromatic rings, which is in term influenced by the substituents present 
on the aromatic rings of the chalcone. A fairly flat chalcone (as shown by X-ray structures) dis-
plays generally a higher reactivity, due to a stabilized conjugation of the π-system compared to a 
chalcone where the aromatic rings are twisted.  
1.6.3 Biological activity of chalcones 
In the present study, the plant chalcones isoliquiritigenin (ISL), butein, calythropsin, 2’,3,4’-
trihydroxy-4-methoxychalcone (THMCH) and 2’,4’-dihyxdroxy-3,4-dimethoxychalcone 
(DMDHCH) and the synthetic chalcones 2’-hydroxychalcone, chalcone, 2’-hydroxy-3,4,4’-
trimethoxychalcone (HTMCH) and 2’,3,4,4’-tetramethoxychalcone (TMCH) were selected (Figure 
11) to investigate their anti-inflammatory and antioxidative activity in RAW264.7 murine mac-
rophages. 
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Figure 11. Structures of natural and synthetic chalcones investigated in this study towards their in vitro anti-
inflammatory and antioxidative activity.  
Synthetic and natural hydroxy- and methoxychalcones are of particular interest as they display a 
wide range of biological properties and exert diverse pharmacological activities including anti-
inflammatory, antifungal, antibacterial, antiviral, antimitotic, antitumor, antituberculosis and 
antimalarial.160 The importance of chalcones as pharmacologically active compounds is closely 
connected to their Michael acceptor reactivity and antioxidant potential, by which they can ad-
dress and affect multiple targets in the cell. By addition to reactive thiol groups on the surface of 
sensor proteins or transcriptional factors, chalcones can trigger the anti-inflammatory and 
cytoprotective Keap1/Nrf2/ARE signaling pathway and on the other side inhibit the pro-
inflammatory pathway regulated by NF-κB.161 In case of the synthetic chalcone 3,3’,4,4’,5,5’-
hexamethoxychalcone, a Nrf2-dependent HO-1 induction as well as a NF-κB down regulation 
was shown.162 The anti-inflammatory chalcone butein was found to be an inhibitor of IKK by 
direct binding on its cysteine residue 179, through which it blocks NF-κB and NF-κB-regulated 
gene products.163 Lee et al. reported the inhibitory effect of butein on NO production, iNOS gene 
expression and NF-κB activity in LPS-stimulated murine macrophages RAW264.7 cells.164 Stud-
ies have also shown that butein induces HO-1 mRNA and protein expression in rat liver cells165 
and that it prevents oxidative damage in human dental pulp cells by inducing HO-1 protein ex-
pression and activity via a Nrf2 dependent pathway.166 The radical scavenging properties of 
butein was investigated towards DPPH and ABTS radicals.167 Chalcone exerts its anti-
inflammatory activity by inhibiting the activation of NF-κB and inducing the HO-1 protein ex-
pression, which is accompanied by an up regulated level of Nrf2 in the nucleus and an increased 
ARE activity in bovine aortic endothelial cells. Furthermore, the overall cytoprotective activity of 
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chalcone may be mediated through a direct modification of cysteine thiol groups on target pro-
teins and regulated by the intracellular GSH level.168 The chemopreventive activity of chalcone 
was shown by its inhibitory effect against pulmonary and mammary carcinogenesis when given 
after carcinogen administration to female rats.169 2’-Hydroxychalcone was found to induce HO-1 
protein expression as well as enzyme activity in RAW264.7 cells69 and bovine aortic endothelial 
cells.66 Additionally, 2’-hydroxychalcone promoted its anti-inflammatory activity in RAW264.7 
cells by reducing iNOS expression, NO production and TNF-α release.69 Isoliquiritigenin (ISL), a 
plant constituent from Dalbergia odorifea (Leguminosae) and Glycyrrhiza uralensis (licorice), has 
been reported to posses estrogenic,170 neuroprotective,171 hepatoprotective,172 anticancer173-175 
and anti-inflammatory activity.176-177 Furthermore an induction of HO-1 expression was reported 
in RAW264.7macrophages178 and rat hepatic stellate cells.179 ISL is a major inducer of quinine 
reductase and activates the ARE.180 The antioxidant and chemoprotective actions of ISL was 
shown in cerebral ischemia model rats, where ISL treatment protected against depletion of anti-
oxidant proteins (superoxide dismutase, catalase and glutathione peroxidase) caused by free 
radical formation.181 The chalcone calythropsin, firstly isolated from Calythropsis aurea was 
found to possess weak antimitotic activity due to its cytotoxic effect.182 Furthermore, 
calythropsin extracted from Faramea salicifolia displayed cytotoxicity against several human 
cancer cell lines.183 DHDMCH and THMCH are abundant in Iryanthera polyneura (Myristicaceae) 
and were isolated 1979 from the trunk of the tree. It is known that Maku Indians of South Amer-
ica use crushed leaves from this tree to treat infected wounds and cuts.184 The chalcone THMCH 
revealed a moderate cytotoxicity against several human tumor cell lines, especially against 
Jurkat cells and was also found to exert an impressive antiproliferative activity against the Jurkat 
cell cycle.185 No anti-inflammatory activity was reported for the naturally occurring calythropsin, 
DHDMCH and THMCH.  
Chalcones possess an unique capability to address certain cysteine residues, which qualify them 
as a valuable tool to modulate biological activity. Several natural and synthetic hydroxy- and 
methoxychalcones were characterized towards their anti-inflammatory and antioxidative activi-
ty, demonstrated by their induction of HO-1 activity and inhibition of NO production in 
RAW264.7 macrophages and also by their radical scavenging capacity in the ORAC assay. A 
structure-activity relationship can be assessed, due to the diverse substitution pattern of 
hydroxy and methoxy groups in 2’,3,4,4’-positions of the two aromatic rings, influencing not only 
the Michael acceptor reactivity but also the overall anti-inflammatory and antioxidative proper-
ty of the chalcone. Furthermore, the chemical reactivity of the chalcones determined by the ki-
netic thiol assay in thia-Michael additions159 was compared to their estimated biological activity. 
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1.7 α-X-Modified enones as a different approach in fine-tuning their 
Michael acceptor reactivity and biological activity 
A promising approach using α,β-unsaturated compounds for the development of new potent 
cytoprotective, chemopreventive and anti-inflammatory drugs is to systematically modify the 
α-position of the α,β-unsaturated carbonyl moiety thus influencing the Michael acceptor reactiv-
ity and the biological activity. Examples of such α-modifications leading to a fine-tuned biological 
activity are found within the class of pentacyclic triterpenoids CDDO186-187 and also among the 
chalcones.188  
1.7.1 α-X-Modification in 2’,3,4,4’-tetramethoxychalcones (α-X-TMCHs) 
In order to manipulate the reactivity of chalcones either a change directly at the Michael system 
or on the aromatic rings, as seen in the chapter before, can be made. The approach of modifying 
the α-position of the α,β-unsaturated carbonyl system is a promising concept, because it should 
lead to a direct and straightforward influence on its reactivity.4 Modified chalcones in α-position 
and their biological studies are known for chalcones with X = halogen,188-189 aromatic,190-191 al-
kyl,189, 192-193 COOEt,188 COOH,194 CN188 and alkoxy.193 But there is no fine-tuning-of-reactivity-
approach, particularly on a chalcone scaffold, which investigates a clear influence of different 
α-X-substituents on the activity in different biological settings. The natural product-like 2’,3,4,4’-
tetramethoxychalcone, TMCH was chosen as a scaffold for a diverse library of α-X-TMCHs, pos-
sessing no free hydroxy groups, so that possible oxidative pathways altering the biological re-
sponse can be excluded. The α-X-TMCHs used in this work were synthesized in our group by 
Nafisah Al-Rifai. As shown in Figure 12, thirteen distinct substituents were introduced in the α-
position of the Michael system along with the α-H-TMCH, where the chalcones were obtained as 
two different double bond isomers. The synthetic approach of the chalcones together with their 
chemical reactivity and their biological evaluation were published recently.195 
 
Figure 12. Structures of α-X-TMCHs tested for their in vitro anti-inflammatory and antioxidative activity. 
For a broad range of reactivity, different electron withdrawing and electron donating substitu-
ents for the α-position were chosen. The more electron withdrawing groups like CN, NO2, CF3 or 
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halogens should increase the electrophilicity of the chalcones, whereas the Ph and Me groups 
should deactivate the Michael acceptor system towards nucleophiles. The Michael acceptor ac-
tivity of the α-X-TMCHs was tested in our group by Nafisah Al-Rifai and Sabine Amslinger via the 
thiol assay (see chapter ‎1.6.2). The reaction constants k2 of the thia-Michael additions to 
cysteamine and thus the electrophilic potential of the α-X-TMCHs are displayed in Table 2. As 
expected, the more electron withdrawing groups CN, NO2, CF3, Br and Cl are increasing the reac-
tivity, in the case of α-CN-TMCH even in a tremendous way, namely more than 6 orders of mag-
nitude when compared with α-COOH-TMCH, the chalcone with the lowest observed reactivity. 
The Me and Ph group along with the COOH group, which is supposed to be deprotonated under 
physiological conditions, reduced the activity compared to α-H-TMCH. Interestingly, the most 
electron negative halogen, α-F-TMCH, acts deactivating on the Michael acceptor reactivity, sug-
gesting that in this case the resonance effect overrules the inductive effect of the halogen.  
Table 2. Results of the kinetic measurements of α-X-TMCHs with cysteamine determined in our group.195  
 
α-X-chalcone k2[a] [M-1s-1] Rel. rate[b] 
CN 5750 ± 130 1,600,000 
NO2 749 ± 9.0 200,000 
CF3 17.1 ± 1.8 4,600 
Br 2.89 ± 0.08 780 
Cl 1.65 ± 0.02 450 
p-NO2-C6H4 0.293 ± 0.025 79 
I 0.282 ± 0.015 76 
COOEt 0.281 ± 0.029 76 
H 0.193 ± 0.019 52 
F 0.0168 ± 0.00035 4.5 
p-OMe-C6H4 0.00856 ± 0.0013 2.3 
Me 0.00750 ± 0.00039 2.0 
Ph 0.00669 ± 0.00029 1.8 
COOH 0.00371 ± 0.000060 1.0 
[a] Reactions were carried out in 100 mM TRIS-HCl pH 7.4, 2 mM 
EDTA/ethylene glycol 20:80, 25 °C under pseudo-first order condi-
tions at concentrations of 40 µM for chalcones (80 µM for NO2 and 
CF3) together with 12 to 500 fold cysteamine; [b] k2 relative to k2 
(COOH). 
Steric effects can also play a crucial role in the reactivity of the chalcones, overcompensating the 
electronic effects of the α-substituents. This can be observed for the less reactive α-I-TMCH 
compared to α-Br-TMCH or α-Cl-TMCH, for example, where the bulky iodo-substituent forces the 
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carbonyl group and the A ring of the chalcone out of the plane, leading to a reduced conjugation 
of the π-electron system as seen in the corresponding X-ray structure.195 The quite distinct 
electrophilicity of α-X-TMCHs as shown in the kinetic assay makes them to excellent structures 
for a biological evaluation. Therefore, based on these results, the α-X-TMCHs were investigated 
for their ability to induce the anti-inflammatory and cytoprotective enzyme HO-1 on protein and 
activity level, using the HO-1 activity assay and Western blot analysis. On the other hand, their 
ability to inhibit the pro-inflammatory protein iNOS and thus the production of NO was tested 
via the Griess assay in the murine macrophage cell line RAW264.7. The cytotoxic concentrations 
of the compounds tested first in the MTT assay were excluded in the activity assays.  
1.7.2 Limno-CP and its α-X-Limno-CP derivatives 
Limophila geoffrayi is a plant used in the traditional medicine of Thailand for detoxification.196 
Inspired by the plant ingredient limnophilaspiroketone, the model compound Limno-CP was 
chosen as a scaffold for a library of α-modified derivatives (α-X-Limno-CPs, Figure 13). It is 
known that 3(2H)-furanones display a rather weak Michael acceptor activity,197 which makes 
them an ideal skeleton to start modifications from. Different substituents were introduced in the 
α-position of the 3(2H)-furanone unit in order to systematically influence the potential Michael 
acceptor based biological activity of these compounds.198  
 
Figure 13. Model compounds α-X-Limno CPs derived from limnophilaspiroketone. 
The α-X-Limno-CPs were synthesized by Simon Lindner in our group.199 Two sets of compounds 
were prepared, one bearing the isopropyl protected phenolic group (i-Pr-α-X-Limno-CP ) and 
the second set with the free phenolic group (α-X-Limno-CP). It could be demonstrated that the α-
modifications have a significant effect on the 13C NMR chemical shifts of the β-carbon as the reac-
tive center of the Michael system, comprising chemical shifts of 184 ppm for α-H Limno-CP up to 
167 ppm for α-F-Limno-CP and down to 185 ppm for α-CN-Limno-CP.198 Based on the 13C NMR 
chemical shifts the Limno-CP derivatives have been considered as moderate Michael acceptors, 
which could be useful in addressing reactive SH groups on specific protein targets. Additionally, 
a potential antioxidative activity can be addressed to the phenolic group on the enone unit. 
Therefore the α-X-Limno-CP compounds were tested towards their anti-inflammatory activity in 
the Griess assay and their antioxidant capacity in the ORAC-fluorescein assay. 
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1.8 The anti-inflammatory activity of both enantiomers of arteludo-
vicinolide A  
Artemisia (Asteraceae) are widely abundant plants playing a special role in the Chinese folk 
medicine.200 First isolated in 1991 from the aerial parts of Artemisia ludoviciana,201 the sesqui-
terpene lactone arteludovicinolide A displays anti-inflammatory activity, demonstrated by the 
inhibition of NO production in LPS activated RAW264.7 macrophages.202 One important struc-
tural feature of the natural product is the α-methylene group on the lactone unit, which is part of 
one of the two Michael acceptor moieties present in the compound. The second Michael acceptor 
functionality is part of the cyclopentenone ring and was found to play an important role in the 
biological activity of such sesquiterpenes.203 The electrophilicity and thus the reactivity towards 
SH-nucleophiles of these two Michael acceptor units is to a certain degree restricted, due to: i) 
the sterical hindrance of the methyl group in β-position of the α,β-unsaturated carbonyl com-
pound on the cyclopropenone ring, and ii) the ester group on the lactone ring deactivating the 
potential Michael acceptor activity. However, the free exo-methylene group should favor the 
attack of a nucleophile on the β-position. Taken together, all these special structural features 
may contribute to a distinct biological activity of these sesquiterpenes.  
 
Figure 14. Structures of both enantiomers of arteludovicinolide A and a derivative lacking the exo-methylene 
group of the lactone ring, which were tested for their anti-inflammatory activity in murine macrophages 
RAW264.7. 
The naturally occurring (+)-arteludovicinolide A, along with the synthetic (-)-enantiomer and a 
derivative of the former, lacking the exo-methylene group on the lactone ring, de-exo-methylene-
(+)-arte A (Figure 14) were synthesized by Andreas Kreuzer (research group of O. Reiser, 
Universität Regensburg)204 and investigated in this work towards their cytotoxic and anti-
inflammatory activity in murine macrophages RAW264.7. The synthesis of compounds together 
with their biological investigations were published recently.205 
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1.9 Enzyme-triggered CO-releasing molecules (ET-CORMs) 
Carbon monoxide (CO) is an important biological signaling molecule and is envisioned as a ther-
apeutic agent because it exerts cytoprotection, vasodilatory and anti-inflammatory properties.206 
CO can influence the activity of the proinflammatory enzyme inducible NO-synthase (iNOS). On 
the transcriptional level, CO can inhibit the activation of the transcription factor NF-κB and thus 
the protein expression of iNOS.85 On the protein level, CO can block the formation of the active 
iNOS dimer207 or bind to the iron on the heme prosthetic group of iNOS and inhibit its catalytic 
activity to produce NO (Figure 15).208 
 
Figure 15. Potential regulation of CO of transcription and protein activity of inducible NO-synthase (iNOS). 
Activation of transcriptional factor NF-κB can be induced by lipopolysaccharide (LPS). 
The use of gaseous CO is however risky and limited, due to its low bioavailability, its high affinity 
to hemoglobin causing hypoxia and the inhibition of the mitochondrial electron transport chain 
resulting in a breakdown of the energy supply. To overcome these problems a new strategy was 
developed, using CO releasing molecules (CORMs) that ensure a controlled delivery of CO direct-
ly to the tissue.209 The first generation of CORMs comprised transition-metal carbonyl complexes, 
while many efforts were made concerning the stability, the water solubility and the CO-release 
under physiological conditions, for a possible application of CORMs in medicine.210 Together 
with the group of H.-G. Schmalz (Universität zu Köln) a new concept was established for enzyme-
triggered CO-releasing molecules (ET-CORMs) based on acyloxydiene-Fe(CO)3 complexes, 
(Figure 17), which were characterized towards their toxicity and inhibition on NO production by 
Birgit Kraus (research group of J. Heilmann, Universität Regensburg) and Sabine Amslinger.211-
212 Further modifications towards water soluble phosphorester-based ET-CORMs were accom-
plished.213 The idea is that upon enzymatic ester cleavage in the cell, the obtained (hydroxycyclo-
hexadiene)Fe(CO)3 complexes subsequently decompose under oxidative conditions to give the 
enone ligand, an Fe3+ ion and three CO molecules (Scheme 5).  
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Scheme 5. Proposed mechanism of action displayed by phosphorester-based enzyme-triggered CO-releasing 
molecules (ET-CORMs).213 The phosphatase-catalyzed cleavage of the phosphorester gives the (hydroxy-
cyclohexadiene)Fe(CO)3 complexes as intermediates, which decompose under oxidative conditions to the 
enone ligand, a Fe3+ ion and three CO molecules. 
As part of a collaboration with the group of H.-G. Schmalz, the biological activity of two ET-
CORMs, rac-17 and rac-18, (Figure 16), which displayed a reasonable water solubility and were 
able to release CO on activation by different acid phosphatases, was investigated in the murine 
macrophage cell line RAW264.7 towards their toxicity and inhibition of LPS induced NO produc-
tion.  
 
Figure 16. Structures of phosphorester-based ET-CORMs tested towards their anti-inflammatory activity.  
The enzyme-triggered decomposition of ET-CORMs releases not only CO and free iron (III) ions 
but also the cycloenone ligand, which can further decompose and exert an anti-inflammatory 
activity or even higher cytotoxicity. Consequently, the overall biological activity of ET-CORMs 
may not only be contributed to the release of CO alone but also to the decomposition products or 
a combination of both. In our recent study, the possible degradation product 2-cyclohexenone, 
obtained upon decomposition of acyloxycyclohexadiene-Fe(CO)3 was shown to strongly contrib-
ute to the overall activity of the monoester complexes of ET-CORMs, demonstrated by a signifi-
cant inhibition of NO production of 2-cyclohexenone in RAW264.7 macrophages.212 
In order to investigate an influence of the possible degradation products on the biological re-
sponse of ET-CORMs, some more phenolic and cyclohexanone derivatives 1-5 (Figure 17) were 
tested towards their toxicity and inhibition of NO production.  
29 
 
 
Figure 17. Structures of possible decomposition products (1-5) of mono- or diesters of acyloxydiene-Fe(CO)3 
complexes of potential ET-CORMs. 
Also a possible involvement of the free ions Fe2+ and Fe3+ on the biological activity of ET-CORMs 
was tested, since it was shown that Fe3+ inhibited NOS activity in LPS-treated murine macro-
phages J774A.1 by controlling its nuclear transcription214 and that Fe2+ ions reduce NO in pa-
tients suffering from ACE inhibitor-induced cough.215 
1.10 Aim of this study 
This work is aimed to characterize and evaluate several natural and synthetic α,β-unsaturated 
carbonyl compounds towards their anti-inflammatory and antioxidant properties in vitro. Using 
the murine macrophage cell line RAW264.7, a reliable and sensitive ELISA-based HO-1 activity 
assay was established in order to screen for new anti-inflammatory and cytoprotective HO-1 
activity inducers, useful as lead structures for drug development. The concept of modulating the 
Michael acceptor reactivity by introducing different substituents in α-position of the α,β-
unsaturated carbonyl moiety in model compounds leading to a fine-tuned biological activity was 
assessed in different biological settings including: i) their inductive effect on the HO-1 activity 
determined by the established HO-1 activity assay, ii) their inhibitory effect on the NO produc-
tion in RAW264.7 macrophages stimulated with LPS and measured by the Griess assay and iii) 
their antioxidant capacity and radical scavenging properties using the cell-free ORAC-fluorescein 
assay.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Cell lines 
For this study the murine macrophage cell line RAW264.7 was used, a kind gift from T. Grune 
(Humboldt Universität Berlin). The cell line was established from murine tumors induced with 
Abelson leukemia virus.216 A second cell line used in this work was the human colon cancer cell 
line HT-29, firstly isolated from primary colorectal adenocarcinoma tumor cells in 1964.217 Sam-
ples of dendritic cells (DC) derived from human monocytes obtained from blood samples of 
healthy donors were kindly provided by the Department of Internal Medicine III, Universitäts-
klinikum Regensburg. 
2.1.2 Cell culture media, buffers and reagents for cell culture 
All cell culture media and reagents were purchased from Biochrom AG, Berlin unless otherwise 
described. 
media/buffer/reagent comment 
RPMI 1640 medium with phenol red, w/o L-glutamine 
 w/o phenol red, w/o L-glutamine 
DMEM 1.0 g mL-1 D-glucose 
Sodium pyruvate 100 mM 
Non-essential amino acids 100 x 
Trypsin/EDTA solution 10 x in PBS 
L-glutamine 200 mM 
FCS Superior heat inactivated: 30 min at 56 °C 
PBS Sigma, Steinheim 
The following fully supplemented culture media were used for cell culture and all cell-based 
assays including the preparation of the final concentrations of test compounds.  
RPMI cell culture medium with 10% FCS and 
2 mM L-glutamine 
500 mL RPMI with phenol red, 50 mL FCS, 
heat inactivated, 5 mL L-glutamine 
Colorless RPMI cell culture medium with 10% 
FCS and 2 mM L-glutamine 
500 mL RPMI without phenol red, 50 mL FCS, 
heat inactivated, 5 mL L-glutamine 
DMEM cell culture medium 500 mL DMEM, 50 mL FCS, heat inactivated, 
5 mL sodium pyruvate, 5 mL non-essential 
amino acids 
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2.1.3 Antibodies, proteins and enzymes 
Anti-bilirubin antibody, 24G7, 1 mg mL-1 Shino-Test, Kanagawa, Japan 
HRP-conjugated anti-mouse antibody, 2 mg mL-1 Rockland, Gilbertsville, PA, USA 
Anti-HO-1 antibody, mouse, monoclonal,              
1 mg mL-1 
StressMarq, Victoria, Canada 
Anti-α-tubulin antibody, mouse, monoclonal, 
clone DM1A, Cat.No. IMG-80196 
IMGENEX, San Diego, CA, USA 
Biliverdin reductase (BVR), recombinant rat 
protein, 1 mg mL-1, 180 nmol min-1 mg-1 
Stressgen, assay designs, Ann Arbor, MI, 
USA 
Protease inhibitor cocktail, complete tablets Roche, Mannheim 
BSA, Cohn Fraction V, pH 5 Biomol, Hamburg 
2.1.4 Kits 
Detergent compatible protein assay  BioRad, Munich 
Super Signal West Dura Extended Duration Sub-
strate 
Thermo Scientific, Rockford, 
IL, USA 
2.1.5 Chemicals and reagents 
(-)-Epicatechin AppliChem, Darmstadt 
1,4-Dithiothreitol Merck, Darmstadt 
2,2'-Azobis(2-methylpropionamidine) dihydro-
chloride (AAPH) Acros Organics, Geel, Belgium 
2-Mercaptoethanol Serva, Heidelberg 
3-[4,5-Dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) 
Sigma-Aldrich, Steinheim 
3-Hydroxycoumarin Sigma-Aldrich, Seinheim 
Ammonium persulfate Merck, Darmstadt 
Bilirubin-IX α Frontier Scientific, Carnforth, UK 
Brij 97 Sigma, Steinheim 
Bromophenol Blue Merck, Darmstadt 
Caffeic acid Acros Organics, Geel, Belgium 
Caffeic acid phenethyl ester (CAPE) Roth, Karlsruhe 
Cardamonin Calibochem (Merck Group), Darmstadt 
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Carnosol Cayman Chemical, Ann Arbor, MI, USA 
Chlorogenic acid Cayman Chemical, Ann Arbor, MI, USA 
Citric acid monohydrate Merck, Darmstadt 
Coomassie brilliant blue G-250  Biomol, Hamburg 
Dexamethasone Sigma-Aldrich, Steinheim 
Disodiumhydrogenphosphate dihydrate Merck, Darmstadt 
Disodiumhydrogenphosphate monohydrate Merck, Darmstadt 
DMSO  Merck, Darmstadt 
EDTA-Na2 x 2 H2O (Titriplex) Merck, Darmstadt 
Ethanol, p.a.  J.T.Baker, Deventer, Holland 
Fluorescein Sigma-Aldrich (Fluka), Steinheim 
FeCl2, anhydrous Sigma-Aldrich, Steinheim 
FeCl3, anhydrous Sigma-Aldrich, Steinheim 
Gelatin from cold water fish skin  Sigma-Aldrich, Steinheim 
Glycerin VWR (Prolabo), Fontenay-sous-Bois, France 
Glycine Merck, Darmstadt 
H2O2 solution, 30% in water Merck, Darmstadt 
Hemin Sigma-Aldrich (Fluka), Steinheim 
Kaempferol Calibochem (Merck Group), Darmstadt 
Lipopolysaccharides (LPS from Escherichia coli 
055:B4) 
Sigma-Aldrich, Steinheim 
Low fat milk powder Saliter, Obergünzburg 
Methanol Merck, Darmstadt 
N-(1-Naphtyl)ethylenediamine dihydro-chloride 
(NED) 
Sigma-Aldrich (Fluka), Steinheim 
N,N,N,N-Tetramethylethylenediamine (TEMED) Sigma-Aldrich, Seinheim 
NADPH Biomol, Hamburg 
Nonidet P-40 (NP 40) Sigma-Alrich (Fluka, BioChemika), Seinheim 
Oltipraz Sigma-Aldrich, Seinheim 
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ortho-Phenylenediamine dihydrochloride (OPD) Acros Organics, Geel, Belgien 
Phosphoric acid, 85%   Fluka, Buchs, Switzerland  
Potassium chloride Merck, Darmstadt 
Potassium hydrogen phosphate Merck, Darmstadt 
Precision Plus Protein Standards Bio Rad, Munich 
Quercetin Cayman Chemical, Ann Arbor, MI, USA 
Resveratrol Cayman Chemical, Ann Arbor, MI, USA 
Rotiphorese Gel 30 (acrylamind-bisacrylamide-
mix) 
Roth, Karlsruhe 
Sodium deoxycholate Merck, Darmstadt 
Sodium salicylate Merck, Darmstadt 
Sodiumdihydrogenphosphate monohydrate   Merck, Darmstadt 
Sodiumdodecylsulfate (SDS)  Sigma-Aldrich, Steinheim 
Sucrose  Sigma-Aldrich, Steinheim 
Sulfanilamide Merck, Darmstadt 
Sulforaphane Sigma-Aldrich, Steinheim 
Sodium nitrite Merck, Darmstadt 
Tin protoporphyrin IX (SnPPIX) Frontier Scientific, Carnforth, UK 
Tris-(hydroxymethyl)-aminomethane (TRIS) Merck, Darmstadt 
Triton X-100 Merck, Darmstadt 
Trolox, 97% Acros Organics, Geel, Belgium 
Tween-20 Merck, Hohenbrunn 
Xanthohumol Roth, Karlsruhe 
Zerumbone Sigma-Aldrich, Steinheim 
2.1.6 Synthesis of compounds 
The following compounds investigated in this work were synthesized in our working group 
(Universität Regensburg). The α-X-Limno-CP derivatives (5-aryl-3(2H)-furanones) were pre-
pared by Simon Lindner. The α-X-tetramethoxychalcones, HTMCH, TMCH and flavokawain A 
were synthesized by Nafisah Al-Rifai. The bilirubin-BSA conjugate and the chalcones ISL, 
DHDMCH, THMCH and butein were prepared by Sabine Amslinger. Calythropsin was prepared 
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by Paul Baumeister. 2’-Hydroxychalcone was synthesized by Killian Wörmann. Further test 
compounds were kindly provided by members of other groups as part of several collaborations. 
The following compounds were provided by different group members of O. Reiser. Both enanti-
omers of arteludovicinolide A and the derivative de-exo-methylene-(+)-arte A were synthesized 
by Andreas Kreuzer. The γ-butyrolactone derivatives, GBL-1 and GBL-2 were synthesized by 
Mohd Tajudin Mohd Ali, diethylaminomethyl-GBL and α-methylene-GBL by Sabrina Fürst. A 
xanthatin derivative AB-1 was synthesized by Andreas Bergmann. MS-342 F9-F18, a 
guaianolide derivative was synthesized by Michael Schwarz. 4-Hydroxy-2-cyclopentenone was 
synthesized by Peter Kreitmeier and eight cyclopentenone derivatives KU 1-KU 8 were synthe-
sized by Kathrin Ulbrich. Four chalcone analogs, MS-C-01, SU-F-01, SU-C-02 and SU-CT-03 were 
synthesized by Mihai Surducan, a visiting PhD student in the group of B. König (Universität Re-
gensburg). The ET-CORMs rac-17 and rac-18 were synthesized and the compounds 1-5 were 
provided by Steffen Romanski, group member of H.-G. Schmalz (Universität zu Köln). 
2.1.7 Buffers and solutions 
All buffers and solutions were prepared with ultrapure water, filtered over a nitrate cellulose 
filter (0.45 nm) and degassed for 10 min in the ultrasound bath. 
2.1.7.1 Cell lysis 
Lysis buffer stock solution (2x), pH 8.0 80 mM TRIS-HCl, 500 mM sucrose, 4 mM 
EDTA, 274 mM NaCl, 20% (v/v) glycerin, 
stored at 4 °C 
TRIS-HCl buffer stock solution, pH 7.4 500 mM in H2O, stored at 4 °C 
Sucrose stock solution 2 M in H2O, stored at room temperature 
EDTA stock solution 125 mM in H2O, stored at room temperature 
NaCl stock solution 1 M in H2O, stored at room temperature 
Triton X-100, 10% (v/v) 
Nonidet P-40, 10% (v/v) 
Sodium deoxycholate, 10% (v/v) 
Brij 97, 10% (v/v) 
SDS, 10% (v/v) 
1 mL detergent, ad 10 mL H2O, stock solu-
tion stored at room temperature protected 
from light 
Complete protease inhibitor cocktail (25x, 
Roche) 
dissolve 1 tablet in 2 mL H2O, stored at 4 °C, 
stable for 1-2 weeks 
Lysis buffer, pH 7.4 40 mM TRIS-HCl, 250 mM sucrose, 2 mM 
EDTA, 137 mM NaCl, 10% (v/v) glycerin, 
0.1% Triton X-100, 4% (v/v) complete pro-
tease inhibitor cocktail, stored at 4 °C 
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2.1.7.2 Protein assay 
BSA stock solution  2 mg mL-1 in BSA buffer, stored at 4 °C 
BSA buffer 150 mM NaCl, 0.05% NaN3, stored at 4 °C 
Bradford reagent 100 mg coomassie brilliant blue G-250, 100 
mL 85% phosphoric acid, 50 mL ethanol, ad 
1 L H2O, dissolved over night in the dark at 
4 °C and filtered twice over round cellulose 
filters, stored in brown flaks at 4 °C 
2.1.7.3 HO enzymatic reaction 
TRIS-HCl/sucrose buffer, pH 7.4 40 mM TRIS-HCl, 250 mM sucrose, stored at 
room temperature 
NADPH stock solution 15 mM in H2O, prepared freshly, kept at 4 °C 
Hemin stock solution 250 µM in DMSO, 100 µL aliquots stored at -
20 °C 
BVR enzyme solution 1 ng mL-1 in BVR buffer, 100 µL aliquots 
stored at -20 °C 
BVR buffer 50 mM TRIS-HCl, pH 8.0 ,1 mM EDTA, 5 mM 
DTT, stored at 4 °C 
Bilirubin stock solution 10 mM in DMSO, prepared freshly 
NaOH 1 M in H2O, stored at room temperature 
HCl 1 M in H2O, stored at room temperature 
2.1.7.4 ELISA for bilirubin quantification 
PBS, pH 7.4 8.0 g NaCl, 0.20 g KCl, 1.44 g Na2HPO4, 0.24 g 
KH2PO4, ad 1 L H2O, stored at 4 °C 
Bilirubin-BSA conjugate  0.71 mg mL-1 in PBS, 200 µL aliquots stored 
at -20 °C 
Coating solution 0.035 µg mL-1 bilirubin-BSA conjugate in 
PBS 
Wash buffer (T-PBS) 0.1% (v/v) Tween-20 in PBS, pH 7.4, stored 
at room temperature 
Blocking solution, 3% G-PBS 3.33 g gelatin, ad 50 mL PBS, pH 7.4, stored 
at 4 °C 
1% G-PBS 1.11 g gelatin, ad 50 mL PBS, pH 7.4 , stored 
at 4 °C 
1. Antibody solution 0.571 µg mL-1 anti-bilirubin antibody, 0.5 
mM sodium salicylate in 1% G-PBS solution, 
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prepared freshly 
2. Antibody solution 0.2 µg mL-1 HRP-conjugated anti-mouse 
antibody in 1% G-PBS solution, prepared 
freshly 
Citrate buffer, pH 5.0 48.6 mM citric acid monohydrate, 102.8 mM 
Na2HPO4 x H2O, stored at room temperature 
Substrate solution 0.4 mg mL-1 OPD, 0.4 µL mL-1 H2O2 (30%) in 
citrate buffer, pH 5.0, prepared freshly 
Stop solution 3 M H2SO4 
2.1.7.5 Liver cytosol extract preparation 
Saline 0.9% (w/v) NaCl in H2O 
TRIS-HCl/sucrose buffer 20 mM TRIS-HCl, 250 mM sucrose, pH 7.4 
2.1.7.6 ORAC-fluorescein assay 
Phosphate buffer, 75 mM, pH 7.4 solution A: 75 mM Na2HPO4, solution B: 75 
mM NaH2PO4, ad solution B to A to adjust to 
pH 7.4, stored at 4 °C 
Fluorescein stock solutions 500 µM in phosphate buffer, 75 mM, pH 7.4, 
dissolved using an ultrasound bath, stored 
at 4 °C protected from light 
500 nM in phosphate buffer, 75 mM, pH 7.4, 
prepared freshly 
Trolox stock solutions 8 mM in phosphate buffer, 75 mM, pH 7.4, 
stored at 4 °C 
800 µM in phosphate buffer, 75 mM, pH 7.4, 
prepared freshly 
AAPH 40 mM in phosphate buffer, 75 mM, pH 7.4, 
prepared freshly 
2.1.7.7 Nitrite detection with Griess 
Griess reagent 20 mg NED, 200 mg sulfanilamide, 70 µL 
H3PO4 (85%), ad 20 mL H2O, dissolve in 
water bath, prepared freshly, stored in the 
dark 
Nitrite standard 1 mM NaNO2 in cell culture media without 
phenol red, stored at 4 °C 
LPS stock solution 200 µg mL-1 in PBS, stored at 4 °C 
2.1.7.8 MTT assay 
MTT reagent 4 mg mL-1 in PBS, stored at 4 °C 
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SDS solution, 10% (w/v) 50 g SDS, ad 500 mL H2O, stored at room 
temperature 
LPS stock solution 200 µg mL-1 in PBS, stored at 4 °C 
2.1.7.9 Western blot 
Electrophoresis buffer (1x), pH 8.3 3.03 g TRIS, 14.4 g glycine, 1.0 g SDS, ad 1 L 
H2O, stored at 4 °C 
Transfer buffer (1x), pH 8.3 3.03 g TRIS, 14.4 g glycine, 20% (v/v) meth-
anol, ad 1 L H2O, stored at 4 °C 
Separating gel buffer (4x), pH 8.8 90.9 g TRIS, 2.0 g SDS, ad 500 mL H2O, 
stored at room temperature 
Stacking gel buffer (2x), pH 6.8 15.14 g TRIS, 1.0 g SDS, ad 500 mL H2O, 
stored at room temperature 
Sample buffer (3x), pH 6.8 727 mg TRIS, 5.0 g SDS, 30.0 g glycine, 10.0 
g sucrose, 3.0 g β-mercaptoethanol, 0.5 g 
bromophenol blue, ad 100 mL H2O, stored at 
room temperature 
Wash buffer (1x), pH 7.4 2.48 g TRIS, 8.77 g NaCl, 0.05% Tween 20,     
ad 1 L H2O, stored at 4 °C 
Low-fat milk solution (1%) 1.25 g low-fat milk dry powder, 125 mL 
wash buffer (1x), prepared freshly 
Low-fat milk solution (5%) 1.25 g low-fat milk dry powder, 25 mL wash 
buffer (1x), prepared freshly 
APS solution (10%) 0.05 g ammonium persulfate, 500 mL H2O, 
prepared freshly and kept at 4 °C 
Separating gel (SDS-PAGE) 12 % (w/v) acrylamide, 375 mM TRIS-HCl 
pH 8.8, 0.1% (w/v) SDS, 0.1% (w/v) APS, 
0.1% TEMED 
Stacking gel (SDS-PAGE) 5% acrylamide, 125 mM TRIS-HCl pH 6.8, 
0.1% (w/v) SDS, 0.1% (w/v) APS and 0.1% 
TEMED 
2.1.8 Equipment 
Analytical balance SI-234, Denver Instruments, Göttingen 
Sartorius research, R160P, Sartorius, 
Göttingen  
Autoclave Typ 23, Melag, Berlin 
Block heater Techne Dri-Block DB-3D, Thermo Dux, Ge-
sellschaft für Laborgeräte mbH, Wertheim 
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Cell culture microscope Olympus CKX41-SF, Olympus, Hamburg 
Centrifuges Sigma 1-14, rotor 152-G, Sigma, Osterode 
Megafuge 1.0 R with rotor 2705, Heraeus 
Sepatech, Osterode 
Jouan BR4i multifunction centrifuge with 
rotor AB 1.14, Thermo Electron Corpora-
tion, Saint-Herblain, France 
Ultracentrifuge TGA 45, Kontron Instru-
ments with rotor TFT 6513, reduced to 
54.000 rpm, Zürich, Switzerland 
Drying oven AL01-03-100, 115 L, Advantage Lab, 
Schilde, Belgium 
Electrophoresis and western blotting unit Mini-Protean Tetra Handcast System, 
BioRad, Munich 
Hot plate magnetic stirrer IKA-RCT basic, saftey control, IKA-Werke, 
Staufen 
Incubator New Brunswick Scientific, Nütringen 
Laminar airflow cabinet Clan LAF, ClausDamm, Fredensborg, 
Denmark 
Luminescent image analyzer LAS 3000 Fujifilm Intelligent Dark Box, Fuji 
Photo Film (Europe) GmbH, Düsseldorf 
Software: Image Reader LAS 3000, Fujifilm, 
Stamford, IL, USA 
Microtiter plate reader Multiskan Spectrum, Thermo, Vantaa, Finn-
land 
Neubauer cell counting chamber Marienfeld, Landau-Königshofen 
pH meter WTW-inoLab pH level 1 with a SenTix-Mic-
glas electrode, WTW, Weilheim 
Platform shaker Rocking platform shaker, VWR Collection, 
VWR, Darmstadt 
Vibrating platform shaker, Titramax 100, 
Hiedolph, Schwabach 
Ultrapure water purification system Milli-Q UF Plus, Millipore. Schwalbach with 
membrane from membranPure, Bodenheim 
Ultrasound bath Brandelin Sonorex Super RK 255-H, 
Brandelin Electronic GmbH & Co. KG, Berlin 
Ultraturex B. Braun, Melsungen AG, Melsungen 
Vacuum pump ME 2C, Vaccubrand GmbH, Wertheim 
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Vortex shaker IKA-Vortex Genius 3, IKA-Werke, Staufen 
IKA-Lab Dancer, IKA-Werke, Staufen 
Water bath WBU 45 Memmert, Schwabach 
2.1.9 Consumables 
Centrifuge tubes, 15/50 mL sterile, for cell culture, Greiner Bio-One, 
Frickenhausen, TPP, Trasadingen, Switzer-
land 
non-sterile, 15 mL, Roth, Karlsruhe 
sterile, 50 ml, VWR , Darmstadt 
Serological pipettes, 5/10/25 mL sterile, for cell culture, Greiner Bio-One, 
Frickenhausen, TPP, Trasadingen, Switzer-
land 
Cell culture flasks, 25/75/150 cm² Greiner Bio-One, Frickenhausen, TPP, 
Trasadingen, Switzerland 
Cell scraper M TPP, Trasadingen, Switzerland 
Microplates 
6-well plates 
 
96-well plates 
 
 
for cell culture, Becton Dickinson Labware, 
Le Pont De Claix, France, TPP, Trasadingen, 
Switzerland 
for cell culture, TPP, Trasadingen, Switzer-
land 
non-steril, non-treated surface, pureGrade, 
BRAND, Wertheim 
for ORAC assay, F-bottom, GreinerBio-One, 
Fricken-hausen 
ELISA immunoplates, Nunc, Rosklide, 
Denmark 
Centrifuge tubes, 1.5/2 mL Eppendorf, Hamburg, Roth, Karlsruhe 
Cellulose nitrite filter pore size 0.45 µm, Satorius Stedim, Göttin-
gen 
PVDF membrane pore size 0.45 µm, Millipore, Billerica, MA, 
USA 
pH test stripes pH fix test stripes, pH 1-14, Roth, Karlsruhe 
Nitrocellulose membrane  pore size 0.55 µm, Bio-Rad, Munich 
Whatman blotting paper 1.0 mm, Roth, Karlsruhe 
Filter paper circles Ø 185 mm, Scheicher & Schuell, Dassel 
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2.2 Methods 
2.2.1 Cell culture 
Murine macrophage cells RAW264.7 were cultured in RPMI 1640 medium with phenol red sup-
plemented with 10% (v/v) heat inactivated fetal calf serum (FCS) and 2 mM glutamine at 37 °C 
in humidified air containing 5% CO2. The adherent cells were split three times a week before 
reaching confluence. For splitting the culture medium was removed, 10 mL of fresh medium was 
added and cells were scraped off the flask bottom. The cell suspension was diluted 1:20 or 1:10 
with 20 mL of fresh culture medium in the same culture flask. Every week the cells were split in 
a new flask.  
The human colon cancer cells HT-29 were grown in DMEM supplemented with 10% (v/v) heat 
inactivated fetal calf serum (FCS), 1% (v/v) non-essential amino acids and 1% (v/v) sodium 
pyruvate. Cells were cultured at 37 °C in humidified air containing 5% CO2. The adherent cells 
were split once a week before reaching confluence. Every second to third day the cell culture 
media was changed. For splitting, the culture medium was removed, cells were washed with 
10 mL of PBS and 2 mL of a trypsin/EDTA solution was added. The adherent cells were then 
incubated for 5 min at 37 °C in order to detach them from the bottom of the cell culture flak. The 
trypsinization was stopped by the addition of 6 mL of fresh DMEM and the cell suspension was 
centrifuged at 700 rpm for 5 min at RT. The cell pellet was resuspended in 5 mL of fresh DMEM 
and the cell suspension was diluted 1:10 with 10 mL of fresh culture medium in a new culture 
flask. 
2.2.1.1 Cell counting 
The cell number in the cell suspension was determined as cells/mL, by using a cell counting 
chamber. Dead cells were stained with a 0.4 mg mL-1 trypan blue solution in PBS and were ex-
cluded from counting.  
2.2.1.2 Cell sample preparation 
Cells were seeded out on 96-well plates for cell viability or protein activity assays (HO-1 or 
Griess assay) at different cell concentrations in 150 µL of medium/well and allowed to attach for 
24 h. For western blot analysis 3 × 106 RAW264.7 cells/well in 5 mL of medium were placed in 
6-well plates and allow to attach for 24 h. After removing the culture medium, cells were incu-
bated with the test compounds diluted in culture media in several concentrations for different 
incubation times, maximum for 24 h. 
2.2.2 Dilution of test compounds 
Stock solutions of test compounds (100 mM) were prepared in DMSO and stored at -20 °C. Final 
test concentrations of compounds were freshly prepared by diluting the stock solution in fully 
supplemented culture medium. The final concentration of DMSO in the medium was below 0.1%. 
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At this concentration the solvent had no effect on the cell viability of RAW264.7 or HT-29 cells or 
other tested activity compared to control cells. The SnPPIX stock solution (10 mM) was prepared 
freshly in a 0.10 mM aqueous solution of NaOH and diluted in culture medium to yield the test 
concentration. The ET-CORMs, FeCl2, FeCl3 and compounds 1-5 (potential decomposition prod-
ucts of ET-CORMs) were diluted in ethanol and stock solutions were prepared at 40 and 400 mM. 
Test concentrations were freshly prepared by diluting the stock solution in culture medium. The 
final concentration of ethanol in the medium was below 0.25%. At this concentration the solvent 
had no effect on the cell viability of RAW264.7 cells or other tested activity compared to control 
cells.  
2.2.3 Viability assay (MTT assay)  
To exclude cytotoxicity of test compounds, a cell viability assay was performed. Cell viability was 
evaluated by determining the mitochondrial function of living cells on the basis of their ability to 
reduce the yellow tetrazolium salt MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide) into a violet formazan dye by mitochondrial reductases.218  
 
Figure 18. The reduction reaction of the tetrazolium salt MTT to a formazan dye, is catalyzed by mitochondri-
al reductases only in living cells and is therefore used to asses cytotoxicity. 
Cells (RAW264.7: 5000/well and HT-29: 20,000/well) were plated into 96-well plates and al-
lowed to attach for 24 h. The total assay volume was 100 µL. Control cells were incubated only 
with culture medium with or without DMSO or EtOH, according to the solvent used in the stock 
solution. The test compounds were added to wells in several concentrations and incubated for 
20 h (Scheme 6). Then, 10 µL of 4 mg mL-1 MTT in PBS were added to each well. After 4 h the 
culture medium was removed and 100 µL of a 10% SDS solution were put in each well to solubil-
ize the formazan product. The absorbance was measured at 560 nm with a microplate reader 
(Multiskan Spectrum Photometer) after 24 h incubation in darkness at room temperature. Cell 
viability was expressed as percent compared to control cells incubated only with medium.  
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Scheme 6. Pipetting scheme for a 96-well plate used in the MTT-cytotoxicity assay. Columns 1 and 12 were 
filled with medium alone, the wells between column 2 and 11 were plated with cells as indicated: control cells 
were incubated with medium alone; stimulated cells were incubated with the test compounds in medium in 
several concentrations; solvent control cells were incubated with medium supplemented with the highest 
solvent concentration used in the assay. 
2.2.4 Viability assay with lipopolysaccharide (MTT-LPS assay) 
RAW264.7 cells were seeded in 96-well plates at a density of 5000 per well, cultured for 24 h, 
and then incubated for 20 h with RMPI medium without phenol red supplemented with test 
compounds in presence and absence of 10 ng mL-1 of LPS (lipopolysaccharide). Controls re-
ceived only culture medium (without phenol red), with or without DMSO or EtOH, according to 
the solvent used in the stock solution, both in presence and absence of 10 ng mL-1 of LPS 
(Scheme 7). Total assay volume was 100 µL. Afterwards, 10 µL of a MTT solution (4 mg mL-1 in 
PBS) were added to each well, and cells were incubated for another 4 h at 37 °C. Subsequently, 
the culture medium was removed from wells and 100 μL of a 10% SDS solution was added, and 
formazan was allowed to dissolve overnight. The absorbance was determined at 560 nm with a 
Multiskan Spectrum Photometer. Cell viability was expressed as percent compared to control 
cells incubated only with medium.  
1 2 3 4 5 6 7 8 9 10 11 12
A 100 100 100
B 75 75 75
control 
cells
C 50 50 50
D 25 25 25
E 10 10 10
F 5 5 5
solvent 
control
G 1 1 1
H 0.5 0.5 0.5
5,000 RAW264.7 cells or 20,000 HT-29 cells/well in 100 mL medium
test 
compound 1
test 
compound 2
test 
compound 3
[µM] [µM] [µM]
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Scheme 7. Pipetting scheme for a 96-well plate used in the MTT-LPS assay. Columns 1 and 12 were filled with 
medium alone, the wells between column 2 and 11 were plated with 5000 RAW264.7cells/well: control cells 
were incubated with medium alone; stimulated cells were incubated with different concentrations of the test 
compound in medium; solvent control cells were incubated with medium supplemented with the highest 
solvent concentration used in the assay. In row A to D cells were incubated without LPS, the cells in row E to H 
were incubated in the presence of 10 ng mL-1 of LPS.  
2.2.5 Nitrite assay (Griess assay) 
The produced NO that accumulated as nitrite in the culture medium was quantified using the 
Griess reaction. RAW264.7 macrophages (8 × 104 cells/well) were plated in 96-well plates and 
allowed to attach for 24 h. 
 
Scheme 8. Pipetting scheme for a 96-well plate used in the Griess nitrite assay. Columns 1 and 12 were filled 
with medium alone, the wells between column 2 and 11 were plated with 80,000 RAW264.7cells/well: control 
cells were incubated with medium alone; stimulated cells were incubated with different concentrations of the 
test compound in medium; solvent control cells were incubated with medium supplemented with the highest 
solvent concentration used in the assay. In row A to D cells were incubated without LPS, the cells in row E to H 
were incubated in the presence of 10 ng mL-1 of LPS. 
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Afterwards, 100 µL of fresh RPMI culture medium without phenol red supplemented with test 
compounds in presence and absence of 10 ng mL-1 LPS were added to the cells. Controls received 
only culture medium (without phenol red) with or without DMSO or EtOH, according to the sol-
vent used in the stock solution, both in presence and absence of 10 ng mL-1 of LPS (Scheme 8). 
The cells were incubated for 24 h. 50 µL of culture medium was mixed with 50 µL of Griess rea-
gent and incubated for 15 min at room temperature. The absorbance was measured at 560 nm 
with a Multiskan Spectrum Photometer and nitrite concentrations were calculated from a stand-
ard curve established with serial dilutions (0/5.0/10/25/50 µM) of NaNO2 in RPMI culture me-
dium without phenol red. Nitrite production was expressed as percent compared to control cells 
incubated only with medium in presence of 10 ng mL-1 LPS. 
2.2.6 Activity assay for heme oxygenase-1 (HO-1) 
2.2.6.1 Stimulation of RAW264.7 macrophages 
For the HO-1 activity assay RAW264.7 cells (8 × 104 cells/well) were plated in 96-well plates, 
allowed to attach for 24 h and exposed to test compounds in various concentrations for 3 to 24 h. 
The total assay volume was 100 µL. Control cells were incubated with culture medium alone. 
(Scheme 9) After removing the culture medium, cells were washed with PBS (150 µL/well) and 
96-well plates were stored at -80 °C until utilized for the HO-1 assay. 
 
Scheme 9. Pipetting scheme for a 96-well plate with cell culture samples used in the HO-1 assay. Columns 1 
and 12 were filled with medium alone, the wells between column 2 and 11 were plated with 80,000 cells/well: 
control cells were incubated with medium alone; stimulated cells were incubated with the test compounds in 
medium; solvent control cells were incubated with medium supplemented with the highest solvent concen-
tration used in the assay.  
1 2 3 4 5 6 7 8 9 10 11 12
A 25
B 10
C 5 [µM]
control 
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E 25 25
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H 1 1
compound 1 compound 3
80,000 RAW264.7 cells/well in 100 µL RPMI culture medium
control cells for 
bilirubin standards
compound 2
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2.2.6.2 Cell lysis 
For cell lysis 150 µL of ice cold lysis buffer (40 mM TRIS-HCl, 250 mM sucrose, 137 mM NaCl, 
10% (v/v) glycerin, 2 mM EDTA, 0.1% (v/v) Triton X-100 detergent, protease inhibitor cocktail 
from Roche, pH 7.4) was added to each well and the 96-well plate was placed on an orbital plate 
shaker and allowed to shake for 15 min at 4 °C.  
2.2.6.3 Determination of protein concentration 
To avoid detergent interference the total protein concentrations in the cell lysate were deter-
mined using the Bio-Rad Detergent Compatible Protein Assay kit which is based on the Lowry 
assay.219 Briefly, 5 µL of sample were mixed with 25 µL of a alkaline copper tartrate solution 
supplemented with a SDS solution and 200 µL of the Folin reagent and incubated for 30 min at 
room temperature according to the manufacturer instructions. The absorbance was read at 
750 nm with a Multiskan Spectrum Photometer. Protein standards were prepared from a 2.0 mg 
mL-1 BSA standard solution by serial dilutions in lysis buffer (1.0/0.5/0.25/0.125/0 mg mL-1 
BSA).  
2.2.6.4 HO enzymatic activity 
90 µL of the collected whole cell lysates were placed in a 96-well plate together with 10 µL of 
bilirubin standards solutions or the HO reaction mixture. Scheme 10 shows a typical 96-well 
sample plate used for the HO activity assay.  
 
Scheme 10. Pipetting scheme for a 96-well plate used in the HO activity assay. 90 µL of whole cell lysate was 
transferred on the plate between column 2 and 11 and incubated with 10 µL of the HO reaction mixture or 
‘bilirubin standards’ for 1 h at 37 °C. Lysates from control cells were incubated with ‘bilirubin standards’ and 
from stimulated cells, control cells and solvent control cells were incubated the HO reaction mixture.  
Bilirubin (BR) standards were prepared in TRIS-HCl/sucrose buffer in several concentrations to 
give a final concentration in the well of 0.5-2500·10-9 M BR in 120 µL. 10 µL of ‘bilirubin stand-
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ards’ were added to 90 µL of whole cell lysate from unstimulated control cells. For ‘zero control’ 
(B0 value) 10 µL of TRIS-HCl/sucrose buffer were added to 90 µL of whole cell lysate of unstimu-
lated control cells. Finally, 10 µL of the HO reaction mixture (Table 3) were added to 90 µL of the 
whole cell lysates from controls and samples. The assay volume was 100 µL. A pipette summary 
for each HO-1 assay sample is shown in Table 4. 
 Table 3. Components of the HO reaction mixture. 
volume/µL assay component 
final concentration in 
100 µL reaction mixture 
0.75 267 mM TRIS-HCl, pH 7.4 40 mM 
1.25 1.2 M sucrose 250 mM 
2.0 15 mM NADPH 300 µM 
1.0 1.0 ng µL-1 BVR 0.01 ng µL-1 
1.0 250 µM hemin 2.5 µM 
4.0 TRIS-HCl/sucrose buffer, pH 7.4 40/250 mM 
90 whole cell lysate (10-30 µg protein)  
 
The reaction was performed at 37 °C in the dark for 1 h and terminated by the addition of 10 µL 
aqueous 1 M HCl. The plate was placed 5 min on ice and the pH was adjusted to 7.4 with 10 µL of 
aqueous 1 M NaOH. The total assay volume was 120 µL. 
Table 4. Pipetting summary for the HO activity assay. 
well 
whole cell lysate 
TRIS-HCl/sucrose 
buffer 
bilirubin 
standards 
HO reaction 
mixture unstimulated stimulated 
‘zero control’ (B0) + - + - - 
‘bilirubin standards’ + - - + - 
sample - + - - + 
control sample + - - - + 
solvent control + - - - + 
 
2.2.6.5 ELISA 
The amount of bilirubin was quantified by the ELISA method described by Izumi et al.52 The bili-
rubin-ELISA is built as a non-competitive, indirect assay (Scheme 11). The HO reaction mixture 
containing the formed bilirubin (BR) was incubated with an excess of the specific anti-bilirubin 
antibody. The free unbound anti-bilirubin antibody was captured on an immunoplate coated 
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with the bilirubin-BSA (BR-BSA)-conjugate and detected with a second horse radish peroxidase 
(HRP)-conjugated antibody. 
 
Scheme 11. The bilirubin-ELISA procedure. (i) Samples from the HO activity assay containing bilirubin were 
incubated with an excess of specific anti-bilirubin antibody. (ii) Mixture was transferred to an immunoplate 
coated with a bilirubin-BSA conjugate (BR-BSA). (iii) Free, unbound anti-bilirubin antibodies were washed 
from the plate. (iv) A second HRP-conjugated antibody was added and allowed to bind to the anti-bilirubin 
antibody. (v) The HRP enzyme substrate was added to detect the anti-bilirubin antibody bound to the 
immunoplate. 
After adding the substrate solution containing ortho-phenylenediamine dihydrochloride (OPD) 
and H2O2, the reaction was stopped with H2SO4 and the absorbance of the yellow product was 
measured at 492 nm. The intensity of the absorbance is proportional to the amount of anti-
bilirubin antibody bound to the immunoplate, which is inversely proportional to the amount of 
bilirubin in the HO reaction mixture. 
Procedure 
1. An ELISA immunoplate was coated with 100 µL/well of bilirubin-BSA conjugate in PBS 
(0.35 µg protein/well) over night at 4 °C.  
2. 100 µL of the samples from the HO reaction mixture (stimulated and unstimulated cells, 
‘zero control’ and ‘bilirubin standards’) were incubated with 100 µL of anti-bilirubin anti-
body in 1% G-PBS (0.571 µg mL-1) on a 96-well plate for 2 h at 37 °C.  
3. Meanwhile, the immunoplate coated with the bilirubin-BSA conjugate was washed three 
times with T-PBS and blocked with 200 µL/well of 3% G-PBS for 1 h at room temperature 
in the dark.  
4. The blocked immunoplate was washed three times with T-PBS. 
5. 100 µL of the anti-BR antibody mixture from step 2. were transferred to the blocked 
immunoplate and incubated for 30 min at 37 °C.  
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6. The immunoplate was washed three times with T-PBS. 
7. 100 µL/well of the second antibody (HRP-conjugated anti-mouse antibody from goat, 
0.2 µg mL-1) in 1% G-PBS were added and incubated for 30 min at 37 °C.  
8. The immunoplate was washed six times with T-PBS. 
9. 100 µL/well of the freshly prepared substrate solution (0.40 g mL-1 OPD and 0.4 µL mL-1 
30% H2O2 in citrate buffer, pH 5.0) were added and incubated in the dark for 5 min at 
room temperature. 
10. The peroxidase reaction was terminated by the addition of 50 µL/well of 3 M H2SO4.  
11. The absorbance was measured at 492 nm in a microplate reader (Multiskan Spectrum 
Photometer). 
2.2.6.6 Analysis of the ELISA 
Because the amount of bilirubin is determined by quantifying the anti-bilirubin antibodies, 
which did not bind to the bilirubin in the sample, the intensity of the signal is indirect propor-
tional to the bilirubin concentration. A sigmoidal calibration curve was plotted as the ratio of 
B/B0 (B = mean absorbance for each ‘bilirubin standard’, B0 = mean absorbance for ‘zero control’) 
against the bilirubin concentrations expressed as lg(x) (x = bilirubin concentration of standard) 
and data was fitted to a four parameter logistic equation. After normalization of the sample as 
B/B0 (B = mean absorbance for each ‘sample’, B0 = mean absorbance for ‘zero control’) unknown 
concentrations of samples (control cells and stimulated cells, here lysates incubated with HO-1 
reaction mixture) were determined using curve fit equation 1.220  
         
         
    
 
  
 
    
Equation 2. 
A1, A2, x0, p: parameters of the four-parameter logistic model, with 
A1 = expected response at zero dose of bilirubin 
p = slope factor 
x0 = IC50, i.e., concentration of bilirubin with an expected response exactly halfway between A1  and A2 
A2 = expected response for infinite bilirubin concentration 
y = B/B0 
B = mean absorbance for ‘bilirubin standard’ or ‘sample’  
B0 = mean absorbance for ‘zero control’  
The HO activity in whole cell lysates was calculated as picomoles bilirubin produced per hour 
per milligram of total protein and the data was expressed as fold HO-1 activity compared to con-
trol cells. For more details section ‎3.1.1, Table 9 . 
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2.2.6.7 Bilirubin quantification via ELISA with HT-29 cells 
HT-29 cells (1 × 105 cells/well) were plated in 96-well plates, allowed to attach for 24 h and in-
cubated for another 24 h. The total assay volume was 150 µL. After removing the culture media, 
cells were washed with PBS (150 µL/well) and 96-well plates were stored at -80 °C until utilized. 
For cell lysis 150 µL of ice cold lysis buffer (40 mM TRIS-HCl, pH 7.4, 250 mM sucrose, 137 mM 
NaCl, 10% (v/v) glycerin, 2 mM EDTA, 0.1-1% (v/v) detergent, protease inhibitor cocktail from 
Roche) was added to each well and the 96-well plate was placed on an orbital plate shaker and 
allowed to shake for 30 min at 4 °C. 90 µL of the collected whole cell lysate was placed in a 96-
well plate and 10 µL of bilirubin standards was added. Bilirubin standards were prepared in 
TRIS-HCl/sucrose buffer in several concentrations (5-50·10-9 M BR). The assay volume was 
100 µL. The reaction was performed at 37 °C in the dark for 1 h and terminated by the addition 
of 10 µL aqueous 1.0 M HCl. The plate was placed 5 min on ice and the pH was adjusted to 7.4 
with 10 µL of aqueous 1.1 M NaOH. The total assay volume was 120 µL. The amount of bilirubin 
was quantified by the ELISA method described above in chapter ‎2.2.6.5. A linear bilirubin cali-
bration curve was plotted as the ratio of B (B = mean absorbance for each ‘bilirubin standard’) 
against the bilirubin concentrations expressed as lg(x) (x = bilirubin concentration of standard) 
and unknown bilirubin concentration in samples was determined by linear regression analysis.  
2.2.6.8 Liver cytosol extract preparation 
Biliverdin reductase (BVR) is an important additive to the HO/BVR enzymatic reaction mixture 
of the HO activity assay, in order to assure a full conversion of the produced biliverdin to biliru-
bin. As a BVR source a cytosol extract gained by ultracentrifugation of guinea pig liver homoge-
nates was used. The guinea pig liver was kindly provided by Sigurd Elz (Lehrstuhl Pharma-
zeutische Chemie I, Universität Regensburg). The guinea pig liver was separated, stored in ice 
cold saline and homogenized in 60 mL of ice cold buffer of 20 mM TRIS-HCl and 250 mM sucrose, 
pH 7.4 by using an ultraturex equipment (Ø 30 cm, B. Braun, Melsungen AG). The obtained ho-
mogenate was centrifuged for 30 min at 4000 rpm, 4 °C. After removing the lipid layer the su-
pernatant was transferred to ultracentrifuge tubes and centrifuged for 1 h at 40,000 rpm (ultra-
centrifuge TGA 45, Kontron Instruments with rotor TFT 6513, Zürich, Switzerland), 4 °C. The 
lipid layer was removed again, and the supernatant which was the cytosolic liver fraction was 
aliquoted and stored at -20 °C.  
The protein concentration of the liver extract was determined by the Bradford method.221 Briefly, 
liver extracts were diluted 1:100 and 1:250 in 20 mM TRIS-HCl, 250 mM sucrose buffer, pH 7.4. 
On a 96-well plate 12 µL of the sample dilutions were incubated with 238 µL of the Bradford 
reagent for 5 min at room temperature and absorption was measured at 595 nm. The mean val-
ues were calculated from three parallels. Protein concentrations were determined by a linear 
regression curve prepared from BSA standard concentrations (1/0.75/0.5/0.25/0.125/0.0625 
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and 0 mg mL-1) in 20 mM TRIS-HCl, 250 mM sucrose buffer, pH 7.4. The protein concentration of 
the liver cytosol extract was 32.7 ± 2.7 mg mL-1.  
2.2.6.9 Determination of HO activity in liver cytosol extracts 
For the HO/BVR enzymatic reaction 3 µL of liver cytosol (0.098 µg) was incubated with 3 mM 
NADPH and 25 µM hemin in lysis buffer (40 mM TRIS-HCl, pH 7.4, pH 7.4, 250 mM sucrose, 
10 mM EDTA, 100 mM NaCl, 0.05% (w/v) SDS detergent, 4% protease inhibitor cocktail). As 
control the liver cytosol was assayed in lysis buffer alone. Assay volume was 100 µL. The reac-
tion mixture was incubated for 1 h at 37 °C and stopped with 10 µL of aqueous 1.0 M HCl. The pH 
was adjusted to 7.4 with 10 µL of aqueous 1.2 M NaOH. The total assay volume was 120 µL. For 
bilirubin standards several concentrations of bilirubin were prepared in TRIS-HCl/sucrose buff-
er added to the lysis buffer to give the final concentrations of 5-75·10-9 M. The amount of biliru-
bin in samples was quantified by the ELISA method described above in chapter ‎2.2.6.5. A linear 
bilirubin calibration curve was plotted as the ratio of B (B = mean absorbance for each ‘bilirubin 
standard’) against the bilirubin concentrations expressed as lg(x) (x = bilirubin concentration of 
standard) and unknown bilirubin concentration in samples was determined by linear regression 
analysis. 
2.2.6.10 HO-1 activity assay with dendritic cells (DC) 
Dendritic cells (DC) were kindly provided by the Department of Internal Medicine III, University 
Hospital of Regensburg. DC were generated from freshly isolated human monocytes as described 
previously.222 After 7 days, DC maturation was induced by 100 ng mL-1 of LPS in the presence or 
absence of the tetramethoxychalcone α-CF3-TMC (0.5 and 1 µM) in order to analyze the effect of 
chalcones on HO-1 activity. Plates were stored at -80 °C until utilized for the HO-1 assay. For cell 
lysis 100 µL of ice cold lysis buffer (40 mM TRIS-HCl, 250 mM sucrose, 137 mM NaCl, 10% (v/v) 
glycerin, 2 mM EDTA, 0.1% (v/v) Triton X-100 detergent, protease inhibitor cocktail from Roche, 
pH 7.4) was added to each well and the 96-well plate was placed on an orbital plate shaker and 
allowed to shake for 15 min at 4 °C. The HO enzymatic reaction was performed as described 
above with a slight modification. 90 µL of the collected whole cell lysate from cell samples was 
placed in a 96-well plate and 10 µL of the HO reaction mixture was added.  
Table 5. Pipetting summary for the HO activity assay with dentritic cells. 
well 
whole cell lysate  TRIS-
HCl/sucrose 
buffer 
bilirubin 
stand-
ards 
HO   
reaction     
mixture unstimulated stimulated lysis buffer 
‘zero control’ (B0) - - + + - - 
bilirubin standards - - + - + - 
sample - + - - - + 
control sample  + - - - - + 
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Bilirubin standards were prepared in TRIS-HCl/sucrose buffer in several concentrations 
(1-2500·10-9 M BR) and 10 µL of ‘bilirubin standards’ were added to 90 µL of lysis buffer. For 
‘zero control’ (B0 value) 10 µL of TRIS-HCl/sucrose buffer were added to 90 µL of lysis buffer 
(Table 5). The assay volume was 100 µL. The reaction was performed at 37 °C in the dark for 1 h 
and terminated by the addition of 10 µL aqueous 1 M HCl. The plate was placed 5 min on ice and 
the pH was adjusted to 7.4 with 10 µL of aqueous 1 M NaOH. The total assay volume was 120 µL. 
The amount of bilirubin was determined by the ELISA method described above. For the quantifi-
cation of the bilirubin a sigmoidal calibration curve was plotted as the ratio of B/B0 (B = mean 
absorbance for each ‘bilirubin standard’, B0 = mean absorbance for ‘zero control’) against the 
bilirubin concentrations expressed as lg(x) (x = bilirubin concentration of standard). The data 
was fitted to a four parameter logistic equation (Equation 2) and unknown concentrations of 
samples were determined: the basal bilirubin level in the cell lysate of untreated control cells 
together with the HO activity in control cells and stimulated cells in presence of LPS. The HO-1 
activity was estimated by comparing the HO activity of treated cells to control cells. 
2.2.6.11 Inhibition of HO activity in RAW264.7 macrophages by SnPPIX 
As a negative control for the HO-1 assay, the HO-1 activity was measured in RAW264.7 cells 
treated with 10 µM of the chalcone DHDMCH and 10 ng mL-1 of LPS for 24 h in the presence of 5 
or 10µM of SnPPIX, an inhibitor of HO-1 activity. The SnPPIX stock solution (10 mM) was freshly 
prepared in a 0.10 mM aqueous solution of NaOH and diluted in culture medium to the corre-
sponding test concentrations. HO-1 activity in stimulated RAW264.7 cells was determined under 
standards assay conditions as described in  
2.2.7 Western blot analysis 
2.2.7.1 Sample preparation 
RAW264.7 cells (3 × 106 cell/well) were plated in 6-well plates and allowed to attach for 24 h. 
The cells were then incubated with different concentrations of test compounds for 3 to 24 h pri-
or to cell harvesting, in total for 24 h. The assay volume was 4 mL/well and 2 wells per test com-
pound were used. Control cells were incubated with culture medium alone. After removing the 
culture medium cells were washed with PBS (5 mL/well), detached from the plate in 1 mL 
PSB/well using a cell scraper and pelleted by centrifugation for 5 min at 14,000 rpm and 4 °C. 
The cell pellet was stored at -80 °C until used for western blotting.  
For cell lysis 400 µL of ice cold lysis buffer (40 mM TRIS-HCl, 250 mM sucrose, 137 mM NaCl, 
10% (v/v) glycerin, 2 mM EDTA, 0.1% (v/v) Triton X-100 detergent, protease inhibitor cocktail 
from Roche, pH 7.4) were added to the cell pellet and incubated for 30 min at 4 °C. Subsequently, 
the lysates were centrifuged (14,000 rpm, 15 min, 4 °C) and the protein amount of the superna-
tant determined by the DC Protein Assay (see section ‎2.2.6.3).  
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2.2.7.2 SDS-PAGE 
From each supernatant 33 µg of protein were heated to 95 °C for 4 min in sample buffer and 
separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using the electrophoresis unit 
Mini-Protean Tetra Handcast System (BioRad). The discontinuous system consisted of a lower 
separating 12%-acrylamide gel and an upper stacking gel containing 5% acrylamide. Gels were 
run for 1 h at 200 V in electrophoresis buffer. Molecular weights of the different proteins were 
estimated using protein markers (Precision Plus Protein Standards, Bio Rad) of known molecu-
lar weight.  
2.2.7.3 Blotting 
The separated proteins in the gel were transferred to a nitrocellulose or PVDF membrane. The 
gel together with the membrane were placed in the transfer cell (Mini-Protean Tetra Handcast 
System, BioRad) filled with transfer buffer between two piles of three blotting papers (Whatman, 
1.0 mm, Roth). The transfer was performed for 1 h at 130 V.  
2.2.7.4 Protein detection 
To avoid unspecific binding of the antibodies, the membrane was blocked with a 5% (w/v) low 
fat milk solution for 1 h on a rocking platform shaker at RT. Two membrane stripes were cut out 
according to the molecular weight of the relevant protein bands, the target protein HO-1 (32 kDa) 
and the loading control α-tubulin (57 kDa). The specific primary antibodies were diluted to an 
adequate working concentration in a 1% (w/v) low fat milk solution (1 µg mL-1 anti-HO-1 anti-
body or anti-α-tubulin antibody (1:500)) and incubated with the membrane stripes on a rocking 
platform shaker for 1 h at RT or over night at 4 °C. Afterwards, the secondary HRP-conjugated 
anti-mouse antibody (0.2 µg mL-1 in a 1% (w/v) low fat milk solution) was incubated with the 
membrane for 30 min at RT on a rocking platform shaker. The membrane was washed in 1% 
(w/v) low fat milk solution for three times 5 min on a rocking platform shaker. A last washing 
step was performed with 1 x washing buffer for 10 min at RT. The immunoreactive bands were 
detected with a chemiluminescence reagent kit (Thermo Scientific, Rockford USA) and visualized 
with a luminescent image analyser (LAS 3000, Fujifilm, Düsseldorf). Relative density of protein 
bands was analyzed by the Multi Gauge 3.0 software (Fujifilm Life science, Tokyo, Japan) and the 
relative intensity of HO-1 protein expression was calculated as the ratio of α-tubulin to HO-1 
protein and data was expressed as fold of control.  
Technical assistance for the gelelectrophoresis, western blotting and protein detection was sup-
plied by Dita Fritsch (group of Sabine Amslinger, Universität Regensburg). 
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2.2.8 ORAC-fluorescein assay 
The radical scavenging activity of test compounds was determined by the cell free oxygen radical 
absorbance capacity-(ORAC)-fluorescein method generating peroxyl radicals from AAPH (2,2'-
azobis(2-methylpropionamidine) dihydro chloride) as a free radical initiator and using fluores-
cein as a fluorescent probe. The assay was carried out in a flat bottom 96-well plate (Greiner 
Bio-One) in 75 mM phosphate buffer (pH 7.4) and the final assay volume was 200 µL. Stock solu-
tions of the test compounds (100 mM) were prepared in DMSO. All dilution steps of the assay 
components were performed in phosphate buffer (75 mM, pH 7.4) to reach the final assay con-
centrations. The final DMSO concentration for the test compounds in phosphate buffer was be-
low 0.01% (v/v). At this concentration the solvent had no effect on the fluorescence decay of 
fluorescein compared to the blank. A typical 96-well plate pipetting scheme for the ORAC-
fluorescein assay is shown in Scheme 12.  
 
Scheme 12. Pipetting scheme for a 96-well plate used in the ORAC-fluorescein assay. Trolox calibration stand-
ards (1-8 µM), 2 test compounds (0.5-10 µM), 0.01% DMSO as solvent control and phosphate buffer (PB, 75 
mM, pH 7.4) as blank together with fluorescein (300 nM) and AAPH (40 mM) were carried out in quadrupli-
cates. 
Several calibration solutions of Trolox (1-8 µM), test compound samples (0.5-10 µM), solvent 
control (0.01% DMSO) and phosphate buffer as blank (75 mM, pH 7.4) were carried out on each 
plate. Table 6 gives the assay components and their final concentration in the assay. Solutions of 
Trolox (20 µL/well, 1-8 µM), test compounds (20 µL/well, 0.5-10 µM), solvent control (0.01% 
DMSO) and phosphate buffer as blank (20 µl/well) together with fluorescein (120 µL/well, 300 
nM) were incubated for 15 min at 37 °C. AAPH (60 µL/well, 12 mM) was added rapidly to the 
reaction mixture and the fluorescence was recorded every 60 seconds for 100-300 min at 37 °C 
(λex 485 nm, λem 535 nm) in a Tecan plate reader (XFluor4 software version V 4). 
1 2 3 4 5 6 7 8 9 10 11 12 
A PB PB Trolox  [µM] solvent  
control 
PB 
B 1 2 3 4 5 6 7 8 
C 
D 
E PB [µM] [µM] PB 
F 0.5 1 4 7 10 0.5 1 4 7 10 
G 
H 
compound 1 compound 2 
with 300 nM fluorescein and 12 mM AAPH/well in 75 mM phosphate buffer, pH 7.4   
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Table 6. Components of the ORAC-fluorescein assay for the Trolox standards. 
assay component 
(in 75 mM phosphate buffer, pH 7.4) 
volume [µL]/well 
final concentration             
(in 200 µL assay volume) 
i. 10-80 µM Trolox 20 1-8 µM 
or 5-100 µM test compound 20 0.5-10 µM 
or 0.1% DMSO (solvent control)  20 0.01% 
or 75 mM phosphate buffer 
(blank) 
20 75 mM 
ii. 500 nM fluorescein 120 300 nM 
iii. 40 mM AAPH 60 12 mM 
Raw data was exported to an Excel sheet for further calculations. ORAC values were calculated 
as described by Davalos et al.88 Each data point was first normalized by multiplying it by the 
factor fluorescenceblank, t=0/fluorescencesample,t=0. and the fluorescence decay curves were plotted 
as relative fluorescence intensity versus time. From the normalized curves, the area under the 
fluorescence decay curve (AUC) was calculated as 
            
     
   
 
Equation 3 
where f0 is the initial fluorescence reading at 0 min and fi is the fluorescence reading at time i. 
The net AUC corresponding to a sample was calculated by subtracting the AUC corresponding to 
the blank. Linear regression equations between net AUC and antioxidant concentration were 
calculated for all the samples. ORAC values were expressed as Trolox equivalents by using the 
standard curve calculated for each assay. Final results were in µmol of Trolox equivalent/µmol 
of test compound.  
2.2.9 Statistical analysis 
Data is presented as the mean ± SD of at least 3 independent experiments carried out in tripli-
cates for HO and MTT assays and in quadruplicates for ORAC, MTT-LPS and NO assays. Signifi-
cances: ***, p < 0.001; **, p < 0.01; *, p < 0.05 versus control. Comparison between groups was 
made using two-sided paired Student’s t test. A p value < 0.05 was considered statistically signif-
icant. Calculations were performed using Microsoft Office Excel 2007 and Origin 8 SR4 (Origin 
Lab Corporation 1991-2008). IC50 values were calculated with the Excel sheet ED50plus v1.0, 
(M.H. Vargas, Mexico).  
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3 Results and Discussion 
3.1 Heme oxygenase-1 (HO-1) activity assay 
Based on the HO enzymatic activity assay and the quantification of bilirubin by an indirect ELISA 
method a combined concept for the HO-1 activity assay was developed. A microtiterplate assay 
format was designed for all steps of the HO-1 assay, including cell culture, stimulation with po-
tential HO-1 inducers, cell lysis, HO enzymatic activity assay and ELISA-based bilirubin quantifi-
cation. The present work is based on assay optimizations made previously in the diploma thesis 
(Hannelore Rücker, Universität Regensburg, October 2009).78 Some ELISA parameters were suc-
cessfully optimized in the diploma thesis, such as the concentration of the bilirubin-BSA conju-
gate for coating the immunoplate and the amount of the anti-bilirubin antibody or the second 
HRP-conjugated antibody, and were used without no further optimization in this work as de-
scribed in Materials and Methods. Further HO-1 assay parameters such as the cell line, the cell 
sample preparation, the parameters for the HO enzymatic reaction and the range of the bilirubin 
standard concentrations were developed and optimized in the present work.  
3.1.1 Development and optimization of the HO-1 activity assay 
3.1.1.1 Cell lines 
The cell line HT-29 was used as an in vitro model to develop the HO-1 assay and was replaced by 
the murine macrophage cell line RAW264.7, which is known to show inducible HO-1 activity.70, 
162 The RAW264.7 cell line has been used in the Griess assay to assess the anti-inflammatory 
activity of natural products such as polyphenols, by determining their influence on the proin-
flammatory pathway that involves NF-κB and thus the induction of iNOS, COX-2 and TNF-α. 
Thereby, the inhibitory effect of tested compounds is assessed, by determining the NO produc-
tion in RAW264.7 stimulated with lipopolysaccharides (LPS). An advantage of the RAW264.7 cell 
line is the fast rate of growth of 3 days, allowing a higher screening efficiency for compounds, 
compared to the human cell line HT-29 which reaches cell confluence after one week. Some HO-
1 assay parameters optimized with the cell line HT-29 as indicated below, were also used in the 
optimization of the HO-1 assay with RAW264.7 cells.  
3.1.1.2 Optimization of the cell lysis 
The lysis buffer was found to be a crucial parameter for the HO-1 assay development. As an in-
tracellular membrane protein, a sufficient amount of soluble HO-1 protein is present when a 
whole cell lysate is prepared. With an increased total protein amount in the whole cell lysate a 
higher HO-1 protein content is assumed. The optimization of a suitable lysis buffer for the cell 
lysis started with the addition of the ionic detergent SDS (1.0% v/v). But, high concentrations of 
56 
 
SDS in the lysis buffer were not recommended due to the risk of protein denaturation during cell 
lysis. Therefore a mild but sufficient detergent in the lysis buffer was necessary.  
 
Figure 19. Structures of non-ionic and ionic detergents used to optimize the lysis buffer in the cell lysis. 
For this purpose the non-ionic detergents Nonidet P-40, Triton X-100 and Brij 97 (Figure 19) 
were screened for their efficiency in the cell lysis of HT-29 cells in the 96-well plate and the re-
sults are summarized in Figure 20.  
 
Figure 20. Influence of different detergent concentrations in the lysis buffer on the cell lysis of HT-29 cells. 
Cell lysis of HT-29 was performed with lysis buffer 2 (LB2, see Table 7) in case of the detergents Nonidet P-40, 
Triton X-100 and Brij 97 and compared to the cell lysis performed with 0.375% SDS in lysis buffer as de-
scribed in Material and Methods. Protein amounts were determined with the detergent compatible protein 
assay (Bio-Rad) as described in Material and Methods. 
HT-29 cells were incubated with the lysis buffer 2 (Table 7) containing the detergents Nonidet 
P-40, Triton X-100 and Brij 97 in the concentration range of 0.1 to 1.0% (w/v) for 1 h at 4 °C on 
an orbital plate shaker. The total protein content of the obtained whole cell lysate was deter-
mined by the detergent compatible protein assay (Bio-Rad) as described in Material and Meth-
ods, section ‎2.2.6.3.  
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Figure 21. Influence of increasing detergent concentrations in the lysis buffer on the absorption signal. 5-50 · 
10-9 M of bilirubin (BR) were added to the lysis buffer (LB2, see Table 7) in presence of different concentra-
tions of detergent as indicated and bilirubin content was detected via ELISA. A representative data set is 
shown. A lower signal indicates higher bilirubin amounts, due to the indirect ELISA method.  
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Additionally, cell lysis with HT-29 cells was performed with lysis buffer (40 mM TRIS-HCl, pH 7.4, 
250 mM sucrose, 10 mM EDTA, 100 mM NaCl, 4% protease inhibitor cocktail) containing 
0.375% of SDS, a slightly changed procedure to the method used in the diploma thesis, in order 
to compare the efficiency of SDS to the mild detergents in the lysis buffer. As shown in Figure 20 
with an increased detergent concentration in the lysis buffer a higher protein content in cell ly-
sate could be determined. Moreover, the overall protein content in the whole cell lysate obtained 
with the mild, non-ionic detergents Nonidet P-40, Triton X-100 and Brij 97 was higher (18-33 µg 
protein/well) compared to the protein content of the lysis buffer with 0.375% SDS (9.0 µg pro-
tein/well), suggesting a more efficient cell lysis when using a non-ionic detergent. 
Next, a possible interference of an increased detergent concentration in the lysis buffer with the 
detection of bilirubin in the sample was investigated and results are depicted in Figure 21. 
Known bilirubin concentrations were added to lysis buffer 2 (Table 7) containing several deter-
gent concentrations as indicated and bilirubin was detected via ELISA.  
An increase in the absorbance signal was observed in presence of increased detergent concen-
trations in the lysis buffer as depicted in Figure 21. A similar behavior was observed for all test-
ed detergents Triton X-100, Nonidet P-40 and Brij 97. Since the absorption signal was indirect 
proportional to the detected bilirubin (BR) in the sample, the results suggest an inhibition of the 
bilirubin detection by an increasing amount of detergent in the lysis buffer. High concentrations 
of detergent in the lysis buffer can interfere with the epitope-antibody interactions in the ELISA 
and inhibit the binding of the anti-bilirubin antibody 24G7 to bilirubin. These results suggest 
that the ELISA procedure tolerates a detergent concentration of 0.1% (w/v) in the lysis buffer. 
At a concentration of 0.1% of detergent in the lysis buffer cell lysis performed well, see Figure 20. 
Therefore, a final detergent concentration of 0.1% in the lysis buffer is a good compromise be-
tween cell lysis and ELISA tolerance.  
Table 7. Contents of different lysis buffers, pH 7.4 screened for the optimization of the HO-1 activity assay. 
lysis buffer 1 (LB1) lysis buffer 2 (LB2) modified RIPA buffer Brij 97 buffer 
137 mM NaCl 137 mM NaCl 150 mM NaCl 150 mM NaCl 
40 mM TRIS-HCl 40 mM TRIS-HCl 50 mM TRIS-HCl 10 mM TRIS-HCl 
250 mM sucrose 250 mM sucrose 0.05% Nonidet P-40 2 mM EDTA 
2 mM EDTA 
10% glycerine 
2 mM EDTA 
10% glycerine 
0.25% sodium deoxy-
cholate 
0.0875% Brij 97 
0.0125% Nonidet P-40 
0.1% Triton X-100 
0.25% sodium deoxy-
cholate 
4% complete protease 
inhibitor cocktail 
(Roche) 
0.1% Triton X-100 
4% complete protease 
inhibitor cocktail 
(Roche) 
0.05% SDS 
4% complete protease 
inhibitor cocktail 
(Roche) 
4% complete protease 
inhibitor cocktail 
(Roche) 
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In order to further improve the lysis buffer system, several lysis buffers containing different de-
tergents at concentrations not higher than 0.1% were investigated. Whole cell lysates of HT-29 
cells were prepared, incubated with known bilirubin concentrations and analyzed via ELISA as 
shown in Figure 22. Here the non-ionic detergents Brij 97, Triton X-100 and Nonidet P-40 or the 
ionic detergents SDS and sodium deoxycholate were compared in the different lysis buffer sys-
tems (Table 7). The highest amount of added bilirubin to the sample was detected with lysis 
buffer 2 containing only 0.1% of Triton X-100, which was shown by a low absorption signal. A 
high absorption level and thus a low detection of bilirubin in the sample was observed in the 
presence of the modified RIPA buffer and the Brij buffer, suggesting an inhibitory effect of the 
detergents present in the buffers. In some cases precipitation in the whole cell lysate was ob-
served during the enzymatic HO reaction step, when the lysis buffer 1 and RIPA which contained 
sodium deoxycholate were used.  
 
Figure 22. Influence of different lysis buffers on the detection of bilirubin (5-50 · 10-9 M) measured in whole 
cell lysates of HT-29 cells via ELISA. Data represents the mean of 3 independent experiments carried out in 
triplicates.  
Based on the results and the observations made, lysis buffer 2 was found to be the optimal lysis 
buffer system in the cell lysis of HT-29 cells. Furthermore, no significant difference in the total 
protein amount of the whole cell lysate of HT-29 cells was obtained upon cell lysis with the dif-
ferent lysis buffers (Table 7). Taken together, lysis buffer 2 containing 0.1% of Triton X-100 gave 
the best results concerning the cell lysis and the compatibility with the bilirubin detection via 
ELISA in the obtained whole cell lysate.  
Cell lysis with the cell line RAW264.7 was also performed with lysis buffer 2 containing 0.1% of 
Triton X-100 and gave good results. The cell lysis incubation time of 1 h at 4 °C could be reduced 
to 15 min at 4 °C without decreasing the amount of total protein in the whole cell lysate. After 
changing the model cell line for the HO-1 assay from HT-29 to RAW264.7 lysis buffer 2 (Table 7) 
was used routinely in the cell lysis of RAW264.7 (see section ‎2.2.6.2) and is mentioned in the 
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following as lysis buffer. The average total protein content in whole cell lysates of RAW264.7 
control cells incubated for 24 h was 0.284 ± 0.067 mg mL-1, corresponding to 25.6 µg per sample. 
3.1.1.3 Optimization of the HO enzymatic reaction conditions 
pH 
The lysis buffer and thus the obtained whole cell lysate serves as reaction mixture for the 
HO/BVR enzymatic reaction. A constant pH of 7.4 of the lysis buffer solution throughout the as-
say is required. The physiological pH of 7.4 is in the maximum activity range of HO56 and is also 
tolerated for biliverdin reductase (BVR) despite the non-optimal pH conditions for this enzyme. 
BVR shows a pH optimum at 8.5-8.7 and requires NADPH as cofactor.223 It was crucial to find 
conditions for the cell lysis and the HO/BVR reaction that are compatible with the highly sensi-
tive bilirubin-ELISA quantification. 
The protease inhibitor cocktail is a necessary additive to the lysis buffer, ensuring the stability of 
enzymes due to protein degradation mechanisms activated when cells are lysed. For the HO-1 
activity assay a convenient protease inhibitor cocktail in tablet form (Roche, Mannheim) was 
used, from which 25-fold stock solutions were prepared in water as recommended by the manu-
facturer to give a pH of 7.0. In a control experiment the pH of the lysis buffer solution was meas-
ured using pH test stripes (Roth, Karlsruhe) to ensure the necessary pH of 7.4 during the HO-1 
assay steps. The results are summarized in Table 8. Addition of the protease inhibitor cocktail to 
the freshly prepared lysis buffer (entry 1) decreased unexpectedly the pH of the buffer substan-
tially from 7.4 to suboptimal reaction conditions for HO and BVR (pH 5.5). Raising the pH of the 
lysis buffer stock solution to pH 7.8 or 8.0 gave for the ready to use lysis buffer in the cell lysis 
the intended pH of 7.4 (entry 1, columns 4 and 5). With an increased pH of 7.8 or 8.0 of the lysis 
buffer stock solution, the pH of the reaction mixture remained also stable during the HO/BVR 
reaction (entry 2, columns 4 and 5).  
Table 8. pH measurements in the lysis buffer solution and the whole cell lysates of RAW264.7 cells during the 
HO-1 assay. Stock solutions of the lysis buffer were prepared with pH 7.4, 7.8 and 8.0 and after addition of 
protease inhibitor (1st entry). Cell lysis was performed as described in Materials and Methods (‎2.2.6.2). The 
pH of the yielding whole cell lysate was then determined in every step of the HO-1 assay as indicated (entry 2-
4) using pH test stripes. 
Entry HO-1 activity assay condition 
pH of lysis buffer stock solution 
7.4 7.8 8.0 
1 lysis buffer ready to use for cell lysis 
(+ protease inhibitor cocktail) 
5.5 7.4 7.4 
2 HO/BVR enzyme assay in whole cell lysate 5.5 7.4 7.4 
3 stop of reaction with 1 M HCl  
and pH readjustment with 1 M NaOH 
1.0 
7.4 
1.0 
7.4 
1.0 
7.4 
4 ELISA (incubation with anti-BR antibody) 7.4 7.4 7.4 
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The suboptimal HO/BVR reaction conditions of pH 5.5 could also be observed when the HO ac-
tivity was determined in RAW264.7 cells using the lysis stock solution with an initial pH of 7.4 
for the HO-1 assay (Figure 23). RAW264.7 cells were stimulated with 10 µM of curcumin for 24 h 
and HO activity was measured via ELISA. Lysis buffer stock solutions with an initial pH of 7.4, 7.8 
and 8.0 were used to prepare lysis buffer the ready to use for cell lysis; HO reaction and ELISA 
was performed as described in Material and Methods. The amount of bilirubin was determined 
using a linear regression analysis of the bilirubin standard curve (5-50 · 10-9 M) measured in 
lysis buffer. Figure 23 shows an increase of HO enzymatic activity due to an increase of the pH of 
the lysis buffer used to prepare the whole cell lysate, suggesting an improvement of the reaction 
condition for both enzymes, HO and BVR.  
 
Figure 23. Influence of the pH of the lysis buffer on the HO activity. RAW264.7 cells were stimulated with 10 
µM of curcumin for 24 h and HO activity was determined via the ELISA based HO-1 assay in whole cell lysate. 
Lysis buffers (lysis buffer 2, Table 7) were prepared using lysis buffers stock solutions with different pH as 
indicated. The amount of bilirubin was determined using a linear regression analysis of the bilirubin stand-
ard curve (5-50 · 10-9 M) measured in lysis buffer. Data represents the mean ± SD of 3 independent experi-
ments carried out in triplicates.  
Taken together, an optimized lysis buffer system using a lysis buffer stock solution with an ini-
tial pH of 8.0 to give the necessary pH of 7.4 in the lysis buffer solutions, improved the condi-
tions of the enzymatic reaction and also of the entire assay. 
Reaction mixture additives: BVR, hemin and NADPH 
Whole cell lysates were directly incubated with the HO/BVR reaction mixture, containing hemin, 
NADPH and a BVR source. In the beginning of the assay development the HO/BVR reaction was 
conducted with a liver cytosol fraction as a BVR source in order to convert biliverdin into biliru-
bin. The liver cytosol, a microsomal fraction received by ultracentrifugation, contained also HO-1 
and/or HO-2 proteins and bilirubin that can overcompensate the measured HO activity present 
in the whole cell lysate sample, which was quickly prepared in the 96-well plate without prior or 
later centrifugation step. In a control experiment, the amount of liver cytosol usually added to 
the whole cell lysate (98 µg/well) for the enzymatic HO/BVR reaction was assayed for its HO 
activity. The liver cytosol fraction was incubated with 3 mM NADPH and 25 µM hemin in lysis 
62 
 
buffer pH 7.4 and for control the liver cytosol was assayed in lysis buffer alone, as described in 
section ‎2.2.6.9. The liver cytosol contained 7.66 ± 1.1 nmol L-1 of bilirubin and the amount in-
creased to 29.2 ± 2.6 nmol L-1 of bilirubin when NADPH and hemin were added to the liver ex-
tract. A fourfold increase in the bilirubin concentration implicated a HO and BVR activity in the 
liver extract. With a protein amount of 98 µg a HO activity of 38.7 ± 3.4 pmol bilirubin h-1 mg-1 
protein of the liver cytosol fraction could be determined. To avoid a overcompensation of the 
bilirubin and HO activity detection in the whole cell lysates when liver cytosol extract in used in 
the HO-1 assay, a purified BVR source was chosen. A commercial BVR recombinant rat protein 
was used for the HO enzymatic reaction in the assay with a specific activity of >180 nmol 
biliverdin mg-1 min-1 for pH 8.5 at 37 °C. Under the HO-1 assay conditions with pH 7.4 and 37 °C 
a 4 fold decrease in BVR activity can be estimated223 and gives for a reaction time of 60 min a 
specific activity for BVR of 2700 nmol mg-1 h-1 or 2.7 pmol ng-1 h-1.  
The necessary excess amount of hemin, NADPH and recombinant BVR in the HO reaction mix-
ture was screened, to insure an accurate HO activity present in the whole cell lysate samples 
especially in higher induced cells. Initially, 1.0 ng BVR, 0.3 mM NADPH and 2.5 µM hemin were 
added to the HO reaction mixture. A more concentrated reaction mixture containing 3.0 mM 
NADPH, 25 µM hemin and 3.7 ng of BVR was also tested. Additionally, combinations of both 
preparations were screened: 3.7 ng BVR, 0.3 mM NADPH, 2.5 µM hemin and 1.0 ng BVR, 3.0 mM 
NADPH, 25 µM hemin. The HO/BVR reaction mixtures were incubated with whole cell lysates of 
control and stimulated RAW264.7 cells (with 10 µM of the chalcone DHDMCH, for structure see 
Figure 11, section ‎1.6) and results are shown in Figure 24.  
 
Figure 24. Effect of low and high concentrations of the HO reaction mixture, containing BVR, NADPH and 
hemin on the HO-1 activity measured by the ELISA-based HO-1 assay in RAW264.7 cells stimulated with 10 
µM of chalcone DHDMCH for 6 h. The amount of bilirubin was determined using a four parameter logistic 
equation fit of the sigmoidal bilirubin standard curve (0.5-2500 · 10-9 M) measured in whole cell lysates.. Data 
represents the mean ± SD of 2-4 independent experiments carried out in triplicates. 
The highest HO activity could be observed in the presence of the reaction mixture containing 
1.0 ng BVR, 0.3 mM NADPH and 2.5 µM hemin, while higher concentrations of each component 
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decreased the HO activity, which can be explained by feedback-inhibition of the substrate. Also 
the combinations of both preparations showed no increase in HO activity. Taken together, the 
results suggest that 1.0 ng BVR, 0.3 mM NADPH and 2.5 µM hemin were sufficient to cover the 
HO activity in the whole cell lysates.  
3.1.1.4 Optimization of the ELISA-bilirubin standard curve 
In the early stages of the HO-1 assay development the bilirubin amount in the sample was quan-
tified based on a linear regression analysis of the bilirubin standard curve measured in lysis 
buffer or cell lysate at concentrations between 5 to 50 · 10-9 M of bilirubin.  
 
 
Figure 25. Representative bilirubin (BR) standard curve for the ELISA-based bilirubin quantification. Biliru-
bin standards (0.5-2500 · 10-9 M) were measured in whole cell lysates of RAW264.7 control cells and a sig-
moidal calibration curve was plotted as the ratio of B/B0 (B = mean absorbance for each ‘bilirubin standard’, 
B0 = mean absorbance for ‘zero control’) against the bilirubin concentrations expressed as lg(BR concentra-
tion). Unknown bilirubin concentrations in samples were determined by a four parameter logistic equation. 
For more details see section ‎2.2.6.6. A, Comparison between the sigmoidal curve fitting (slim line) as indicat-
ed above and the less exact linear curve fitting in the range of 2.5-50 · 10-9 M bilirubin (thick line). B, Detec-
tion range of bilirubin in the assay is presented together with the average bilirubin content in unstimulated 
control cells incubated for 24 h. 
Later on during assay development and new optimized parameters the range of the bilirubin 
standard curve was extended to 0.5-2500 · 10-9 M in order to create the full, for ELISA measure-
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ments typical sigmoidal response curve, which was fitted by a four parameter logistic equation 
in order to quantify the unknown bilirubin in the sample (Figure 25). The typical sigmoidal bili-
rubin standard curve is shown in Figure 25 A, where the added bilirubin amounts (0.5-2500 nM) 
were analyzed in presence of whole cell lysates of unstimulated RAW264.7 cells, were the sig-
moidal and linear curve fit are compared. With the more precise sigmoidal curve fitting analysis 
the quantification of the bilirubin was more accurate, since the bilirubin amount detected in un-
stimulated control cells was near the non-linear range of the standard curve (Figure 25 B). The 
detection range of the ELISA-based HO activity assay was calculated from the bilirubin standard 
curves (which were gained within two years) to be 0.567 ± 0.301 (90% B/B0) to 82.1 ± 25.0 
(10% B/B0) pmol bilirubin in 120 µL assayed sample (compare with Figure 25 B). The average 
bilirubin content in unstimulated control cells was 1.49 ± 0.76 pmol. The average total protein 
content in whole cell lysates (control cells incubated for 24 h) was 0.284 ± 0.067 mg mL-1, corre-
sponding to 25.6 µg per sample.  
3.1.1.5 Quantification of bilirubin and HO-1 activity determination in RAW264.7 macro-
phages 
Bilirubin concentrations for the standard curve were measured in the whole cell lysate to mimic 
the composition of the unknown samples as well as possible, since bilirubin is present in the 
cells. Endogenous bilirubin originates from general HO activity, where both HO-2 and HO-1 ac-
tivity would be included. According to the data obtained by western blot analysis, HO-1 protein 
was present in non-stimulated control cells (see Figure 26 A). Thus, the comparison of the nor-
malized data for control and stimulated cells gave the increase in HO-1 activity. Table 9 de-
scribes an example for the calculation of the HO-1 activity in RAW264.7 cells stimulated with 
25 µM of rosolic acid for 6 h. The bilirubin content in the samples was estimated by the four pa-
rameter logistic curve fit equation (Equation 2) of the bilirubin standard curve measured in 
whole cell lysate as described in Figure 25. The total protein content in the whole cell lysate was 
determined for each sample using a protein assay kit (Bio Rad). The HO activity was determined 
as pmol bilirubin h-1 mg-1 total protein and HO-1 activity was expressed as fold HO-1 activity 
compared to control cells. 
Table 9. Calculation of the HO-1 activity in RAW264.7 cells stimulated with 25 µM of rosolic acid for 6 h.  
 Control cells Stimulated RAW264.7 cells with 
25 µM rosolic acid for 6 h 
Bilirubin [nmol L-1] 11.3 ± 3.6 30.6 ± 10.5 
Total protein [µg per 90 µL of sample] 19.0 ± 7.4 20.5 ± 7.3 
HO activity [pmol h-1 mg-1 protein] 80.9 ± 33.5 205.8 ± 94.8 
x-fold HO-1 activity 1.00 ± 0.0 2.56 ± 0.41 
 The data represent the mean ± SD of 4 independent experiments carried out in triplicates. 
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3.1.2 Time course of HO-1 protein expression and HO-1 activity in RAW264.7 
macrophages exposed to chalcone DHDMCH 
In an initial screening 2’,4’-dihyxdroxy-3,4-dimethoxychalcone (DHDMCH) was identified as a 
potent inducer of HO-1 activity in RAW264.7 cells (see section ‎3.3, Figure 39). 10 µM of 
DHDMCH was used to investigate the time-dependent HO-1 protein expression and HO-1 activi-
ty in RAW264.7 macrophages (Figure 26).  
 
Figure 26. Time-dependent induction of HO-1 by the chalcone DMDHCH (10 µM) in RAW264.7 cells for the 
incubation time indicated. A, HO-1 protein expression (Western blotting), a representative blot of 3 inde-
pendent experiments is shown. B, Relative intensity of HO-1 protein expression, ratio of α-tubulin to HO-1 
expressed as fold of control (0 h). Relative density of protein bands from Western blots was analyzed by the 
software Multi Gauge 3.0 (Fujifilm Life Science) and data is expressed as mean ± SD of three independent blots. 
C, Induction of HO-1 activity. Cells were treated with DHDMCH for the indicated periods and HO-1 activity was 
examined by the HO-1 activity assay via ELISA. Data is expressed as mean ± SD of at least 3 independent ex-
periments. 
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Between 3 and 12 h the HO-1 protein levels increased over time, reached maximum HO-1 pro-
tein level at 12 h, remained elevated after 18 and slightly increased after 24 h (Figure 26, A, B). 
In comparison, the HO-1 activity maximum occurred after 6 h (4.0 fold) and decreased after 12 h 
(Figure 26, C). After 18 h HO-1 activity dropped to 2.0 fold but seemed to recover to 3.3 fold af-
ter 24 h. This result suggests that despite the fact that similar amounts of HO-1 are present at 12, 
18 and 24 h, the HO-1 protein is not fully active after 18 h or that post-translational inhibi-
tion/inactivation occurs over time. The raise of HO-1 activity after 24 h may account for a gen-
eral change in the lysate, which influences the HO activity assay or for newly synthesized active 
HO-1 which could be induced by alternative mechanisms or metabolites of DHDMCH.  
3.1.2.1 HO-1 activity in different cell lysate fractions derived from RAW264.7 cells 
stimulated with 10 µM of DHDMCH 
Whole cell lysates and crude extracts (supernatant fraction after centrifugation) prepared from 
RAW264.7 cells incubated with 10 µM of DHDMCH for 3-24 h were analyzed in parallel for HO-1 
activity by the ELISA-based HO-1 activity assay. The HO-1 activity was compared to the HO-1 
protein expression examined by Western blot analysis. Cell lysate samples were prepared and 
analyzed as described in Figure 27 and results are shown in Figure 28. 
 
Figure 27. Sample preparation for the comparison of Western blot analysis to ELISA analysis of lysates from 
RAW264.7 cells incubated with 10 µM of the chalcone DHDMCH for 3-24 h (see Figure 28). A detailed proce-
dure of the methods is given in chapters ‎2.2.7 and ‎2.2.6. 
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For Western blot analysis the supernatant fraction of the whole cell lysate (crude extract) was 
used. In comparison, whole cell lysates prepared in the 96-well plate were used for the HO-1 
activity assay. Additionally, the crude extracts (Western blot samples) were diluted to a ade-
quate total protein concentration of 200-300 µg ml-1 and analyzed by the ELISA-based HO-1 ac-
tivity assay. Three independent experiments were performed. HO-1 activity determined in the 
crude extracts reached a maximum after 6 h and remained elevated between 12 and 24 h 
(Figure 28, B). The level of HO-1 activity 
follows the level of HO-1 protein expres-
sion (Figure 28, A) over time. A similar 
trend in HO-1 activity was observed with 
the whole lysate samples (Figure 28, C), 
which correlated quite good with the 
HO-1 protein expression. Furthermore, a 
difference in the HO-1 activity deter-
mined between the different fractions of 
cell lysates could be observed. In the par-
tially purified, supernatant fraction of the 
cell lysate (crude extract) a higher HO-1 
activity was found in comparison to the 
HO-1 activity detected in whole cell ly-
sates. This result was expected, since the 
HO protein represents only a fraction of 
the total proteins present in the whole 
cell lysate prepared in the 96-well plate. 
The results suggest that a reasonable 
amount of HO protein can be ‘detected’ in 
the whole cell lysate in order to deter-
mine the HO-1 activity.  
Figure 28. Comparison of HO-1 activity in dif-
ferent cell lysate fractions to HO-1 protein 
expression. RAW264.7 cells were treated with 
DMDHCH (10 µM) for the indicated incubation 
times. A, Relative intensity of HO-1 protein 
expression, ratio of α-tubulin to HO-1 ex-
pressed as fold of control (0 h). B, HO-1 activity 
of crude extracts. C, HO-1 activity of whole cell 
lysates determined by the ELISA-based HO-1 
activity assay. 
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3.1.3 Inhibition of HO-1 activity in DHDMCH or LPS stimulated RAW264.7 macro-
phages by SnPPIX 
In order to further validate the HO-1 assay RAW264.7 cells were exposed to DHDMCH and/or 
lipopolysaccharide (LPS) in presence and absence of the specific HO-1 activity inhibitor tin-
protoporphyrin IX (SnPPIX).224 LPS is a known inducer of HO-1 in RAW264.7 cells,138, 225 which 
causes a proinflammatory response by induction of inducible NO synthase (iNOS)226 that in turn 
leads to an activation of HO-1.  
 
Figure 29. Influence of DHDMCH (10 µM), LPS (10 ng mL-1) and SnPPIX on RAW264.7 cells in the indicated 
combinations when incubated for 24 h. A and B, induction of HO-1 activity; C and D, cell viability (MTT assay). 
Level of significance: ***, p < 0.001; **, p < 0.01; *, p < 0.05 versus control (cells were treated with medium 
alone); #, p < 0.001 versus DHDMCH; $, p < 0.001 versus LPS; §, p < 0.05 versus DHDMCH and LPS; &, p < 0.01 
versus DHDMCH; ~, p < 0.05 versus LPS; @, p < 0.01 versus DHDMCH and LPS. 
In LPS stimulated RAW264.7 cells HO-1 activity was induced (2.3 ± 0.2 fold) and was further 
elevated to 6.2 ± 2.5 fold in the presence of the chalcone DHDMCH. This induction was reduced 
by 52% to 70% when the cells were treated with 5 µM or 10 µM of SnPPIX, respectively (Figure 
29 A and B). Together with LPS the induction of HO-1 activity was abolished by 5 µM of SnPPIX, 
while the induction by DHDMCH was only reduced by 61%. The observation that HO-1 induction 
is only reduced to half by 5 µM of SnPPIX in the presence of the highly active chalcone and even 
less by additional LPS suggests that the amount of HO-1 inhibitor with 5 µM is not quite suffi-
cient to abolish the induced HO-1 activity. But, an equal observation for the HO-1 induction of 
the chalcone was also made when 10 µM of SnPPIX were used (Figure 29, B). Interestingly, with 
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10 µM of inhibitor, the combined HO-1 induction of DHMCH and LPS could be further inhibited 
but reached only the reduced HO-1 activity level of DHDMCH alone. This suggests that there is 
still sufficient HO-1 activity left, which derives from the chalcone and cannot be abolished by the 
amount of 10 µM of SnPPIX inhibitor. Cell viability tests only allowed for a maximum concentra-
tion of 10 µM SnPPIX, since SnPPIX in absence of LPS revealed cytotoxicity of at 20 µM (Figure 
29, D). No cytotoxic effect was observed in the range of 1 to 20 µM of SnPPIX in the presence of 
LPS. Noteworthy is the moderate cytotoxic effect of the chalcone with 5 µM SnPPIX in absence 
and presence of LPS (Figure 29, C), which should be kept in mind the HO-1 activity is evaluated 
when under these conditions.  
3.1.4 Heme oxygenase-1 activity in human dendritic cells (DC) 
As part of the innate immune system dendritic cells (DC) play a key role providing a crucial link 
between the innate and the adaptive immune response.227 DC are able to recognize and capture 
antigens, carrying them to the next lymphoid organ and present them to native T-cells thus acti-
vating the adaptive immune defense system. The activated dendritic cells exert also a variety of 
cytokines that influence the activity of T cells. The cells are used in DC-based immunotherapy 
against cancer and infectious diseases.228-229 It is known that HO-1 is expressed in human DC 
derived from monocytes and that upon HO-1 induction the function of the dendritic cells can be 
altered regarding the maturation state of the cells and their ability to exert the anti-
inflammatory cytokine IL-10.230 Furthermore, the involvement of the Nrf2-ARE pathway leading 
to HO-1 gene expression was elucidated in DC after treatment with several electrophiles and 
pro-oxidative agents.231 
Dendritic cells derived from human monocytes obtained from blood samples of healthy donors 
(kindly provided by the Department of Internal Medicine III, University Hospital of Regensburg) 
were investigated for their heme oxygenase activity in presence of the α-CF3-substituted 
tetrametoxychalcone (TMCH) derivative α-CF3-TMCH (for structure see Figure 12). The adher-
ent dendritic cells were stimulated with 0.5 and 1 µM of α-CF3-TMCH in presence of 100 ng mL-1 
LPS for 24 h and the HO-1 activity in the whole cell lysate was determined. For this test the HO-1 
activity assay was slightly modified. Due to the limited amount of samples the bilirubin stand-
ards were prepared only in lysis buffer instead of the usual cell lysate. This assay modification 
allowed to determine the basal bilirubin level in the cell lysate of untreated DC stimulated with 
LPS together with the HO activity in control DC and DC treated with the chalcone in presence of 
LPS. The results are displayed in Figure 30. 
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Figure 30. Heme oxygenase-1 activity of α-CF3-substituted TMCH (α-CF3) determined in human dendritic cells 
(DC). Cells were treated with α-CF3-TMCH at the indicated concentration in presence of 100 ng mL-1 LPS for 24 
h. From the HO activity determined by the ELISA-based HO-1 activity assay (left diagram), the fold induction 
of HO-1 activity for α-CF3-TMCH compared to control cells was calculated (right diagram). Data represent the 
mean ±SD of 4 independent experiments carried out in triplicates. p > 0.05, Student’s t-test.  
The heme oxygenase activity in DC stimulated with LPS could be elevated in presence of the 
chalcone derivative α-CF3 at a nanomolar concentration (500 nM) from 153 ± 40 to 277 ± 57 
pmol bilirubin h-1 mg-1 total protein. Thus the HO-1 activity was induced by 2.0 ± 0.8 fold by α-
CF3-TMCH at 0.5 µM. This inductive effect was not observed at a higher concentration, although 
at 1 µM no cytotoxic effects occurred (confirmed by microscopic analysis), suggesting a alterna-
tive pathway in DC consuming the chalcone. However, the results were statistically not signifi-
cant, suggesting that 24 h may not be an optimal time to stimulate the DC and that rather a 
shorter incubation time with the chalcone is required. This observation was made in murine 
macrophages RAW264.7, were the α-CF3-TMCH showed a significant inductive effect on HO-1 
protein expression and activity after 6 h of stimulation. However no effect on HO-1 activity was 
observed in RAW264.7 cells after an incubation time of 24 h with 0.5 µM α-CF3-TMCH, see sec-
tion ‎3.4.2. Taken together these results confirm the applicability of the HO-1 activity assay in 
primary human cells.  
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3.2 Screening of natural products and drugs towards their HO-1 acti-
vity in RAW264.7 macrophages 
A structurally diverse group of 18 natural products and synthetic compounds with pharmacolog-
ically interesting activity were screened for their HO-1 induction behavior using the ELISA-
based HO-1 activity assay in the model cell line RAW264.7. The structures are given in Figure 9. 
The cytotoxicity of compounds in RAW264.7 cells was determined prior to the HO-1 activity 
screen and toxic concentrations were excluded from further testing. 
3.2.1 Influence of natural products and drugs on the viability of RAW264.7 mac-
rophages 
The viability of RAW264.7 cells exposed to test compounds for a period of 24 h was determined 
by the MTT assay. Most of the natural products and the synthetic drugs showed a cytotoxic effect 
at 25 or 50 µM (Figure 31 and Figure 32). The natural compounds chlorogenic acid, caffeic acid, 
(-)-epicatechin and 3-hydroxycoumarin revealed no cytotoxicity ≤100 µM. Interestingly, a mod-
erate but significant proliferative effect on RAW264.7 cells exposed to 1 and 5 µM of zerumbone 
was observed. The most toxic compound was the synthetic drug dexamethasone at 500 nM fol-
lowed by CAPE (5 µM) and sulforaphane (10 µM). In preliminary experiments dexamethasone 
was found to be toxic in the range of 100-0.5 µM, displaying a cell viability of 60-70%.  
 
Figure 31. Influence of natural products and synthetic drugs on the viability of RAW264.7 macrophages. Cells 
were incubated with the test compounds at the indicated concentrations for 24 h and cell viability was de-
termined by the MTT assay. 
 
72 
 
 
Figure 32. Influence of natural products and synthetic drugs on the viability of RAW264.7 macrophages. Cells 
were incubated with the test compounds at the indicated concentrations for 24 h and cell viability was de-
termined by the MTT assay. 
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3.2.2 Effect of natural products as well as the two drugs oltipraz and dexame-
thasone on HO-1 activity in RAW264.7 macrophages 
The HO-1 inducer activity of a diverse group of compounds was estimated in RAW264.7 murine 
macrophages using the ELISA-based HO-1 activity assay. The compounds were tested at 4 con-
centrations after 6 and 24 h of stimulation (Figure 33-Figure 35). The indicated test concentra-
tions had no effect on the cell viability after an incubation of 24 h as determined by the MTT as-
say, see Figure 31 and Figure 32.  
 
Figure 33. HO-1 activity was determined in whole cell lysates via the ELISA-based HO-1 activity assay. 
RAW264.7 cells were incubated with test compounds in several concentrations as indicated for 6 and 24 h. 
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Figure 34. HO-1 activity was determined in whole cell lysates via the ELISA-based HO-1 activity assay. 
RAW264.7 cells were incubated with test compounds in several concentrations as indicated for 6 and 24 h. 
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Figure 35. HO-1 activity was determined in whole cell lysates via the ELISA-based HO-1 activity assay. 
RAW264.7 cells were incubated with test compounds in several concentrations as indicated for 6 and 24 h. 
From the 18 compounds tested, 13 proved to induce HO-1 activity in RAW264.7 cells (Table 10) 
with carnosol (8.2 fold at 25 µM) and sulforaphane (3.0 fold at 5 µM) showing the highest induc-
tion after 6 h. The chalcones flavokawain A and cardamonin as well as rosolic acid and 
zerumbone gave a 2.7-2.5 fold induction after 6 h. A lower, but clear induction of 2.3-1.5 fold was 
determined for curcumin, (-)-epicatechin, quercetin, CAPE, kaempferol and xanthohumol after 
the same incubation time. While the majority of the tested compounds showed a higher induc-
tive power after 6 h compared to 24 h, rosolic acid revealed a higher HO-1 activity after 24 h (3.9 
fold at 25 µM). The same applies to dexamethasone, which was inactive after 6 h but showed an 
HO-1 activity induction of 2.0 fold at 0.1 µM. After 24 h only 9 compounds were significantly 
active. A comparison of all compounds at 10 µM follows the same general trend as alluded before. 
Chlorogenic acid, caffeic acid and 3-hydroxycoumarin could not induce HO-1 in RAW264.7 cells, 
which was also found for the known HO-1 inducer resveratrol and the phase II protein inducer 
oltipraz.  
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Table 10. Influence of tested compounds on induction of HO-1 activity in RAW264.7 cells together with their 
toxicity limit (highest non-toxic concentration) determined by the MTT test. 
  Fold induction of HO-1 activity
b 
Compound 
Toxicitya 
limit [µM] 
Maximum 6 h 
(conc [µM]) 
Maximum 24 h 
(conc [µM])  
6 h                       
at 10 µM 
24 h              
at 10 µM 
3-Hydroxycoumarin > 100 ns ns ns ns 
Caffeic acid > 100 ns ns ns ns 
CAPE 1.0 1.93 ± 0.80 (0.25) ns - c - c 
Carnosol 25 8.15 ± 1.93 (25) 1.88 ± 0.22 (25) 3.85 ± 1.08 1.72 ± 0.42 
Chlorogenic acid > 100 ns ns ns ns 
(-)-Epicatechin > 100 2.27 ± 0.91 (50) 1.84 ± 0.54 (25) ns ns 
Curcumin 10 2.29 ± 0.86 (10) ns 2.29 ± 0.86 ns 
Kaempferol 25 1.88 ± 0.31 (10) 1.78 ± 0.39 (25) 1.88 ± 0.31 ns 
Quercetin 10 2.20 ± 0.59 (10) ns 2.20 ± 0.59 ns 
Resveratrol 10 ns ns ns ns 
Rosolic acid 25 2.56 ± 0.41 (25) 3.86 ± 0.40 (25) 1.58 ± 0.28 ns 
Zerumbone 10 2.54 ± 0.73 (10) 2.01 ± 0.71 (10) 2.54 ± 0.73 2.01 ± 0.71 
Sulforaphane 5.0 3.00 ± 1.65 (5) 1.69 ± 0.76 (5) - c - c 
Dexamethasone 0.25 ns 2.04 ± 0.67 (0.10) - c - c 
Oltipraz 25 ns ns ns ns 
Cardamonin 5.0 2.59 ± 1.20 (5) ns - c - c 
Xanthohumol 10 1.52 ± 0.40 (10) 1.20 ± 0.46 (10) 1.52 ± 0.40 1.20 ± 0.46 
Flavokawain A 10 2.73 ± 1.20 (0.5) 1.99 ± 0.50 (10) 1.97 ± 0.79 1.99 ± 0.50 
a Cytotoxicity of test compounds was measured via MTT assay and the highest non-toxic concentrations are 
presented for an incubation time of 24 h (toxicity limit). b Significant stimulation of maximum HO-1 activity is 
shown as fold of induction at concentrations, which were not toxic (cell viability > 80%). Cells were incubated 
for 6 and 24 h with compounds at the indicated concentrations and HO-1 activity (fold of control, p ≤ 0.05) was 
determined in whole cell lysates via the ELISA-based HO-1 activity assay. ns, not significant, c no data was 
gained due to toxicity at this concentration. 
The ability of CAPE, curcumin and rosolic acid to induce HO-1 activity in RAW264.7 cells deter-
mined with the HO-1 activity assay is in line with previous studies where these compounds were 
found to induce HO-1 activity in other cell lines (see Table 1). Our findings are also in agreement 
with the literature for xanthohumol, (-)-epicatechin, zerumbone, sulforaphane and carnosol, 
since their inductive potential on HO-1 mRNA and/or protein level was determined in other cell 
models (see Table 1). The two flavonoids quercetin and kaempferol were reported to induce HO-
1 protein expression in RAW264.7 cells at concentrations of 100 µM,139, 232 which we found to be 
cytotoxic in our assay. Nevertheless, the group reports an increase of HO-1 protein expression 
after 8 h with a maximum peak at 12 h which decreases after 24 h in the presence of 100 µM of 
flavonoid, which is similar to our findings showing a higher activity of the compounds after 6 h 
rather than 24 h. In a recent study quercetin was found to increase the HO-1 protein level in a 
concentration-dependent manner (0.5-10 µM) after 24 h of stimulation in RAW264.7 cells. Here 
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the group found a cytotoxic effect of quercetin in the range of 25-100 µM.233 For caffeic acid and 
chlorogenic acid our finding is in line with the literature, where they were found to be inactive. 
Moreover, 3-hydroxycoumarin which induced the phase II protein NQO1 in murine hepato-
cytes119 did not increase HO-1 activity in RAW264.7 cells.  
The activation of the Nrf2 signaling pathway was shown to be essential for the chemopreventive 
actions of oltipraz,116 therefore a possible induction of HO-1 activity by oltipraz was assumed. 
Also induction of HO-1 on protein and activity level was shown for the structurally related 
dithiolethiones in hepatocytes.234 The mechanism by which Nrf2 is induced by dithiolethiones is 
an increase of the intracellular H2O2 production upon reductive cleavage of the S-S bond of 
dithiolethiones leading to generation of O2• radicals.235 However, in our HO-1 activity assay 
oltipraz showed no inductive activity after 6 and 24 h in RAW264.7 cells. 
3.2.3 Effect of natural products and dexamethasone on the HO-1 protein expres-
sion in RAW264.7 macrophages 
In addition to the HO-1 activity measurements, some selected compounds were also investigated 
towards their ability to increase the HO-1 protein expression in RAW264.7 cells in order to eval-
uate the results in the HO-1 activity assay. The results of the Western blot analysis are shown in 
Figure 36.  
 
Figure 36. Effect of natural products and the drug dexamethasone on HO-1 protein expression. RAW264.7 
macrophages were incubated with compounds at different concentration for 6 and 24 h as indicated and 
Western blot analysis was performed with 33 µg of protein. con, control; Res, resveratrol; Dex, dexame-
thasone; Zer, zerumbone; Carn, carnosol; Card, cardamonin; Flav, flavokawain A. 
The most potent natural compounds found in the HO-1 activity screen, zerumbone, carnosol, 
cardamonin, flavokawain A and rosolic acid revealed also an inductive activity on the HO-1 pro-
tein level, confirming the results of the HO-1 activity assay. Resveratrol induced HO-1 protein 
expression after 6 h of incubation with RAW264.7 cells and decreased to control level after 24 h. 
Similar observations were made with dexamethasone. 
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Resveratrol was found to be inactive after 6 and 24 h in the HO-1 activity assay, suggesting that 
the HO-1 protein expressed after 6 h remains inactive in the RAW264.7 cells upon resveratrol 
treatment. One can assume that alternative pathways may be triggered by resveratrol that can 
suppress the activity of the expressed HO-1 protein, since it is known that resveratrol can acti-
vate multiple signaling pathways in the cell. Resveratrol has shown to stimulate HO-1 expression 
in human cells143 as a respond to the activation of the proinflammatory NF-κB. On the contrary, 
it was also shown that in RAW264.7 macrophages resveratrol exerts anti-inflammatory activity 
by suppressing the NF-κB signaling pathway.123 These reports may suggest that HO-1 induction 
by resveratrol in RAW264.7 cells may be in parts mediated by the activation of the NF-κB path-
way. Another mechanism of action of resveratrol was found in rat cells, where the induction of 
HO-1 expression was triggered by activating the Nrf2/ARE pathway as well as the ERK path-
way.130 Beside this, resveratrol could not induce HO-1 protein expression or enzyme activity67 in 
rat astrocytes, only an increase in mRNA level could be observed.146 In conclusion these reports 
suggest that HO-1 induction by resveratrol relies on activation of multiple signaling pathways 
and that its activity can be cell type specific.  
The glucocorticosteriod dexamethasone could elevate the HO-1 protein expression after 6 h 
while after 24 h the expression level of HO-1 decreased to control level in RAW264.7 cells at a 
concentration of 100 nM. On the contrary, no significant HO-1 activity was determined in 
RAW264.7 cells after 6 h, although some non significant induction of HO-1 activity was observed 
(Figure 34). Unexpectedly, HO enzyme activity doubled after 24 h upon dexamethasone treat-
ment of RAW264.7 cells, which cannot be fully explained, since no HO-1 protein expression was 
detected after 24 h. In HeLa cells dexamethasone could induce HO-2 mRNA and protein level by 
activating the GRE (glucocorticoid response element) present in the promoter region of the HO-
2 gene, while HO-1 mRNA was not detected. Also a increase in HO activity was observed in HeLa 
cells upon treatment with dexamethasone.150 These findings may explain our observations of the 
increase in HO activity without an increase in HO-1 protein expression after 24 h. The detected 
HO activity may derive in this case from HO-2 induction in RAW264.7 cells by dexamethasone. 
These findings are interesting and need to be further investigated concerning the influence of 
dexamethasone on HO-2 in RAW264.7 cells. 151 
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3.3 Characterization of chalcones towards their anti-inflammatory, 
antioxidative and cytoprotective activity 
A group of natural and synthetic hydroxy and methoxychalcones (Figure 11) was characterized 
towards their anti-inflammatory and antioxidant behavior in RAW264.7 murine macrophages. 
Furthermore, a cell-free ORAC-fluorescein assay performed under physiological conditions was 
used to determine the radical scavenging properties of the chalcones and establish an antioxi-
dant capacity compared to the vitamin E derivative Trolox.  
3.3.1 Effect of chalcones on the viability of RAW264.7 macrophages 
The cytotoxicity of chalcones in RAW264.7 cells was determined and toxic concentrations 
(< 80% viability) were excluded from further testing. Most of the chalcones showed cytotoxic 
effects at 25 µM, however ISL, THMCH and 2’-hydroxychalcone were toxic at 50 µM. The most 
toxic chalcone found, was calythropsin at 5 µM. Calythropsin is known for its cytotoxic effects.182-
183  
 
Figure 37. Influence of chalcones on the viability of RAW264.7. Cells were treated with the test compounds at 
the indicated concentrations for 24 h and cell viability was determined by the MTT assay.  
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Interestingly, ISL showed a significant proliferative effect up to 20% on RAW264.7 cells at 5 and 
10 µM (Figure 37). The potential cytotoxic effect of these chalcones was further investigated in 
LPS-stimulated RAW264.7 macrophages, where the compounds were incubated together with 
10 ng mL-1 LPS for 24 h and viability was assessed by the MTT-LPS test (Figure 38). Here, the 
cytotoxic concentrations were eliminated from further testing, relevant in the iNOS inhibition 
assay, were LPS-stimulated RAW264.7 cells were used to determine the influence of chalcones 
on the NO production. The chalcones were tested in the same concentration range as in the MTT 
assay without LPS addition except for 2’-hydroyxchalcone and calythropsin, were their influence 
in presence of LPS was tested at lower concentrations. All chalcones show a similar toxicity pat-
tern, but a higher toxicity level in the presence of LPS when compared with their influence on 
RAW264.7 cells without LPS stimulation. This can be explained by a minor effect of LPS on the 
cell viability of RAW264.7 cells (> 80% viability, see Figure 29, C), which could influence the 
toxicity of the chalcones. LPS is a cell wall component of gram-negative bacteria, acting as a bac-
terial endotoxin and inducing an inflammatory state in cells.236-237  
 
Figure 38. Influence of chalcones on the viability of LPS-stimulated RAW264.7. Cells were treated with the test 
compounds at the indicated concentrations and in the presence of 10 ng mL-1 LPS for 24 h and cell viability 
was determined by the MTT-LPS assay.  
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3.3.2 Influence of chalcones on HO-1 activity and HO-1 protein expression 
The natural and synthetic chalcones were screened for their HO-1 induction behavior (Table 11) 
using the ELISA-based HO-1 activity assay. The compounds were tested typically at 4 concentra-
tions that had no strong influence on the cell viability (> 80%) after 6 and 24 h of stimulation, 
which were found to be good time points for DHDMCH (see Figure 26). All of the 9 tested 
chalcones proved to induce HO-1 activity in RAW264.7 cells (Figure 39 and Figure 40) with 
DHDMCH showing the highest induction after 6 h of incubation (6.1 fold at 10 µM), which could 
still be observed after 24 h (3.8 fold). Interestingly, all tested chalcones showed a significant HO-
1 activity induction after 6 h, a relatively short incubation time. While ISL, butein, DHDMCH and 
TMCH showed a prolonged inductive activity after 24 h, the other chalcones displayed a signifi-
cant activity only after 6 h and were inactive after 24 h. 
Table 11. Influence of chalcones on induction of HO-1 activity in RAW264.7 cells together with their toxicity 
limit (highest non-toxic concentration) determined by the MTT test. 
  Fold induction of HO-1 activity
b 
Compound 
Toxicitya 
limit [µM] 
Maximum 6 h 
(conc [µM]) 
Maximum 24 h 
(conc [µM]) 
6 h                       
at 10 µM 
24 h              
at 10 µM 
DHDMCH 15 6.05 ± 2.31 (10) 3.84 ± 1.47 (10) 6.05 ± 2.31 3.84 ± 1.47 
ISL 25 3.43 ± 1.53 (25) 1.93 ± 0.70 (25) 2.00 ± 0.71 1.40 ± 0.38 
Butein 10 3.07 ± 1.79 (10) 1.91 ± 0.31 (10) 3.07 ± 1.79 1.91 ± 0.31 
TMCH 10 2.96 ± 0.23 (10) 2.35 ± 0.32 (10) 2.96 ± 0.23 2.35 ± 0.32 
THMCH 10 2.91 ± 1.05 (10) ns 2.91 ± 1.05 ns 
2'-Hydroxychalcone 25 2.38 ± 0.57 (5.0) ns 2.05 ± 0.84 ns 
Chalcone 10 2.15 ± 0.67 (10) ns 2.15 ± 0.67 ns 
Calythropsin 1 2.17 ± 0.63 (0.1) ns -c -c 
HTMCH 10 1.52 ± 0.17 (1.0) ns ns ns 
a Cytotoxicity of test compounds was measured via MTT assay and the highest non-toxic concentrations 
are presented for an incubation time of 24 h (toxicity limit). b Significant stimulation of maximum HO-1 
activity is shown as fold of induction at concentrations, which were not toxic (cell viability > 80%). Cells 
were incubated for 6 and 24 h with compounds at the indicated concentrations and HO-1 activity (fold of 
control, p < 0.05) was determined in whole cell lysates via the ELISA-based HO-1 activity assay. ns, not 
significant, c no data was gained due to toxicity at this concentration. 
A concentration dependent induction of HO-1 activity was observed for ISL (6 h), butein (24 h) 
and DHDMCH (6 and 24 h), whereas for calythropsin and 2’-hydroxychalcone an indirect con-
centration dependence was found, for both after 6 h. A hormetic-like dose response was detect-
ed for THMCH at 6 h, where at a lower dose the activity was higher than at higher concentrations. 
A slight tendency to hormesis was observed for chalcone (6 h) and butein (6 h), although at low 
concentration the data was not significant, due to a high deviation of these data points. The 
chalcone HTMCH showed no concentration dependent HO-1 activity.  
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Figure 39. HO-1 activity was determined in whole cell lysates via the ELISA-based HO-1 activity assay. 
RAW264.7 cells were incubated with test compounds in several concentrations as indicated for 6 and 24 h. 
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Figure 40. RAW264.7 cells were incubated with the chalcone TMCH at 1 and 10 µM as indicated for 6 and 24 h 
and HO-1 activity was determined in whole cell lysates via the ELISA-based HO-1 activity assay.  
The data in the HO-1 activity screen showed that hydroxy-rich chalcones, such as ISL and butein, 
are in favor for a high induction of HO-1 activity, suggesting a combination between antioxidant 
activation mechanisms and Michael acceptor reactivity. The positive influence of the 2’-hydroxy 
group on the HO-1 activity was observed when comparing 2’-hydroxychalcone (2.4 fold) to 
chalcone (1.4 fold) at 5 µM. However, this effect could not be observed in the case of HTMCH 
compared to the tetramethoxychalcone TMCH, where the HO-1 activity decreased from 3.0 to 
1.5 fold after 6 h, when the 2’-hydroxy group was present in the chalcone. Interestingly, the 
tetramethoxychalcone, TMCH showed a quite similar inductive activity as butein, suggesting 
different activation mechanisms of the chalcones, which come into play for HO-1 activation. The 
introduction of methoxy groups into the chalcone seems to retain the activity of these, when 
comparing the elevation of HO-1 activity from 2.2 fold in the case of chalcone to 3.1 and 3.0 fold 
for butein and TMCH, respectively after 6 h. The two regioisomers, concerning the methoxy 
groups, calythropsin and THMCH displayed a similar induction of HO-1 activity after 6 h in a 
nanomolar range of 2.2 fold at 100 nM and 2.5 fold 500 nM, respectively. A strong inducer in our 
screen was DHDMCH, the most potent chalcone in the HO-1 assay with a 6.1 fold increase of HO-
1 activity at 10 µM after 6 h, which showed also an induction on HO-1 protein expression (Figure 
26 A). The specific substitution motif on both aromatic rings, the two less electron donating 
methoxy groups on the B-ring and the two stronger electron donating hydroxy groups on the A-
ring, seems to retain the reactivity of the α,β-unsaturated carbonyl moiety, since its double bond 
can be regarded as a push-pull double bond. Together with DHDMCH, butein and TMCH dis-
played the highest inductive HO-1 activity after a prolonged incubation time of 24 h, making 
these compounds most promising for parent chalcones for further investigations concerning the 
HO-1 activity in vitro.  
For the most chalcones tested our data on HO-1 activity is in line with literature results. Similar 
to our results, butein was found to induce HO-1 activity in a concentration and time dependent 
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fashion in human dental pulp cells between 2.5 and 20 µM with a maximum induction after 18 h 
of stimulation.166 Motterlini et al. showed that 2’-hydroxychalcone (2’-HOC) induces heme 
oxygenase activity in RAW264.7 after 6 h at a concentration of 15 and 30 µM (2 fold induction 
compared to control level). But they also showed that at concentrations ≥30 µM 2’-HOC de-
creased the cellular metabolism of macrophages,69 which means that data gained at 30 µM of 
2’HOC has to be interpreted carefully. ISL showed in the HO-1 activity assay a high inductive 
activity of HO-1 after 6 h (3.4 fold), which decreases after 24 h to a 1.9 fold induction compared 
to control cells. This data supports the findings of the group of Lee et al.,178 where in the pres-
ence of 10 µM ISL an increase of HO-1 protein was detected after 4 h and reached a maximum 
level after 12 h of incubation in RAW264.7 cells. However, the effect of ISL after 24 h of stimula-
tion was not reported.  
3.3.3 Effect of chalcones on nitrite production 
The inhibitory influence of chalcones on the NO production, and thus iNOS activity in RAW264.7 
macrophages stimulated with LPS for a period of 24 h was investigated. The NO production was 
determined by the nitrite level in LPS-stimulated RAW264.7 cells via the Griess assay. Amongst 
the tested compounds, 7 out of 9 displayed a significant inhibitory activity on the nitrite produc-
tion, only chalcone and calythropsin were inactive (Figure 41). The selected test concentrations 
had no cytotoxic effect (viability > 80%, see Figure 38) on RAW264.7 macrophages that could 
influence the results. All active chalcones showed a concentration dependent reduction of NO 
generation. Table 12 summarizes the observed maximum inhibition of NO production for the 
chalcones, which was for the most potent to the less active ones at their toxicity limit. 
Table 12. Inhibition of NO production in LPS-stimulated RAW264.7 macrophages determined by the Griess 
assay. Significant maximum NO inhibition values are given together with the toxicity limit (highest non-toxic 
concentration) determined by the MTT assay in presence of 10 ng mL-1 LPS after an incubation time of 24 h. 
Compound 
Toxicity limit 
[µM] 
Maximum inhibition 
of NO production, % 
(conc. [µM]) 
TMCH 10 96.9 ± 11.9 (10) 
DHDMCH 10 72.9 ± 7.7 (10) 
Butein 5 54.5 ± 4.3 (5.0) 
HTMCH 10 52.2 ± 16.5 (10) 
THMCH 10 42.7 ± 3.1 (10) 
ISL 10 38.0 ± 7.4 (10) 
2’-Hydroxychalcone 25 43.6 ± 8.7 (25) a 
Chalcone 10 ns 
Calythropsin 1 ns 
ns, not significant (no significant NO inhibition observed). a 2’-
Hydroxychalcone gave at 10 µM a NO inhibition of 19.6 ± 8.4%. 
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Figure 41. Influence of chalcones on NO production. RAW264.7 cells were exposed to 10 ng mL-1 LPS alone 
(control) and LPS in presence of chalcones in the indicated concentrations for 24 h and the accumulated ni-
trite concentration present in the culture media was determined by the Griess assay. 
Interestingly, the fully methoxylated chalcone TMCH was found to be the most active compound 
(97 ± 12% inhibition of NO release at 10 µM) followed by the A-ring dihydroxylated chalcone 
DHDMCH (73 ± 7.7% NO inhibition at 10 µM). The chalcone HTMCH, with three methoxy groups, 
however, showed a slightly decreased NO inhibition of 52 ± 17% at 10 µM, which was similar to 
the activity of butein (four OH groups) with 55 ± 4.3% measured at 5 µM, due to higher cytotoxi-
city of butein. This points to a particularly important influence of the OH group in 2’-position. 
Also THMCH and ISL (three OH groups) displayed similar inhibitory activity of NO production at 
10 µM with 43 ± 3.1% and 38 ± 7.4%, respectively. The importance of the 2’-OH group becomes 
again clear, when the active 2’-hydroxychalcone (20 ± 8.4%, 10 µM) is compared to the inactive 
unsubstituted chalcone. On the other hand, this effect could not be observed on HTMCH, when 
compared with the tetramethoxychalcone TMCH. The regioisomers calythropsin and THMCH 
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differ in their cytotoxicity in LPS-stimulated RAW264.7, but are quite similar in their lack of in-
hibitory activity against NO release at 1 µM. Calythropsin displayed a higher cytotoxicity (toxici-
ty limit 1 µM) and was inactive in decreasing the NO production, whereas THMCH was found to 
be a good inhibitory agent at higher concentrations (43 ± 3.1%, 10 µM) and less cytotoxic (tox-
icity limit 25 µM). In this case the para-position of the methoxy group on the B-ring is more acti-
vating than in the para-position on the A-ring. Taken together, two observations concerning the 
SAR of the chalcones can be made: i) the inhibition of the NO production is increasing from 
chalcone to butein, with an increased number of hydroxy groups on the chalcone, which can be 
explained by a higher antioxidant activity of the hydroxychalcones (as seen in Figure 42) and ii) 
an higher number of methoxy groups on the chalcone leads also to an increased inhibitory activ-
ity of NO production, were a combination of antioxidant activity and Michael acceptor activity 
can be assumed. 
Similar to the findings of Lee et al.,164 butein showed in the present study a concentration de-
pendent inhibition of NO production with a 54% inhibition at 5 µM and a small activity at 1 µM. 
But in our study higher concentrations of butein were excluded, because it showed a cytotoxic 
effect on RAW264.7 cells in presence of 10 ng L-1 LPS at 10 µM, a concentration that was report-
ed to have no influence on cell viability. Abuarqoub et al. reported a high inhibition of NO pro-
duction in the presence of 5-30 µM of 2’-hydroxychalcone in RAW264.7 cells treated with 1000 
ng mL-1 of LPS.69 In contrast, our results showed only a moderate inhibitory activity of 44% at 
25 µM, despite the fact that at higher concentration the 2’-hydroxychalcone was cytotoxic. One 
possible explanation is that in the other study69 a 100 fold higher LPS concentration was used to 
stimulate the inflammatory state of the macrophages, which increases the iNOS induction and 
may thus influence the outcome of the assay. Lee et al. reported a concentration dependent inhi-
bition of NO production in LPS-stimulated RAW264.7 cell for ISL,178 which was much higher 
(86% at 10 µM) that in our observations (38% at 10 µM). An explanation could be the fact, that 
the group used a natural derived sample of ISL in their biological tests, which was extracted 
from dried heartwoods of D. odorifera compared to the synthetic ISL used in the present study. It 
is hypothesized that bioactive compounds retain a residual complexity after extraction and de-
pending on the assay conditions, they can display a different biological result than the chemical-
ly pure compound. This was exemplified by a recent study with ISL.158 
3.3.4 Antioxidant capacity of chalcones 
The antioxidant activity of the chalcones was investigated by the cell-free ORAC-fluorescein as-
say, where the radical scavenging activity was determined over time and compared to the anti-
oxidant agent Trolox, a water-soluble vitamin E derivative.  
Two structure characteristics contribute to the radical scavenging and reduction potential of 
chalcones: i) the α,β-unsaturated carbonyl moiety, reacting in a Michael addition-like reaction 
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with the radical and stabilizing the radical species by the conjugated π-electron system and ii) 
the hydroxy groups on the aromatic rings, which can in some cases oxidized to quinones238 (see 
Scheme 4). According to this, the results of the ORAC-fluorescein assay summarized in Table 13 
clearly show that hydroxy groups are the key to antioxidant behavior. ISL and THMCH bearing 
three hydroxy groups reached 3 Trolox equivalents followed by butein with four hydroxy groups 
displays 2.6 Trolox equivalents. As expected, the simple chalcone, lacking any additional groups 
with radical scavenging or antioxidant functionality, showed no significant antioxidant capacity. 
Instead, the addition of one OH group in 2’-position increased the antioxidant activity more than 
twice to reach almost Trolox activity, as for 2’-hydroxychalcone. 
Table 13. Antioxidant activity of chalcones and the positive control ascorbic acid. 
Compound 
Trolox equivalents 
(conc [µM]) 
ISL 3.18 ± 0.52 (0.5-10) 
THMCH 3.08 ± 0.26 (0.1-2.0) 
Butein 2.63 ± 0.15 (0.5-5.0) 
Calythropsin 1.40 ± 0.11 (0.1-5.0) 
DHDMCH 1.36 ± 0.23 (0.5-2.0) 
2’-Hydroxychalcone 0.961 ± 0.196 (0.5-10) 
Chalcone 0.390 ± 0.136 (0.5-10) 
HTMCH 0.292 ± 0.114 (0.5-10) 
TMCH 0.241 ± 0.099 (0.5-10) 
Ascorbic acid (Vit. C) 0.642 ± 0.164 (0.5-10) 
The ORAC-fluorescein assay was carried out in 
75 mM phosphate buffer pH 7.4 at 37 °C and anti-
oxidant capacity is expressed as Trolox equi-
valents in the indicated concentration range. 
A subsequent substitution of the hydroxy groups by methoxy groups in the 2’,3,4,4’-substituated 
chalcones leads to a decrease of antioxidant capacity (Figure 42). In the chalcone screen the best 
antioxidant activities were found as expected for the most hydroxy-rich compounds, ISL, butein 
and THMCH. The loss of activity in the case of calythropsin compared to its regioisomer THMCH 
was not expected, since the catechol group on the calythropsin is expected to contribute signifi-
cantly to the antioxidant capacity. The results indicate that the position of the hydroxy group has 
an influence on the radical scavenging and antioxidant activity, which is in this case higher when 
the OH group is present on the A-ring rather than on the B-ring of the chalcone.  
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Figure 42. Antioxidant capacity of chalcones and vitamin C measured by the ORAC-fluorescein assay and ex-
pressed as Trolox equivalents. The assay was carried out in 75 mM phosphate buffer pH 7.4 at 37 °C. The anti-
oxidant capacity values are depicted in order of the less substituted compound chalcone to the fully 
methoxylated chalcone TMCH. Levels of significance: ***, p < 0.001; **, p < 0.01; *, p < 0.05 versus Trolox.  
3.3.5 Structure-activity relationship (SAR) of hydroxy- and methoxychalcones 
Table 14 summarizes the results of the biological and chemical characterization of the chalcones. 
The table was extended by the results of the kinetic measurements in the thiol assay, performed 
by Nafisah Al-Rifai and Sabine Amslinger.159 The calculated reaction rates of the thia-Michael 
addition between the chalcones and cysteamine were displayed as k2 values in M-1 s-1. The tested 
chalcones gave quite different reactivities in the Michael additions of thiols, displaying k2 values 
from 5.08 to 0.193 M-1 s-1, demonstrating an overall good to very good electrophilicity.  
A structure-activity relationship (Scheme 13) can be established to a certain extent regarding 
the anti-inflammatory and antioxidant activities of the chalcones.  
An increased antioxidant activity of hydroxychalcones was observed with an increasing number 
of hydroxy groups present on the chalcone, demonstrated by their radical scavenging activity in 
the ORAC assay. Furthermore, the results show that antioxidant behavior and anti-inflammatory 
activity of hydroxychalcones are closely related. The well known natural chalcones ISL and 
butein, both containing 3 and 4 hydroxy groups, respectively, showed a high inductive effect on 
HO-1 activity (3 fold) and were good antioxidants as expected, due to their high potential of 
scavenging free oxygen radicals (3 Trolox equiv.). They showed also similar k2 values and mod-
erate inhibitory activity on NO production. Therefore ISL, butein and also THMCH can be re-
garded as bifunctional antioxidants. The correlation of potencies as phase II protein inducer and 
radical scavengers is known for hydroxychalcones and other Michael acceptors and was associ-
ated, at least amongst the natural occurring Michael acceptors, with their overall chemo-
protective properties.119  
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Scheme 13. Structure-activity relationship of 2’,3,4,4’-substituted hydroxy and methoxychalcones regarding 
their anti-inflammatory and antioxidant activity, as well as their Michael acceptor reactivity based on the k2 
values. Relative increase (↑) or decrease (↓) of activity/reactivity is given. 
A subsequent methylation of the hydroxy groups on butein enhanced the Michael acceptor reac-
tivity, demonstrated by increasing k2 values. In comparison, the induction of HO-1 activity dou-
bled from 3 to 6 fold, when the B-ring was fully methylated (DHDMCH) and HO-1 activity was 
reduced to 3 fold in the presence of the fully methylated chalcone (TMCH). A methylation on the 
4’-position on the A-ring however caused a loss of inductive activity towards HO-1 (HTMCH) or 
high cytotoxicity (calythropsin). A similar trend for the methylation pattern could be also ob-
served for the inhibitory activity towards NO production, where a methylation on the B-ring 
favors a higher anti-inflammatory activity than a substitution in 4’-position on the A-ring. In this 
case TMCH showed a higher activity compared to DHDMCH. 
A change in the position of a methyl group, either on the B- or the A-ring as in the case of the two 
regioisomers THMCH and calythropsin, can have a great influence on the Michael acceptor reac-
tivity. Calythropsin showed a weaker reactivity (k2 value) compared to THMCH. This can be ex-
plained by the fact, that the double bond of the α,β-unsaturated carbonyl moiety may be regard-
ed as a push-pull double bond. Here the less electron donating methoxy group compared to a 
hydroxy group on the C-4 on the B-ring restores more reactivity in the Michael acceptor system 
than the methoxy group in the A-ring. Regarding the biological activity however, both chalcones 
differ rather in their cytotoxicity than in their anti-inflammatory activity, with calythropsin be-
ing the more toxic chalcone (toxicity limit at 1 µM). Their activity towards HO-1 induction was 
quite similar in the nanomolar range, and they were also inactive in the inhibition of NO produc-
tion, when compared at 1 µM. Only at higher concentrations of THMCH a significant inhibition of 
NO production could be observed. 
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Generally, a 2’-OH substitution compared to the non-substituted or methoxy substituted 
chalcone leads to an increased Michael acceptor reactivity, demonstrated by higher k2 values. In 
the case of 2’-HOC compared to chalcone, the overall anti-inflammatory activity is increased, 
which can be contributed to the 2’-hydroxy group. For the chalcones HTMCH and TMCH, howev-
er, the effect of the 2’-OH group could not be observed concerning their biological activity. TMCH 
showed a higher anti-inflammatory potential compared to HTMCH, demonstrated by a higher 
induction of HO-1 activity and suppression of the inflammatory NO production. This can be ex-
plained by the fact, that both methoxychalcones are moderate electrophiles (k2 values) due to 
the higher electron density in the molecule, which influences their anti-inflammatory activity 
compared to the non-substituted chalcone. It seems that a certain reactivity threshold must be 
hit for an increased anti-inflammatory activity, which is the case for weak to moderate electro-
philes such as TMCH.  
The importance of the α,β-unsaturated carbonyl moiety has been demonstrated to be crucial for 
the biological activity of chalcones.239 Our findings conclude that the overall biological activity of 
chalcones depends on the Michael acceptor reactivity of chalcones and that electronic effects 
due to different substitution patterns on the chalcone can influence the reactivity of the Michael 
acceptor and thus their biological activity. The observed correlations demonstrate that the 
electrophilicity of the chalcones is a major factor determining their potency as inducers of the 
cytoprotective HO-1 activity and as inhibitors of inflammatory NO production. Here, a rather 
moderate Michael acceptor reactivity is needed for a more efficient anti-inflammatory activity, in 
the chalcone screen this was found to be in the range of 0.4 to 0.2 M-1 s-1. Strong electrophilic 
chalcones can be consumed by other metabolic pathways, such as a reaction with the cellular 
electrophile sensor GSH, without reaching their target protein. Therefore moderate electrophiles 
are in favor, because their can bypass such cellular traps and react with the target thiols on 
Keap-1 or NF-κB in order to promote their anti-inflammatory activity. Despite of the crucial α,β-
unsaturated carbonyl functionality, also alternative mechanisms of chalcones such as non-
covalent interactions, isomerization or the potential activity of metabolites should be considered.  
 
 
 
Table 14. Evaluation of chalcones towards their biological (anti-inflammatory and antioxidant) and chemical activity. 
Name Structure Toxicity limit 
[µM] 
Maximum HO-1 activ-
ity, fold of control 
(conc. [µM]) 
Maximum inhibition 
of NO production, % 
(conc. [µM]) 
Trolox equivalents k2 [M-1 s-1] values 
with cysteamine b 
Chalcone 
 
10 2.15 ± 0.67 (10) ns 0.390 ± 0.136 3.04 ± 0.10 
2’-Hydroxychalcone 
 
25 2.38 ± 0.57 (5.0) 43.6 ± 8.68 (25) 0.961 ± 0.196 5.08 ± 0.04 
ISL 
 
25/10a 3.43 ± 1.53 (25) 38.0 ± 7.41  (10) 3.18 ± 0.52 0.258 ± 0.010 
Butein 
 
10/5.0a 3.07 ± 1.79 (10) 54.5 ± 4.27 (5.0) 2.63 ± 0.15 0.271 ± 0.027 
THMCH 
 
10 2.91 ± 1.05 (10) 42.7 ± 3.05 (10) 3.08 ± 0.26 0.417 ± 0.008 
Calythropsin 
 
1.0 2.17 ± 0.63 (0.1) ns 1.40 ± 0.11 0.325 ± 0.011 
DHDMCH 
 
15 6.05 ± 2.31 (10) 72.9 ± 7.68 (10) 1.36 ± 0.23 0.464 ± 0.039 
HTMCH 
 
10 1.52 ± 0.17 (1.0) 52.2 ± 16.5 (10) 0.292 ± 0.114 0.717 ± 0.041 
TMCH 
 
10 2.96 ± 0.23 (10) 96.9 ± 11.9 (10) 0.241 ± 0.099 0.193 ± 0.019 
Toxicity of chalcones was measured with the MTT assay in presence or absence of LPS, in the case of the concentrations marked with a, different toxicity limits were found 
in presence of LPS. b, k2 values were determined via the kinetic thiol assay, at a chalcone concentration of 40 µM, by N. Al-Rifai and S. Amslinger.  
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3.4 Characterization of α-X-TMCHs towards their anti-inflammatory, 
antioxidative and cytoprotective activity 
3.4.1 Effect of α-X-TMCHs on the viability of RAW264.7 macrophages 
The cytotoxicity of the α-X-chalcones (α-X modified 2’,3,4,4’-tertramethoxychalcones, α-X-
TMCHs, Figure 12) was determined in a concentration range of 1-25 µM in RAW264.7 cells via 
the MTT assay. The results are summarized in Figure 43. The influence of the α-X-TMCHs was 
also tested in the presence of LPS-stimulated RAW264.7 macrophages with the MTT-LPS assay, 
see Figure 44, in order to exclude an influence of LPS on the cytotoxicity of the compounds. Here 
again, only at non-toxic concentrations the α-X-TMCHs were used for further testing.  
The α-CF3-TMCH was found to be the most toxic compound in the α-X-TMCH series, here a lower 
test concentration range was required (Figure 43 C and Figure 44 C), with the highest non-toxic 
concentration in the nanomolar range (500 nM). The halogens displayed a cytotoxic effect above 
1-5 µM, except for the barely active α-F-TMCH, showing no cytotoxic effect even at 25 µM. The α-
X-TMCHs follow the rule that the more reactive/electrophilic the compounds, the more toxic 
they are. However, the two most reactive chalcones α-CN-TMCH and α-NO2-TMCH had no major 
toxic influence on the cells at 25 and 10 µM, respectively, suggesting that these relatively potent 
electrophiles could be neutralized in the cell before exerting toxicity. In the α-X-TMCH sequence 
the chalcones α-COOEt-TMCH to α-COOH-TMCH (Figure 43 B and Figure 44 B) had a toxic influ-
ence on RAW264.7 viability above 10 or 25 µM, similar to the most chalcones tested, see Figure 
37 and Figure 38 in the previous chapter ‎3.3.1. α-COOEt-TMCH showed an interesting cytotoxic 
behavior, displaying a bell-shaped dose-response curve, which was not observed when LPS was 
present in the assay. Here, one has to be careful evaluating the data of its biological activity, 
since a reduced viability (< 80%) was gained at 1 µM of α-COOEt-TMCH. If one compares the 
results of the cell viability of the α-X-TMCHs in absences or presence of LPS, only α-Cl-TMCH and 
the aromatic α-p-NO2-C6H4-TMCH and α-p-OMe-C6H4-TMCH showed a higher toxicity in the 
presence of LPS. For the other α-X-TMCHs the addition of LPS had no influence on their cytotoxic 
behavior.  
  
93 
 
 A 
 
 B 
 
 C 
α-CF3 TMCH [µM] 0.01 0.05 0.1 0.25 0.5 1 
Viability               
[% of control] 
94.8 ± 13.5 105.6 ± 12.6 111.7 ± 11.0 104.1 ± 6.5 100.3 ± 9.4 78.1 ± 13.3 
 
Figure 43. Influence of α-X-TMCHs on the viability of RAW264.7 murine macrophages. Cells were treated with 
chalcones at the indicated concentrations (1-25 µM) for 24 h and cell viability was determined by the MTT 
assay. A, B: Labels on the x-axis indicate the substituent X in the α-position of the α,β-unsaturated carbonyl 
moiety of the TMCH. C: The influence on cell viability of the α-CF3-TMCH was determined at concentrations 
below 1 µM as shown in the table. The level of significance was left out for a better overview. Viability ≤ 80% 
of control were considered as cytotoxic.   
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 A 
 
 B 
 
 C 
α-CF3-TMCH [µM] 0.01 0.05 0.1 0.25 0.5 1 
Viability                
[% of control] 
89.7 ± 0.8 102.5 ± 13.7 97.9 ± 14.4 87.3 ± 5.2 86.3 ± 11.4 65.7 ± 10.6 
 
Figure 44. Influence of α-X-TMCHs on the viability of LPS-stimulated RAW264.7 murine macrophages. Cells 
were treated with chalcones at the indicated concentrations in the presence of 10 ng mL-1 LPS for 24 h and cell 
viability was determined by the MTT-LPS assay. A, B: Labels on the x-axis indicate the substituent X in the α-
position of the α,β-unsaturated carbonyl moiety of the TMCH. The influence on cell viability of the α-CF3-
TMCH was determined at concentrations below 1 µM as shown in table C. The level of significance was left out 
for a better overview. Viability ≤ 80% of control were considered as cytotoxic.  
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3.4.2 Influence of α-X-TMCHs on HO-1 activity and HO-1 protein expression 
The α-X-TMCHs were tested for their ability to induce the heme oxygenase-1 (HO-1) activity 
using the ELISA-based HO-1 assay as well as the protein expression using Western blot analysis 
in RAW264.7 macrophages. The results of the screen on HO-1 activity are depicted in Figure 45.  
 
 
 
Figure 45. Influence of α-X-TMCHs on HO-1 activity in RAW264.7 macrophages. Cells were treated with differ-
ent α-X-TMCHs at 1 µM for the indicated periods. Labels on the x-axis indicate the substituent X in the α-
position of the α,β-unsaturated carbonyl moiety of the 2’,3,4,4’-tetramethoxychalcone (TMCH). 
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Here the series of α-X-TMCHs was tested at 1 µM in order to compare their different inductive 
behavior on HO-1 activity. α-CF3-TMCH was tested at 0.5 µM due to cytotoxicity at higher con-
centrations. The HO-1 activity was determined after different stimulation times of the RAW264.7 
cells with the chalcones for 3, 6 and 24 h. As shown in Figure 45 the inductive effect of the α-X-
TMCHs was time dependent, reaching their maximum inductive activity after 6 h of incubation. 
While after a very short stimulation time of 3 h, only α-Br-TMCH and α-Cl-TMCH showed a sig-
nificant 2 fold induction of HO-1 activity, more compounds were able to induce HO-1 activity 
after 6 h. Here, α-CF3-TMCH (0.5 µM) together with α-Br-TMCH and α-Cl-TMCH induced HO-1 
activity in the range of 2.7-2.1 fold. Also the unsubstituted α-H-TMCH chalcone displayed a 2.6 
fold induction of HO-1 activity. No significant activity showed α-COOEt-TMCH, α-F-TMCH, α-Me-
TMCH, the α-aromatic -TMCHs and α-COOH-TMCH at 1 µM. For most α-X-TMCHs the activity 
decreased after 24 h, only α-I-TMCH displayed a 1.9 fold inductive activity towards HO-1 after 
this prolonged stimulation time.  
The observation that α-COOH-TMCH showed no activity against HO-1 correlates very well with 
its chemical reactivity (Table 2), since at pH 7.4 the deprotonated carboxylate group present in 
α-position deactivated the Michael acceptor reactivity of the chalcone. Interestingly, the most 
chemically reactive electrophiles found in Table 2, α-CN-TMCH and α-NO2-TMCH, showed no 
activity at all at 1 µM. This suggests that the chalcones are too strong electrophiles and might 
rather be consumed by GSH, which is present in cells in a relatively high concentration, before 
reaching their target, in this case the SH-groups on the surface of Keap1. 
In Figure 46 the influence of the α-X-TMCHs on the HO-1 protein expression is shown at 1 µM 
(0.5 µM for α-CF3-TMCH) after 6 h of stimulation. α-CF3-TMCH, α-Br-TMCH and α-Cl-TMCH were 
able to induce HO-1 protein expression in RAW264.7 cells to a high level, whereas α-I-TMCH and 
α-H-TMCH displayed a moderate inductive effect compared to the level of HO-1 in unstimulated 
control cells. The other α-substituted TMCHs showed no inductive effect according to the results 
of the HO-1 activity assay.  
 
Figure 46. Influence of α-X-TMCHs on HO-1 protein expression. RAW264.7 cells were treated for 6 h with 
TMCHs at 1 µM (0.5 µM for α-CF3-TMCH) and HO-1 was detected in cell lysates by Western blot analysis.  
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To a certain level there is a correlation between the inductive effect of the α-X-TMCHs on protein 
level and the activity of HO-1. But, although the protein level of HO-1 was elevated in the case of 
α-I-TMCH after 6 h, the enzymatic activity could be observed only after 24 h. An explanation for 
this time shift could be, that the expressed HO-1 native protein is in this case not fully folded to 
the enzymatic active protein. The α-X-TMCHs, which displayed at 1 µM no induction of HO-1 
protein expression, α-COOEt-TMCH and α-F-TMCH showed also no significant induction of HO-1 
activity. For the most potent TMCHs, α-CF3-TMCH, α-Br-TMCH, α-Cl-TMCH, but also α-H-TMCH, 
the induced protein expression leads also to an enhanced HO-1 activity after 6 h in RAW264.7 
cells. The most chemically potent electrophiles in the α-X-TMCH series, α-CN-TMCH and α-NO2-
TMCH showed also on protein level no inductive effect of HO-1, suggesting an alternative path-
way of the chalcones in the cell, such as a reaction with GSH.  
3.4.3 Effect of α-X-TMCHs on nitrite production 
The inhibitory effect of the α-X-TMCH series on the proinflammatory pathway regulated by NF-
κB was examined. For this, the amount of NO produced by the proinflammatory protein iNOS 
was determined in LPS-stimulated RAW264.7 macrophages via the Griess assay. The inhibition 
of NO production was examined at different non-toxic concentrations of the α-X-TMCHs and the 
result of the Griess assay is shown in Figure 47. All α-X-TMCHs showed an inhibitory activity 
against NO generation in LPS-stimulated macrophages, except for the α-aromatic p-OMe-C6H4-
TMCH and α-Me-TMCH, which displayed a significant increase in NO production of 35 ± 15%, 
suggesting a proinflammatory activity of this chalcone. Most of the active compounds revealed a 
concentration dependent inhibitory effect on iNOS activity, only α-CN-TMCH seemed not to fol-
low this observation. While the strongest reduction of NO release was detected in the presence 
of 10 µM α-H-TMCH (Table 15), the most active chalcone in our screening was α-CF3-TMCH with 
a 85 ± 9% inhibition of NO production at 0.5 µM. For the active α-X-TMCHs it was possible to 
calculate the IC50 values of their NO inhibition and the values are given in Table 15. α-CF3-TMCH 
showed an IC50 value of NO production of 120 nM, followed by α-Br-TMCH with 640 nM. 
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Figure 47. Influence of α-X-TMCHs on NO production. RAW264.7 cells were exposed to 10 ng mL-1 LPS alone 
(control) or in presence of TMCHs in the indicated concentrations for 24 h and the accumulated nitrite con-
centration present in the culture medium was determined by the Griess assay.  
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Table 15. Inhibition of NO production in LPS-stimulated RAW264.7 macrophages by α-X-TMCHs determined 
by the Griess assay. Significant maximum NO inhibition and IC50 values are given together with the toxicity 
limit (highest non-toxic concentration) determined by the MTT assay in presence of 10 ng mL-1 LPS after an 
incubation time of 24 h. 
α-X-TMCH 
Toxicity 
limit (µM) 
Inhibition of NO pro-
duction % maximum 
(conc [µM]) 
IC50,                    
NO production  
[µM] 
CN 25 16.4 ± 8.7 (1.0) nd 
NO2 10 26.9 ± 7.9 (10) nd 
CF3 0.5 84.6 ± 8.9 (0.5) 0.120± 0.062 
Br 1 67.4 ± 11.7 (1.0) 0.640 ± 0.179 
Cl 1 47.2 ± 14.6 (1.0) 0.992 ± 0.482 
p-NO2-C6H4 10 35.8 ± 2.3 (10) nd 
I 5 72.2 ± 9.7 (5.0) 3.15 ± 0.70 
COOEt 10 66.8 ± 8.5 (10) 6.65 ± 0.53 
H 10 96.9 ± 11.9 (10) 4.44 ± 1.29 
F 25 86.6 ± 18.9 (25) 12.9 ± 5.6 
p-OMe-C6H4 10 ns nd 
Me 10 -34.7 ± 15.2 (5.0) nd 
Ph 25 27.9 ± 13.4 (25) nd 
COOH 25 20.8 ± 3.7 (25) nd 
ns, not significant (no significant NO inhibition observed); nd, not deter-
mined due to low activity in the non-toxic concentration range. 
In order to compare the quite different inhibitory influence of the α-substituent on the NO pro-
duction in RAW264.7 cells, the activities of the α-X-TMCHs are summarized in Figure 48 at 1 and 
5 µM in order of their chemical reactivity according to Table 2. A clear trend in activity is appar-
ent, beginning with α-CF3-TMCH, the inhibitory activity of the α-X-TMCHs follows directly the 
order of their chemical reactivity as electrophiles: at 1 µM CF3 > Br > Cl > I and at 5 µM I > H > F. 
Due to their low electrophilic reactivity towards thiols in the thia-Michael addition reactions 
(see k2 values in Table 2), α-p-OMe-C6H4-TMCH, α-Me-TMCH, α-Ph-TMCH and α-COOH-TMCH 
showed no activity, in case of α-Ph-TMCH and α-COOH-TMCH a small inhibition only at higher 
concentrations was observed. α-p-NO2-C6H4-TMCH does not follow the reactivity-activity rela-
tionship, as it remained inactive compared to the chalcones α-I-TMCH, α-COOEt-TMCH and α-H-
TMCH, which show all together a similar chemical reactivity. Nevertheless in the series of the α-
aromatic chalcones, p-NO2-C6H4-TMCH displayed a higher NO inhibition of 36 ± 2% at 10 µM 
compared to α-Ph-TMCH (28 ± 13% at 25 µM) and the completely inactive α-aromatic p-OMe-
C6H4-TMCH, which are more electron-rich derivatives. Similar to the results of the HO-1 assay, 
both chalcones α-CN-TMCH and α-NO2-TMCH showed only low inhibitory activity of 13 ± 9% 
and 25 ± 8% at 5 µM towards NO production, supporting the idea of a consumption by GSH in 
the cell.  
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Figure 48. Comparison of α-X-TMCHs of their inhibition of NO production. RAW264.7 cells were exposed to 10 
ng mL-1 LPS in presence of 1 and 5 µM α-X-TMCHs for 24 h. Accumulated nitrite concentration present in cell-
culture medium was determined by the Griess assay. #, α-X-TMCHs were cytotoxic at 5 µM and were therefore 
excluded from testing. Data was taken from Figure 47. 
3.4.4 Conclusion 
The influence of the different α-substituents on the α,β-unsaturated carbonyl unit in the 2’,3,4,4’-
tetramethoxychalcones (α-X-TMCHs) was investigated towards their in vitro anti-inflammatory 
activity based on their chemical reactivity estimated by the thiol assay in preliminary studies by 
Nafisah Al-Rifai and Sabine Amslinger.195 The overall electronic and steric effects are of im-
portance for the reactivity and thus the biological activity of α-X-TMCHs. The results of the bio-
logical studies showed that indeed the anti-inflammatory activity of 2’,3,4,4’-tetramethoxy-
chalcones can be modified by a simple substitution in α-position of the Michael acceptor moiety. 
A clear correlation can be established between their chemical reactivity and their biological ac-
tivity, that is the inhibition of NO production as well as the induction of HO-1 on protein expres-
sion and activity, suggesting the involvement of the α-X-TMCHs in both inflammatory pathways, 
regulated by NF-κB and Nrf2, respectively. Particularly, for the chalcones α-CF3-TMCH, α-Br-
TMCH, α-Cl-TMCH, α-I-TMCH and much less α-H-TMCH a direct correlation between their chem-
ical reactivity and biological activities could be observed. α-H-TMCH displayed a much higher 
anti-inflammatory activity than expected from its chemical reactivity, suggesting the activation 
101 
 
of several pathways leading to an increase in the anti-inflammatory response. More limitations 
to the reactivity-activity relationship could play a role, such as off-target reactions like H-
bonding of the ester group or π-interactions with the additional aryl unit of p-NO2-C6H4-TMCH, 
that overwrite their intermediate electrophilic behavior. This is also true for the two most po-
tent electrophiles in the α-X-TMCH series, α-CN-TMCH and α-NO2-TMCH, that may be consumed 
by alternative pathways, such as a reaction with the electrophile sensitive peptide GSH. With our 
α-X-TMCHs we created a library of chalcones with a distinct chemical reactivity and biological 
activity, were a small reactivity window has to be hit to reach an effective biological response of 
the chalcone. In this regard a clear reactivity-activity relationship of the α-X-TMCHs can be con-
cluded: 
 (Michael acceptor reactivity) vs. (anti-inflammatory activity)* 
CF3 > Br > Cl > I > H > F 
*inhibition of NO production and induction of HO-1 protein expression and activity 
With these promising results in hand further tests will be needed to investigate the mechanism 
of action of these chalcones in vitro, which will also benefit further studies on structure-activity 
relationship, i.e. which particular targets are aimed by the chalcones on inflammation pathways 
regulated by Keap1-Nrf2 and NF-κB and which role plays GSH on their biological response. The 
α-CF3-TMCH seems particularly attractive for such studies because it exerts anti-inflammatory 
activity in the nanomolar range.  
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3.5 Characterization of α-X-Limno-CP derivatives (5-aryl-3(2H)-
furanones) towards their anti-inflammatory and antioxidative ac-
tivity 
3.5.1 Effect of α-X-Limno-CPs on cell viability and nitrite production of RAW264.7 
macrophages 
The viability of LPS-induced RAW264.7 macrophages was determined in the presence of the 
α-X-Limno-CP and i-Pr-α-X-Limno-CP compounds (for structure see Figure 13) and cytotoxic 
concentrations were excluded from further testing (Figure 49). 
 
Figure 49. Influence of α-X-Limno-CPs on RAW264.7 macrophage viability. Cells were exposed to 10 ng mL-1 
LPS alone (control) and LPS in presence of α-X-Limno-CP (α-X, A) or i-Pr-α-X-Limno-CP (i-Pr-α-X, B) in the 
indicated concentrations for 24 h and cell viability was determined by the MTT-LPS assay. 
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The α-X-Limno-CPs displayed a moderate cytotoxicity against RAW264.7cells in the range of 60-
70% viability at 75 µM. While α-F-Limno-CP and α-Br-Limno-CP showed no significant toxicity, 
α-H-Limno-CP, α-Cl-Limno-CP, α-I-Limno-CP, α-CN-Limno-CP, α-CONH2-Limno-CP and α-Ph-
Limno-CP had a negative effect on cell viability in the range of 50-75 µM. In contrast, the pro-
tected i-Pr-α-X-Limno-CPs revealed a higher cytotoxic effect, except for i-Pr-α-Cl-Limno-CP, 
which showed the same cytotoxic pattern.  
 
  
Figure 50. Effect of α-X-Limno-CP on the NO production. RAW264.7 cells were exposed to 10 ng mL-1 LPS alone 
(control) and LPS in presence of α-X-Limno-CP (α-X, A) or i-Pr-α-X-Limno-CP (i-Pr-α-X, B) in the indicated 
concentrations for 24 h and the accumulated nitrite concentration present in the culture media was deter-
mined by the Griess (nitrite) assay.  
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i-Pr-α-I-Limno-CP and i-Pr-α-H-Limno-CP exerted an intermediate cytotoxicity and reached 40% 
of cell viability at 75 µM. i-Pr-α-CONH2-Limno-CP followed by i-Pr-α-CN-Limno-CP showed the 
lowest cytotoxicity level at a concentration of 5 µM and 10 µM, respectively. The halogenated 
i-Pr-α-X-Limno-CPs and the i-Pr-α-Ph-Limno-CP exerted their moderate toxic effect at 50 and 75 
µM. In order to estimate the anti-inflammatory activity of the α-X-Limno-CPs, their influence on 
the NO production by iNOS in LPS-stimulated RAW264.7 macrophages was investigated (Figure 
50) using the Griess (nitrite) assay. Amongst the eight investigated i-Pr-α-X-Limno-CPs, i-Pr-α-F-
Limno-CP was the most active inhibitor of NO production, with a suppression of 58 ± 12% of LPS 
induced NO formation at 50 µM. When compared at 25 µM i-Pr-α-Br-Limno-CP and i-Pr-α-I-
Limno-CP were the most potent inhibitors of NO production followed by i-Pr-α-F-Limno-CP and 
i-Pr-α-H-Limno-CP and finally by i-Pr-α-Cl-Limno-CP and i-Pr-α-Ph-Limno-CP. i-Pr-α-CN-Limno-
CP and i-Pr-α-CONH2-Limno-CP remained inactive in the non-toxic concentration range (Table 
16). Beside the fact that the protected i-Pr-α-X-Limno-CPs displayed in general a higher inhibito-
ry activity than the α-X-Limno-CPs, the α-Br-Limno-CP exhibited the highest inhibition of NO 
release in this screen of 82 ± 7% at 75 µM followed by a inhibition of 38 ± 11% at 50 µM.  
Table 16. Inhibition of NO production of Limno CPs in LPS-stimulated RAW264.7 cells determined by the 
Griess assay. Significant NO inhibition values at 25 µM are given together with the toxicity limit (highest non-
toxic concentration) determined by the MTT-LPS assay. 
Limno-CP 
Toxicity 
limit (µM) 
Inhibition of NO production, 
% of control at 25 µM 
Maximum inhibition of NO 
production, %, (conc. [µM]) 
i-Pr-α-H 25 37.8 ± 6.5 37.8 ± 6.5 (25) 
i-Pr-α-F 50 38.2 ± 12.8 57.6 ± 11.6 (50) 
i-Pr-α-Cl 25 25.0 ± 11.3 25.0 ± 11.3 (25) 
i-Pr-α-Br 25 41.3 ± 11.8 41.3 ± 11.8 (25) 
i-Pr-α-I 25 41.6 ± 9.7 41.6 ± 9.7 (25) 
i-Pr-α-CN 10 -a -a 
i-Pr-α-CONH2 5 -a -a 
i-Pr-α-Ph 25 22.3 ± 9.6 22.3 ± 9.6 (25) 
α-H 25 12.7 ± 5.5 12.7 ± 5.5 (25) 
α-F 75 ns ns 
α-Cl 25 ns ns 
α-Br 75 ns 82.2 ± 6.5 (75) 
α-I 25 22.8 ± 8.1 22.8 ± 8.1 (25) 
α-CN 25 ns ns 
α-CONH2 25 ns ns 
α-Ph 50 16.6 ± 8.6 45.3 ± 12.6 (50) 
ns, not significant (no significant NO inhibition observed); a, not determined, due to toxicity at 
this concentration. 
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However, at 25 µM α-Br-Limno-CP remained unreactive, whereas α-I-Limno-CP, α-Ph-Limno-CP 
and α-H-Limno-CP inhibited NO production to 23 ± 8%, 17 ± 9% and 13 ± 6%, respectively. Even 
more, α-Ph-Limno-CP showed a higher inhibitory activity up to 45 ± 13% at 50 µM. The com-
pounds α-F-Limno-CP, α-Cl-Limno-CP, α-CN-Limno-CP and α-CONH2-Limno-CP showed no sig-
nificant inhibition of NO production.  
In summary, the isopropyl protecting group on the phenolic unit in the Limno-CPs enhances the 
anti-inflammatory activity. The isopropyl protected i-Pr-α-X-Limno-CP revealed a higher toxicity 
against LPS-induced RAW264.7 cells, but also an increased inhibition of NO production com-
pared to the α–X-Limno-CPs with the free OH group. This can be explained by an electron-poorer 
β-position activating the Michael acceptor reactivity, when the free phenolic hydroxy group is 
alkylated. Also a higher lipophilicity may be assumed, leading to a better uptake of the isopropyl 
protected compounds by the cell membrane. In both cases α-CN-Limno-CP and α-CONH2-Limno-
CP, which were expected to activate the Michael acceptor reactivity, remained inactive. The re-
sults of the NO inhibition screening showed that a modulation of the α-position of the α,β-
unsaturated carbonyl moiety in the 3(2H)-furanone unit is not clearly influencing the inhibitory 
activity on the NO production. The Limno-CP derivatives exert only a moderate anti-
inflammatory activity compared for example to the α-X-TMCHs, which may not only derive from 
NF-κB inactivation but also from alternative activation on off-set targets, such as certain kinases, 
which may indirectly lead to an inhibition of NO production.  
3.5.2 Antioxidant capacity of α-X-Limno-CPs 
The antioxidant capacities of the Limno-CPs were investigated by the cell free ORAC-fluorescein 
assay by determining the radical scavenging activity over time towards peroxyl radicals gener-
ated from AAPH and compare it to the antioxidant standard Trolox, a water soluble vitamin E 
derivative. Two structure characteristics contribute to the radical scavenging property: i) the 
α,β-unsaturated carbonyl moiety, reacting in a Michael addition-like reaction with the radical 
and stabilizing the radical species by the conjugated π-electron system and ii) the phenolic 
hydroxy group on the 5-aryl-3(2H)-furanone unit which can be oxidized.  
The results summarized in Figure 51 clearly show an antioxidant activity of the α-X-Limno-CPs, 
due to the free hydroxy group on the phenolic moiety on the 3(2H)-furanone, with α-H-Limno-
CP displaying the highest Trolox equivalents (3.78 ± 0.69). When the hydroxy group is masked 
by the isopropyl protecting group, the antioxidant capacity of the i-Pr-α-X-Limno-CPs is abol-
ished, independent of the α-substituent. 
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Figure 51. Antioxidant capacity of α-X-Limno-CPs measured by the ORAC-fluorescein assay and expressed as 
Trolox equivalents at 1 µM. The assay was carried out in 75 mM phosphate buffer pH 7.4 at 37 °C. Level of 
significance: ***, p < 0.001; **, p < 0.01; *, p < 0.05 versus Trolox. 
α-CONH2-Limno-CP showed a high antioxidant capacity value (3.26 ± 0.10), suggesting that the 
amide group itself reacts as a H-atom donor, stabilizing the radical species by the conjugated 
π-electron system, without necessarily influencing the Michael system. On the other hand, the 
influence of the α-substituent on the radical scavenging activity of the Michael acceptor system 
could be observed in the case of α-F-Limno-CP (2.15 ± 0.26), where α-F acts in this system as a 
π-electron donor (β-C: 167 ppm vs. 183 ppm for α-H) due to a positive resonance effect, which 
also contributes to the stabilization of the radical species in the conjugated π-system. This can 
explain the decreased activity of α-F-Limno-CP compared to α-H-Limno-CP, but also why α-F-
Limno-CP displayed the highest activity in the halogen series of α-X-Limno-CP. The halogenated 
as well as α-CN-Limno-CP and α-Ph-Limno-CP displayed similar antioxidant capacities as Trolox, 
which may be only connected to the free phenolic hydroxy group, since no clear influence of the 
α-modification on the radical scavenging reactivity could be observed.  
3.5.3 Conclusion 
In order to predict biological activity by manipulating the chemical reactivity through 
α-modifications, 13C NMR studies can be useful to determine the relative electrophilicity of the 
β-carbon as the reactive center of the Michael system. This approach was used to study the 
chemical implications of antitumor and antiviral activities of prostaglandins.240 However, con-
cerning the Limno-CP model compounds a modulation of their anti-inflammatory activity based 
only on 13C NMR characterization of the β-carbon seems not sufficient. The Limno-CP derivatives 
have been considered as atypical and moderate electrophiles, due to their overall electron rich 
α,β-unsaturated carbonyl system. Typically, enone systems with chemical shifts of 120–170 ppm 
show intermediate to high reactivities in 1,4-additions. Especially, exomethylenic enone entities 
like in helenalin with a 13C NMR value of 122 ppm are very reactive.241 Also for the α-X-TMCHs, 
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which showed a broad spectrum of very high to moderate reactivities in thia-Michael additions, 
the chemical shifts of the β–carbon were in the range of 120 to 153 ppm.195 In the case of the 
Limno-CP system, more low-field shifted values of 167 to 185 ppm for the β-carbon were 
achieved. Moreover, in kinetic measurement of the 1,4-addition with cysteamine in the thiol as-
say performed by Katrin Winter242 the Limno-CP derivatives showed no reaction, due to their 
poor electrophilicity. Also the steric hindrance of the double-substituted β-carbon hampers a 
possible attack of reactive thiols of target proteins. In comparison to the α-X-TMCHs, the Limno-
CPs exerted a lower cytotoxicity but also a rather poor anti-inflammatory activity. On the other 
hand, the α-X-Limno-CPs, at least α-H-Limno-CP, α-F-Limno-CP and α-CONH2-Limno-CP dis-
played a good antioxidant activity, namely radical scavenging activity, rather than a distin-
guished Michael acceptor reactivity, demonstrated by the ORAC-fluorescein assay.  
Taken together, pivotal for the approach of introducing α-modifications in an α,β-unsaturated 
carbonyl system in order to reach a high specificity of their biological activity, a reliable scaffold 
with a moderate but sufficient electrophilicity is needed.  
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3.6 Characterization of both enantiomers of arteludovicinolide A to-
wards their anti-inflammatory activity 
3.6.1 Influence on the viability and nitrite production of RAW264.7 macrophages  
Both enantiomers of arteludovicinolide A and a derivative, de-exo-methylated-(+)-arte A (Figure 
14), were tested for their cytotoxic effect and their ability to inhibit the production of NO in 
RAW264.7 macrophages stimulated with lipopolysaccharide (LPS, 10 ng mL-1) for 24 h. The re-
sults are depicted in Figure 52.  
 
Figure 52. Influence of test compounds on the viability (left column) and the nitrite production (right column) 
of RAW264.7 cells stimulated with 10 ng mL-1 of LPS. Cell viability of was determined by the MTT assay in 
presence of 10 ng mL of LPS for the indicated concentrations of the compounds at an incubation time of 24 h 
(left side of chart). The NO production (Griess assay) was measured under the same conditions at non-toxic 
concentrations as indicated (right side of the chart).  
Additionally, IC50 values (inhibition of 50%) of the cell viability (without LPS stimulation) and 
the NO production could be determined and are summarized in Table 17.  
While (+)- and (-)-arteludovicinolide A displayed a similar cytotoxic pattern, with IC50 values of 
49.3 ± 2.7 and 45.3 ± 2.6 µM, their inhibitory influence on NO production differed significantly. 
The (+)-enantiomer exhibited a significantly higher inhibitory effect on NO production with a 
IC50 value of 4.87 ± 1.07 µM compared to the unnatural (-)-enantiomer with an IC50 value of 
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10.3 ± 5.7 µM. In order to investigate the contribution of the second Michael acceptor on the 
cyclopentenone moiety to the biological activity, besides the exo-methylene group on the lactone, 
the derivative compound was also tested. However, the derivative showed no cytotoxic effect 
between the concentration range of 0.5-100 µM and displayed a weak inhibition of NO release 
(IC50 values of 50.2 ± 18.3 µM).  
Table 17. IC50 values of compounds tested for viability and NO production in RAW264.7 stimulated with LPS.  
 
IC50 [µM],  
cell viability 
IC50 [µM],  
NO production 
(+)-Arteludovicinolide A 49.3 ± 2.7 µM 4.87 ± 1.07 µM 
(-)-Arteludovicinolide A 45.3 ± 2.6 µM 10.3 ± 5.7 µM 
de-exo-methylene-(+)-Arte A > 100 µM 50.2 ± 18.3 µM 
Inhibition of cell viability and NO production in RAW264.7 macrophages in presence of 
test compounds for 24 h.  
These results clearly disagree with the data previously reported on the anti-inflammatory activi-
ty of (+)-arteludovicinolide A, demonstrated by the inhibition of NO production in RAW264.7 
macrophages. Our results show a 15 times higher anti-inflammatory activity compared to the 
previous report on an IC50 value of 70.4 µM.202 Moreover, the measurements were in a much 
higher concentration range of the compound (≥ 45 µM), which is according to our results already 
in the cytotoxic range. One has to mention that the data reported previously was taken with 
RAW264.7 cells stimulated with a higher concentration of LPS (1 µg mL-1, 100 times concentrat-
ed than our LPS), which can influence the biological readout.  
3.6.2 Influence of both enantiomers of arteludovicinolide A on the heme 
oxygenase-1 (HO-1) activity in murine macrophages RAW264.7 
The two more active compounds (+)-and (-)-arteludovicinolide A were further tested for their 
ability to induce heme oxygenase-1 in RAW264.7 macrophage cells by the ELISA-based HO-1 
activity assay at a non-cytotoxic concentration of 10 µM (preliminary MTT results) at two differ-
ent stimulation times for 6 and 24 h (Table 18). After 6 h of stimulation only the naturally occur-
ring (+)-arteludovicinolide A displayed a 2.1 fold induction of HO-1 activity in RAW264.7 cells, 
while (-)-arteludovicinolide A remained inactive. However, both enantiomers could induce HO-1 
activity after 24 h to 2 fold activity compared to control cells. An epimerization of the (-)-
enantiomer into a more active form after a prolonged incubation time in the cell culture media 
may be considered. 
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Table 18. Influence of both enantiomers of arteludovicinolide A [10 µM] on the induction of HO-1 activity in 
RAW264.7 cells measured via the HO-1 activity assay together with their influence on the cell viability deter-
mined by the MTT test. 
 
 Fold induction of HO-1 activity at 10 µM 
Cell viability at 10 µM, 
% of control 
6 h 24 h 
(+)-Arteludovicinolide A 97.3 ± 8.2 2.14 ± 0.70 1.91 ± 0.28 
(-)-Arteludovicinolide A 97.9 ± 17.8 ns 2.03 ± 0.16 
Cytotoxicity of test compounds was measured at 10 µM after 24 h via MTT assay and cell viability is 
presented. Significant stimulation of HO-1 activity (p ≤ 0.05) is shown as fold of induction when cells 
were incubated for 6 and 24 h with compounds at 10 µM and HO-1 activity was determined in whole 
cell lysates via the ELISA-based HO-1 activity assay. ns, not significant.  
3.6.3 Summary 
The naturally occurring (+)-arteludovicinolide A and its synthetic enantiomer (-)-arteludo-
vicinolide A were shown to display anti-inflammatory activity at non-cytotoxic concentration in 
RAW264.7 murine macrophages. Both enantiomers were able to inhibit the production of NO, 
regulated by the proinflammatory NF-κB pathway and on the other hand to induce the activity of 
the anti-inflammatory and cytoprotective enzyme HO-1, which is activated by the Nfr2/Keap1/ 
ARE signaling pathway. In both cases, the (+)-arteludovicinolide A displayed a higher activity 
then the (-)-enantiomer, with a 2.14 fold induction of HO-1 activity after 6 h and an IC50 value of 
4.87 µM in NO inhibition compared to an insignificant modulation of HO-1 activity and an IC50 
value of 10.3 µM, respectively. Interestingly after a longer incubation time of 24 h both com-
pounds were able to induce the HO-1 activity (2 fold) compared to control cells. This observa-
tion may suggest an epimerization of the (-)-enantiomer under cell culture conditions leading to 
a more active form of the compound. This remains to be investigated. Additionally, it was shown 
that the exo-methylene group in the lactone ring is crucial for the anti-inflammatory activity of 
the natural product.  
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3.7 The anti-inflammatory activity of iron dienylphosphate tri-
carbonyl complexes as enzyme-triggered CO-releasing molecules 
(ET-CORMs) 
The biological activity of two phosphorester-based ET-CORMs, rac-17 and rac-18 (Figure 16) 
was investigated in the murine macrophage cell line RAW264.7 by determining their influence 
on the cell viability and the LPS induced production of NO. Both racemic ET-CORMs where syn-
thesized by Steffen Romanski (research group of H.-G. Schmalz, Universität zu Köln). The syn-
thesis of these water soluble ET-CORMs and the biological evaluation of some selected com-
pounds were recently published.213 The phosphate ester complexes rac-17 and rac-18 differ in 
their cytotoxicity and also in their inhibitory activity on NO production in RAW264.7 cells stimu-
lated with 10 ng mL-1 LPS (Figure 53). The compound rac-17 was found to be the more active 
compound, displaying an IC20 value of 252 ± 39 µM and an inhibition of NO production of 31 ± 
8% at 100 µM, whereas rac-18 was inactive in the test concentration range of 1-100 µM without 
displaying a significant toxicity even at 1.0 mM (Table 19).  
 
Figure 53. Influence of ET-CORMs rac-17 and rac-18 on the viability (left column) and the nitrite production 
(right column) of RAW264.7 cells stimulated with 10 ng mL-1 of LPS. Cell viability of was determined by the 
MTT assay for the indicated concentrations of the compounds at an incubation time of 24 h. The NO produc-
tion (Griess assay) was measured under the same conditions at non-toxic concentrations. Data represent at 
least three independent experiments performed in quadruplicates.  
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Table 19. Evaluation of the cytotoxic and anti-inflammatory activity of two water-soluble ET-CORMs in 
RAW264.7 murine macrophages. 
ET-CORM 
IC20 [µM],  
cell viability 
Inhibition of NO production  
at 100 µM [%] 
rac-17 252 ± 39 31.0 ± 8.3 
rac-18 > 1000a -b 
Inhibition of cell viability and NO production in RAW264.7 macrophages 
stimulated with 10 ng mL-1 LPS in presence of test compounds for 24 h. a An 
IC50 value for rac-17 could not be determined due to the overall low toxicity. 
b No significant NO inhibition compared to control cells was found.  
Upon enzymatic triggered CORMs degradation free Fe3+ ions are released, which could also in-
fluence the anti-inflammatory activity of ET-CORMs.214 For this purpose the free ions Fe2+ and 
Fe3+ were assessed towards their effect on the viability and on the NO production in RAW264.7 
cells (Figure 54). Both FeCl2 and FeCl3 proved to be cytotoxic with IC20 values of 33.7 ± 17.2 µM 
for FeCl2 and 39.8 ± 15.3 µM for FeCl3 and an IC50 value > 100 µM for both compounds. However, 
no inhibitory influence on the NO production in RAW264.7 cells was observed for Fe2+ and Fe3+ 
at non-toxic concentrations (1-25 µM).  
 
Figure 54. Results of the in vitro assays performed with RAW264.7 cells stimulated with 10 ng mL-1 of LPS 
together with FeCl2 and FeCl3. Charts on the left side refer to MTT tests after an incubation time of 24 h at 
different concentrations. Charts to the right display the influence on NO production (Griess assay) of the iron 
chlorides at non-toxic concentrations. Data represent at least three independent experiments performed in 
quadruplicate.  
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Furthermore, the degradation products obtained upon decomposition of acyloxycyclohexadiene-
Fe(CO)3 complexes can also contribute to the biological activity of ET-CORMs, since it was shown 
for cyclohexenones to strongly contribute to the overall activity of the monoester complexes of 
ET-CORMs.212 Therefore, some phenolic and cyclohexanone derivatives, as possible decomposi-
tion products of the ligand released from structurally different acyloxycyclohexadiene-Fe(CO)3 
complexes (Figure 55) where investigated towards their cytotoxic activity and their influence on 
the NO production in RAW264.7 macrophages (Figure 54 and Table 20).  
 
Figure 55. Structures of tested potential decomposition products of ET-CORMs. 
The potential ET-CORM decomposition products showed overall low cytotoxicity, except for the 
3-cyclohexenone 2, which displayed an IC50 value of 43.1 ± 6 µM, followed by compound 5 with 
an IC20 value of 66.2 ± 30 µM. All compounds revealed a concentration dependent inhibitory 
effect on the NO production in RAW264.7 cells at non-toxic concentrations. Whereas compounds 
1, 3, 4 and 5 displayed a similar maximum inhibitory activity in the range of 39-42%, compound 
2 was found to be the most potent inhibitor with a 70 ± 16% inhibition of NO production at 
10 µM. The IC50 value for the NO inhibition was calculated at non-toxic concentrations and gave 
6.6 ± 3.3 µM for compound 2.  
Table 20. Evaluation of the cytotoxic and anti-inflammatory activity of potential ET-CORMs decomposition 
products in LPS-stimulated RAW264.7 macrophages.  
 Cytotoxicity Inhibition of NO production [%] 
Compound Toxicity limit [µM] IC50 [µM] Maximum inhibition Inhibition at 10 µM IC50 [µM] 
1 100 >100a 39.4 ± 15.6 24.4 ± 11.9 >100a 
2 10 43.1 ± 5.5 70.0 ± 16.2 70.0 ± 16.2 6.6 ± 3.3 
3 100 >100a 40.3 ± 13.5 26.8 ± 11.0 >100a 
4 100 >100a 42.2 ± 7.8 33.1 ± 5.2 >100a 
5 75 IC20 = 66.2 ± 30.2 39.5 ± 11.2 26.9 ± 4.4 >100a 
Cytotoxicity of test compounds was measured via MTT-LPS assay and the NO production was determined by the 
Griess assay in RAW264.7 cells stimulated with 10 ng mL-1 of LPS for an incubation time of 24 h. The toxicity 
limit determines the highest non-toxic concentrations. a IC50 value was not determined due to a low toxicity or 
activity.  
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Figure 56. Results of the in vitro assays performed with RAW264.7 cells stimulated with 10 ng mL-1 of LPS 
together with possible ET-CORM decomposition products 1-5 (see Figure 17). Chart on the left side refer to 
MTT tests after an incubation time of 24 h at different concentrations. Chart to the right display their influ-
ence on NO production (Griess assay). Data represent at least three independent experiments performed in 
quadruplicate.  
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Interestingly, the effect of phenol 1 and its dihydroxy derivative 3 on the viability of the murine 
macrophages was very low, showing no relevant toxicity in the range of 0.5 to 100 µM. Surpris-
ingly, the 3-cyclohexenone 2 exerted a relatively high toxic effect and a strong inhibitory effect 
on the NO production although no α,β-unsaturated unit is present in the system. This may sug-
gest a potential isomerization of the 3-cyclohexenone under cell culture conditions to the active 
2-cyclohexenone. Compounds 4 and 5, which can derive from hydrolysis of the corresponding 
diester complexes (see Figure 17) showed relatively moderate anti-inflammatory activity and a 
weak cytotoxicity. This was also found for the aromatic compounds 1 and 3, which could de-
compose from the corresponding hydroxycyclohexadiene-Fe(CO)3 complexes (see Figure 17). In 
conclusion, the determined activity of the possible decomposition products contribute signifi-
cantly to the overall activity of the corresponding acyloxycyclohexadiene-Fe(CO)3 complexes 
and may even account for most of their activity.  
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3.8 Characterization of further compounds towards their cytotoxic, 
antioxidative and anti-inflammatory activity 
3.8.1 Cytotoxic activity of two γ-butyrolactone derivatives on the human colon 
cancer cell line HT-29 
Two functionalized γ-butyrolactones, GBL-1 and GBL-2, both bearing an acetic acid benzyl ester 
moiety, were tested for their cytotoxic effect in the human colon cancer cell line HT-29. The 
compounds were synthesized by Mohd Tajudin Mohd Ali (research group of O. Reiser, 
Universität Regensburg).243 The results of both γ-butyrolactones on their inhibitory effect on the 
cell viability of HT-29 cells is summarized in Table 21 and IC50 and IC20 values were calculated 
from nine different test concentrations in the range of 1-500 µM. The γ-butyrolactone com-
pounds showed only weak cytotoxicity against the human colon cancer cell line HT-29, whereas 
GBL-2, bearing a α,β-unsaturated moiety, displayed a slight toxicity with an IC50 value of 463 µM 
compared to the azide GBL-1 with an IC50 value over 500 µM.  
Table 21. Effect of γ-butyrolactones on the viability of human colon cancer cells (HT-29). Cells were treated 
with test compounds (1-500 µM) for an incubation time of 24 h and cell viability was determined by the MTT 
assay. 
 
 
GBL-1 
 
GBL-2 
IC20 [µM] 241± 92 184 ± 41 
IC50 [µM] > 500 463 ± 132 
3.8.2 Biological activity of different sesquiterpene lactone derivatives, 
γ-butyrolactones and 4-substituted cyclopentenones 
Several compounds derived from sesquiterpene lactones, γ-butyrolactone derivatives and 
cyclopentenones with different substituents in 4-position were investigated towards their cyto-
toxic and anti-inflammatory activity in the murine macrophages RAW264.7 and the human co-
lon cancer cells HT-29. Additionally, some compounds were also tested for their radical scaveng-
ing properties in the cell-free ORAC-fluorescein assay. The results of the activity screening to-
gether with the structures of the compounds is summarized in Table 22. The compounds were 
synthesized by different members of the research group of O. Reiser (Universität Regensburg) as 
indicated in the table. The compound AB-1 derived from the anti-tumor244 and anti-
inflammatory245-247 sesquiterpene lactone xanthatin (Figure 57) was investigated towards its 
anti-inflammatory activity in LPS-stimulated RAW264.7 macrophages by determining the inhibi-
tion of NO production, which gave an IC50 value of 7.1 ± 1.2 µM. Furthermore, its toxicity towards 
the macrophage cell line was estimated with an IC50 value of 46.3 ± 1.7 µM. The xanthatin deriva-
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tive possesses two Michael acceptor moieties which may contribute to its anti-inflammatory 
activity, one at the side chain of the 7-membered ring and the second representing the 
α-methylene-γ-lactone unit. These structural requirements were reported to be essential for the 
anti-inflammatory activity of xanthatin, where an IC50 value of 5 µM for the inhibition of NO pro-
duction in RAW264.7 cells was reported.247 
 
Figure 57. Structure of the sesquiterpene lactone xanthatin and its derivative AB-1, which was investigated 
towards its toxicity and anti-inflammatory activity in RAW264.7 macrophages. 
A derivative compound from the guaianolide family, MS-342 F9-18, bearing a γ-butyrolactone 
unit beside a cyclopentenone moiety, was screened for its toxicity in two cell lines. The guaia-
nolide derivative showed no significant effect on the viability of human colon cancer cells HT-29 
in the concentration range of 10-50 µM and also no relevant cytotoxic effect at concentrations up 
to 75 µM towards the murine macrophages RAW264. A weak effect on the viability of RAW264.7 
cells was detected at 100 µM (73.6 ± 8.9%). Furthermore, since the compound consists of sever-
al moieties that can also act as antioxidant and radical scavenger, the antioxidant capacity in the 
cell-free ORAC-fluorescein assay was determined. Compared to the vitamin E derivative Trolox, 
MS-342 F9-18 revealed a third of the Trolox antioxidant capacity (0.30 ± 0.06 Trolox equiva-
lents) in the range of 0.5-10 µM, suggesting an overall weak radical scavenging-based antioxi-
dant activity.  
Two γ-butyrolactone derivatives were tested for their cytotoxicity in RAW264.7 murine macro-
phages and IC50 values could be estimated (entry 3 and 4 in Table 22). It is proposed, that the 
diethylamino-substituted γ-butyrolactone serves as a precursor for the α-methylene γ-butyro-
lactone, which once present in the cell can release the free active α-methylene unit upon elimina-
tion of diethylamine. The results of the screen showed that both compounds have weak cytotoxic 
effects on RAW264.7 cells. However, a higher toxicity was observed for the α-methylene lactone 
with an IC50 value of 236 ± 14 µM compared to the precursor (IC50 = 315 ± 22 µM). The potential 
decomposition product of the precursor, diethylamine, was found to have no effect on the cell 
viability. 
The 4-hydroxy-2-cyclopenteone molecule is a versatile scaffold and its application in the synthe-
sis towards divers drug target molecules is very broad.248 The distinct chemical property of 
cyclopentenones, i.e. the α,β-unsaturated carbonyl moiety, by which they can react as a Michael 
acceptor with thiols on regulatory proteins makes them to a key functional unit for the biological 
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activity of natural products.249 Eight derivatives of 4-hydroxy-2-cyclopenteone (KU 1-KU 8),250 
with several substituents in 4-position were screened towards their cytotoxic and anti-
inflammatory activity in RAW264.7 cells at concentration of 100/10/1 µM. Also the 4-hydroxy-
2-cyclopenteone was tested for its toxicity towards both cell lines, displaying an IC50 value of 
39.7 ± 5.7 µM against RAW264.7 cells and a similar toxicity limit (non-toxic concentration) of 
10 µM towards HT-29 colon carcinoma cell. The MTT viability assay of the eight cyclopentenone 
derivatives with the RAW264.7 cell line stimulated with 10 ng mL-1 of LPS revealed a concentra-
tion dependent toxicity of the compounds in the range of 100-1 µM and IC50 values could be cal-
culated. While all compounds showed a nearly complete toxicity at 100 µM, except for KU 6 
(64.0 ± 7.8% cell viability at 100 µM), all compounds had no effect on cell viability at 1 µM. The 
concentration of the compounds needed to reduce the cell viability to 50% (IC50) was deter-
mined in the range of 33-47 µM, whereas KU 5 was found to be the most toxic compound in the 
screen (IC50 value of 33.1 ± 3.6 µM). Subsequently, the test compounds were tested at 1 µM for 
their ability to inhibit the production of NO in RAW264.7 cells. Here, KU 1 and KU 6 were inac-
tive at 1 µM and revealed only at higher concentrations of 10 µM an inhibition of NO production. 
Compounds KU 2, KU 3, KU 4, KU 7 and KU 8 showed a weak to moderate inhibition of NO pro-
duction at 1 µM. The most active derivative was the TBS-protected 4-hydroxy-2-cyclo-hexenone 
(KU 5) displaying an inhibition of NO production of 72 ± 7% at 1 µM. In contrast, the 4-hydroxy-
2-cyclopentenone showed no relevant inhibition of NO production at the non-toxic concentra-
tion of 1 µM (3.4 ± 2.7%). These results suggest, that a substitution in 4-positon of the 
4-hydroxy-2-cyclopentenone has a weak effect on the inhibition of NO production in the case of 
the carbonates (KU 2 and KU 4), the naphtoate (KU 3) or the acetate (KU 8). Their weak effect 
may be explained by a possible hydrolysis in the culture medium/cell, which leads to the less 
active 4-hydroxy-2-cyclopentenone. However, the activity could be enhanced in the case of the 
tert-butyldimethylsilyl (TBS) protecting group (KU 5). That is important to note for potential 
variations in the substitution pattern of future cyclopentenone compounds tested for their bio-
logical activity.  
 
 
 
Table 22. Overview of data gained from screening for biological activity and radical scavenging and antioxidant properties (ORAC assay) of different compounds.a  
  Cytotoxicity Anti-inflammatory activity Antioxidant activity 
Name Structure Cell line IC50 value [µM] 
Viability,                   
% of control 
(conc. [µM])c 
Toxicity limit 
Inhibition of NO produc-
tion (%) 
Trolox equivalents 
Xanthatin derivative AB-1, 
Andreas Bergmann 
 
RAW264.7  46.3 ± 1.7 8.5 ± 1.0 (100) 10 µM IC50 = 7.11 ± 1.22 µMd nd 
 
MS-342 F9-F18, Michael 
Schwarz 
 
 
RAW264.7 nd 73.6 ± 8.9 (100)b 75 µM nd 
0.300 ± 0.061 
(0.5-10 µM) HT-29 nd 94.0 ± 12.4 (50)b > 50 µM - 
Diethylaminomethyl-GBL, 
Sabrina Fürst 
 
 
RAW264.7 315 ± 22b 4.95 ± 0.96 (1000)b 250 µM nd nd 
α-methylene-GBL, Sabrina 
Fürst  
RAW264.7 236 ± 14b 5.29 ± 1.18 (1000)b 100 µM nd nd 
4-Hydroxy-2-
cyclopentenone, Peter 
Kreitmeier  
 
RAW264.7 39.7 ± 5.7b 20.1 ± 2.5 (100)b 10 µM 3.39 ± 2.65 (1 µM) 0.287 ± 0.023 
(0.5-7 µM) 
HT-29 nd 74.3 ± 10.6 (25)b 10 µM - 
(±)-4-Hydroxy-4-
(hydroxymethyl) cyclopent-
2-enone, Kathrin Ulbrich 1  
RAW264.7 47.0 ± 6.4 9.37 ± 0.62 (100) 10 µM 
-16.0 ± 25.1 (1 µM)      59.8 
± 20.0 (10 µM) 
nd 
(±)-tert-Butyl(4-oxo-
cyclopent-2-en-1-yl) carbo-
nate, Kathrin Ulbrich 2  
 
RAW264.7 35.5 ± 7.3 8.22 ± 1.43 (100) 1 µM 16.3 ± 13.5 (1 µM) nd 
1
1
9
 
 
 
 
  Cytotoxicity Anti-inflammatory activity Antioxidant activity 
Name Structure Cell line IC50 value [µM] 
Viability,                   
% of control 
(conc. [µM])c 
Toxicity limit 
Inhibition of NO produc-
tion (%) 
Trolox equivalents 
(S)-4-Oxocyclopent-2-en-1-
yl 1-naphthoate, Kathrin 
Ulbrich 3 
 
RAW264.7 46.0 ± 4.3 8.35 ± 1.14 (100) 1 µM 8.19 ± 15.4 (1 µM) nd 
(±)-Methyl(4-oxocyclopent-
2-en-1-yl) carbonate, Kath-
rin Ulbrich 4  
RAW264.7 36.7 ± 6.2 8.30 ± 1.32 (100) 1 µM 15.0 ± 7.6 (1 µM) nd 
(±)-4-((tert-
Butyldimethylsilyl)oxy)-
cyclopent-2-enone, Kathrin 
Ulbrich 5 
 
RAW264.7 33.1 ± 3.6 8.20 ± 1.46 (100) 1 µM 72.1 ± 7.2 (1 µM) nd 
(S)-2-(4-Oxocyclopent-2-
en-1-yl)isoindoline-1,3-
dione, Kathrin Ulbrich 6 
 
 
RAW264.7 > 100 64.0 ± 7.8 (100) 10 µM 
5.77 ± 15.5 (1 µM) 75.4 ± 
11.1 (10 µM) 
nd 
(S)-4-(6-Chloro-9H-purin-
9-yl)cyclopent-2-enone, 
Kathrin Ulbrich 7  
 
RAW264.7 36.1 ± 5.7 8.13 ± 1.44 (100) 1 µM 34.2 ± 13.7 (1 µM) nd 
(±)-4-Oxocyclopent-2-en-1-
yl acetate, Kathrin Ulbrich 8   
RAW264.7 38.0 ± 5.0 8.39 ± 1.55 (100) 1 µM 21.8 ± 13.3 (1 µM) nd 
a The compounds used in the biological testing were synthesized by different group members of O. Reiser (Universität Regensburg) as indicated. Cytotoxicity with RAW264.7 cells 
was determined via the MTT-LPS assay in the presence of 10 ng mL-1 of LPS. b Cytotoxicity in the cell lines HT-29 and RAW264.7 was determined by the MTT assay after an incuba-
tion time of 24 h, no LPS was added here. c Cell viability at highest test concentration of the compound. The toxicity limit refers to the non-toxic concentration of compounds (viability 
> 80%). The NO production was determined by the Griess assay in RAW264.7 cells stimulated with 10 ng mL-1 of LPS at non-toxic concentrations of compounds. d Here, an IC50 value 
could be calculated. Antioxidant capacity of compounds was measured by the ORAC-fluorescein assay and expressed as Trolox equivalents. nd, not determined.  
 
1
2
0
 
 
121 
 
3.8.3 Biological activity of chalcone-analogs 
Three different chalcone derivatives and one flavone derivative (SU-F-01) synthesized by Mihai 
Surducan (visiting PhD student in the group of B. König, Universität Regensburg) were tested for 
their anti-inflammatory activity in RAW264.7 murine macrophages (Table 23). All chalcone ana-
logs possess instead of the A-ring a thiazol unit bearing a phenyl ring in 2-position of the thiazol 
ring. Two para-substituted chalcone derivatives on the B-ring of the MS-C-01 scaffold were in-
vestigated towards their influence on the anti-inflammatory activity, namely SU-CT-03 with a 
more activating NO2 group and SU-C-02 with a deactivating OMe group towards a possible Mi-
chael addition with SH-groups on target proteins regulating inflammatory pathways. In order to 
exclude cytotoxic effect of the compounds, their influence on the viability of RAW264.7 cells in 
presence of 10 ng mL-1 of LPS after 24 h was determined via the MTT-LPS assay. Subsequently, 
the compounds were tested for their ability to inhibit the NO production in RAW264.7 macro-
phages at non-toxic concentrations. Due to the poor solubility of the compounds in the cell cul-
ture medium, a high dilution was necessary to overcome this problem. The chalcone derivatives 
showed an overall weak toxicity. A moderate but significant reduction of cell viability was ob-
served for MS-C-01 and SU-CT-03 at 1 and 0.5 µM. At non-toxic test concentrations compounds 
showed no relevant inhibition of the NO production in RAW264.7 macrophages.  
Table 23. Evaluation of different chalcone analogsa towards their toxicity and anti-inflammatory activity. 
  Cytotoxicity Anti-inflammatory activity 
Name Structure 
Viabilityb,                  
% of control 
(conc. [µM]) 
Toxicity limitc 
Maximum inhibition 
of NO productiond 
(%), (conc.) 
MS-C-01  
 
79.8 ± 7.44 (1) 250 nM -5.74 ± 5.56 (250 nM) 
SU-F-01 
 
 
88.9 ± 11.1 (5) 5 µM -4.14 ± 17.2 (5 µM) 
SU-C-02 
 
 
92.5 ± 15.8 (5) 5 µM 10.8 ± 14.5 (5 µM)  
SU-CT-03 
 
73.4 ± 8.64 (1) 250 nM 1.39 ± 4.12 (250 nM) 
a The compounds used in the biological testing were synthesized by Mihai Surducan, a visiting PhD student in the 
group of B. König (Universität Regensburg). b Cytotoxicity was determined via the MTT-LPS assay in the presence 
of 10 ng mL-1 of LPS and cell viability is given for the highest test concentration of the compound. c The toxicity 
limit refers to the non-toxic concentration of compounds. d The NO production was determined by the Griess assay 
in LPS-stimulated RAW264.7 macrophages at non-toxic concentrations of compounds.  
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4 Summary 
To fight chronic inflammation in autoimmune diseases such as rheumatic arthritis and multiple 
sclerosis or cancer is an exigency. Therefore the inhibition of proinflammatory proteins such as 
inducible NO-synthase (iNOS) and the activation of anti-inflammatory proteins such as heme 
oxygenase-1 (HO-1) are important measures to be addressed. Many natural products and syn-
thetic compounds with an α,β-unsaturated carbonyl moiety reveal a variety of biological proper-
ties, including antioxidant, anti-inflammatory and cytoprotective properties. α,β-Unsaturated 
carbonyl compounds possess Michael acceptor activity and can react with nucleophilic sulfhy-
dryl groups on key cysteins to regulate the inhibition of NF-κB and the activation of Nrf2, which 
are the transcriptional factors needed for the expression of iNOS and HO-1, respectively. 
Heme oxygenase-1 is a redox sensitive, inducible stress protein converting heme to CO, Fe2+ and 
biliverdin, which is further reduced to bilirubin by biliverdin reductase (BVR). Thereby, the 
overall anti-inflammatory, chemopreventive and chemoprotective effect connected to the HO-1 
activity is a result of the heme degradation. An ELISA-based HO-1 assay was developed and 
proved to be a reliable and easy cell line-based assay in order to screen compound libraries to 
find new HO-1 inducers, which could be used as lead structures for drug development. The HO-1 
activity assay combines the HO enzyme reaction in presence of recombinant BVR with the quan-
tification of the reaction product bilirubin by an indirect sandwich enzyme-linked immuno-
sorbent assay (ELISA) using the murine macrophage cell line RAW264.7. The detection of the 
total bilirubin level in whole cell lysates requires only a fraction of the total protein amount, that 
is 10-30 µg per sample. By comparing the bilirubin levels in stimulated cells and control cells, 
the HO-1 activity can be expressed as ‘fold of control’ based on pmol bilirubin h-1mg-1 total pro-
tein. The reliable HO-1 activity assay was developed in a 96-well plate format allowing the 
screening of multiple compounds in parallel. 18 small molecules, mainly natural products with 
an α,β-unsaturated carbonyl unit as well as the drugs dexamethasone and oltipraz were tested 
and the activity of most known HO-1 inducers was confirmed. The diterpene carnosol was found 
the most potent HO-1 inducer in the screen of HO-1 activity (8.2 ± 1.9 fold after 6 h) followed by 
rosolic acid with an induction of HO-1 activity of 3.9 ± 0.4 fold after 24 h. Amongst the natural 
chalcones, cardamonin and flavokawain A were identified as new potent HO-1 inducers. The 
most potent HO-1 activity inducer was found to be the 2’,4’-dihydroxy-3,4-dimethoxychalcone 
(DHDMCH), with a maximum induction of HO-1 activity of 6.1 ± 2.3 fold. Moreover, the time de-
pendence of HO-1 protein expression for DHDMCH was compared to its enzyme activity, which 
was further evaluated in presence of lipopolysaccharide (LPS) and the specific HO-1 inhibitor tin 
protoporphyrin IX (SnPPIX). Furthermore, the HO-1 activity assay was successfully applied on 
human primary dendritic cells, were the HO-1 activity of the α-CF3-TMCH was determined.  
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Natural and synthetic hydroxy- and methoxychalcones were characterized towards their anti-
inflammatory and antioxidant behavior in RAW264.7 murine macrophages. Particularly, their 
influence on the induction of the anti-inflammatory and cytoprotective protein HO-1 and the 
inhibition of the proinflammatory protein iNOS, more specifically the reduction of NO produc-
tion was investigated. Additionally, a cell-free assay performed under physiological conditions 
was used to determine the radical scavenging properties of the chalcones and establish an anti-
oxidant capacity compared to the vitamin E derivative Trolox. The overall biological activity of 
chalcones depends on their Michael acceptor reactivity, which can be influenced by different 
substitution patterns on the aromatic rings, as well as on the presence of free hydroxy groups on 
the aromatic rings of the chalcone. By these means, introducing methoxy groups in 2’,4’-position 
on the A-ring or in 3,4-positions on the B-ring enhances the anti-inflammatory activity, while an 
increasing number of hydroxy groups leads to a higher radical scavenging activity of chalcones. 
The observations demonstrate that an indirect influence on the electrophilicity of Michael accep-
tors can indeed determine the potency of chalcones as inducers of HO-1 activity and as inhibi-
tors of inflammatory NO production. On the other hand, a hydroxy-rich chalcone like butein, 
which is a relatively weak Michael acceptor, can act as a powerful antioxidant determined by its 
radical scavenging properties.  
A direct change at the Michael system can also alter the reactivity and thus the biological activity 
of enones. The approach of modifying the α-position of the α,β-unsaturated carbonyl system is a 
promising concept, because it should lead to a direct and straightforward influence on its reac-
tivity. The chemical reactivity of α-X-enones depends on the nature of the α-substituent, thus 
activating or deactivating the Michael acceptor reactivity toward thiols responsible for a biologi-
cal response. The influence of different α-X-substituted 2’,3,4,4’-tetramethoxychalcones (α-X-
TMCHs) on the induction of HO-1 protein expression and HO-1 enzymatic activity and on the 
other hand the inhibition of NO production, regulated by iNOS was determined in RAW264.7 
murine macrophages. A clear correlation could be established between the reactivity of α-X-
TMCHs, demonstrated by their thia-Michael addition reaction with cysteamine (k2 values) and 
their biological activity. The results demonstrate that a rather moderate electrophilicity of α-X-
TMCHs is a crucial factor determining their potency to induce HO-1 activity or inhibit NO pro-
duction. This could be observed for the most electrophilic TMCHs in our screen, α-CN-TMCH and 
α-NO2-TMCH, displaying relatively high k2 values in the thia-Michael addition reaction. Both 
TMCHs were only weak inhibitors of iNOS activity and showed no induction of HO-1 activity or 
protein expression, which may suggest an alternative pathway of the chalcones in the cell, such 
as a consumption by GSH, thus preventing them to reach their target SH-groups. The more in-
termediate electrophiles (with lower k2 values), α-CF3-TMCH, α-Br-TMCH and α-Cl-TMCH how-
ever, displayed a high activity in the biological screening of the α-X-TMCHs. Here, α-CF3-TMCH 
was the most active chalcone, with an IC50 value of NO production of 120 ± 62 nM and a 2.7 ± 0.5 
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fold induction of HO-1 activity in RAW264.7 macrophages. The importance of a sufficient Mi-
chael acceptor activity of α-X-modified enones required for a reasonable biological activity was 
demonstrated by the model compounds α-X-Limno-CPs, derived from the natural product 
limnophilaspiroketone. The α-X-Limno-CPs exerted a weak anti-inflammatory activity in inhibit-
ing the NO production in RAW264.7 macrophages, due to their overall electron rich enone sys-
tem making them weak electrophiles compared to the α-X-TMCHs.  
A water soluble phosphorester-based enzyme-triggered CO-releasing molecule (ET-CORMs) was 
found to moderately inhibit the NO production (31 ± 8% at 100 µM for rac-17) in RAW264.7 
macrophages. Thereby, an expected influence of the iron ions Fe2+ and Fe3+, which can derive 
upon oxidative decomposition of the ester (cyclohexadiene)Fe(CO)3 complex, on the inhibitory 
activity of the ET-CORMs was not found. In contrary, for some possible decomposition products 
of acyloxy(cyclohexadiene)Fe(CO)3 complexes as ET-CORMs, such as phenolic and cyclo-
hexanone derivatives, a significant activity was determined, which can contribute to the activity 
of the corresponding ET-CORMs. These results confirm previous findings that cyclohexenones, 
especially 2-cyclohexenone, may strongly contribute to the overall activity of such ET-CORMs as 
the acyloxy(cyclohexadiene)Fe(CO)3 complexes. 
The naturally occurring (+)-arteludovicinolide A and its synthetic enantiomer (-)-arteludo-
vicinolide A were shown to display anti-inflammatory activity, demonstrated by their ability to 
inhibit the NO production and induce HO-1 activity in RAW264.7 macrophages. (+)-Arteludo-
vicinolide A was the more active enantiomer, displaying an inhibitory effect of the NO produc-
tion with an IC50 value of 4.9 ± 1.1 µM and an induction of HO-1 activity of 2.1 ± 0.7 fold after 6 h 
of incubation. The functional groups on these sesquiterpenes, a α-methylene group and a 
cyclopentenone ring may be involved in their biological activity, since it was shown that the 
α-methylene group in the lactone ring is crucial for the anti-inflammatory activity of the natural 
product. Furthermore, a diverse group of synthetic compounds and natural product derivatives 
bearing the cyclopentenone ring or a γ-butyrolactone moiety were found to exert weak to mod-
erate cytotoxicity in RAW264.7 macrophages or HT-29 colon cells and weak to moderate anti-
inflammatory activity in RAW264.7 cells. 
In conclusion, the Michael acceptor functionality of electrophilic enones proved to be crucial for 
their biological activity, regarding their potency as inducers of the cytoprotective and anti-
inflammatory HO-1 activity and protein expression and as inhibitors of proinflammatory iNOS 
activity. α,β-Unsaturated carbonyl compounds are a very useful class of substances. A systematic 
manipulation of the Michael acceptor reactivity by modifying the α-position of the enone system 
leads to a fine-tuned biological activity in chalcone scaffolds. This approach might be highly val-
uable for drug design in order to predict the biological activity. 
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